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Introduction:  Type 2 diabetes is a known risk factor for cognitive decline and dementia and 
continues to be one of the most common non-communicable diseases in the world. Obesity, a 
hallmark of type 2 diabetes is often associated with general inactivity and chronic increased 
levels of systemic inflammation. The literature suggests that obesity, along with systemic 
inflammation and inactivity levels are associated with cognitive decline and dementia in the 
general population. There is uncertainty as to what effect (if any) obesity, systemic 
inflammation and activity levels have on people with diabetes. 
Aims:  To determine whether systemic inflammation, obesity and physical (in) activity levels are 
associated with cognitive decline and/or dementia in older people with type 2 diabetes. 
Methods:  The Edinburgh Type 2 Diabetes Study (ET2DS) is a representative prospective cohort 
of 1066 men and women living in Scotland, aged 60-75 years at baseline. Cognitive data was 
gathered by means of a comprehensive cognitive test battery, at baseline and at year 10 follow-
up. Other data on medical history, vascular events, circulating biomarkers, physiological 
examination and activity levels was also gathered at each phase of data collection. Criteria were 
developed to determine probable cases of dementia at year 10 follow-up. Principal component 
analysis (PCA) was used to derive a latent general cognition variable ‘g’ using imputed data to 
provide a summary score of the different cognitive tests. Multivariable regression analysis was 
used to assess the association of risk factor variables with general cognition, cognitive decline 
and dementia. Statistical models adopted the correction method, where baseline cognitive 
ability was used to correct for follow-up cognitive ability, in order to provide an indication of the 
association of a risk factor on cognitive decline. Logistic multivariable regression models were 
used to explore the effect of risk factors on incident dementia.  Adjustment variables included a 
wide range of demographic, vascular-related and diabetes-related risk factors. 
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Results:  In the ET2DS, associations were found between waist to hip ratio (WHR) and cognitive 
decline (standardised beta= -0.076; p=0.020), in fully adjusted models but not with body mass 
index (BMI). Waist circumference (WC) was found to be associated with cognitive decline 
(standardised beta= 0.059; p= 0.032), however in fully adjusted models this association was no 
longer statistically significant. Findings supported a possible association of higher plasma 
fibrinogen (standardised beta= -0.059; p=0.032) and IL-6 (standardised beta= -0.064; p=0.018) 
with cognitive decline, however in fully adjusted models this association was no longer 
statistically significant.  
Physical activity and sedentary behaviour were shown to be associated with a decline in 
cognitive ability (standardised beta= 0.171; p<0.001, standardised beta= -0.135; p<0.001, 
respectively), in fully adjusted models. 
Obesity-related variables associated with incident dementia included BMI (OR 0.95; 95% CI 
0.90- 0.99; p<0.05), WC (OR 0.97; 95% CI 0.95-0.99; p<0.05) and percentage body fat (OR 0.94; 
95% CI 0.90-0.98; p<0.01). Baseline inflammation marker IL-6 was identified as a possible risk 
factor for incident dementia (OR 1.56; 95% CI 1.08- 2.27; p < 0.05). Physical activity and 
sedentary behaviour were also associated with dementia prevalence at year 10 (OR 0.53; 95% CI 
0.36 - 0.78; p<0.001, OR 2.01; 95% CI 1.31 – 3.08; p<0.001, respectively). 
Conclusions:  Specific measures of obesity, inflammation and activity level were associated with 
cognitive decline and risk of dementia, in older people with type 2 diabetes. Care must be taken 
when interpreting these results as causal relationships cannot be inferred and further work 
must take place to confirm the directionality of these associations. These results, in the context 
of other work, may be used to reveal possible underlying biological mechanisms of diabetes 
related cognitive decline and dementia and guide work on preventative therapies or 
interventions for this disease. 
6 
Lay Abstract 
Type 2 diabetes is a disease that affects many people worldwide and has been shown to 
increase the risk of dementia and cognitive decline, namely the slowing thinking skills such as 
memory and information processing. People who are overweight, often as a result of lack of 
exercise, are more likely to develop diabetes and obesity has been shown to increase 
inflammation in the body. There is uncertainty as to what the main risk factor is for cognitive 
decline and dementia. The aim of this study was to find if level of obesity, physical activity and 
inflammation are associated with cognitive decline and dementia in older people with diabetes. 
 
The Edinburgh type 2 diabetes study uses information collected over a period of 10 years from a 
large group of men and women aged 60-75 years, with type 2 diabetes, living in Scotland. 
Cognitive ability was measured by psychological tests that look at memory, information 
processing, problem solving ability and other thinking skills, and was measured both at the start 
of the study and after 10 years. Other medical information on lifestyle such as smoking, diseases 
such as heart attacks, and medications was also collected. A questionnaire on weekly exercise 
was used, and measurements such as body mass index and waist to hip ratio, both of which 
giving indications as to how much fat is stored in the body and how it is distributed, were 
recorded. After 10 years the number of people who developed dementia were recorded.  By 
using statistical techniques, associations between obesity and cognitive decline were modelled 
as were the associations between obesity and people who developed dementia. The analysis 
was carried out in such a way that it was possible to see to what extent level of inflammation 
influenced the relationships between obesity and cognitive decline or dementia in the group. 
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The main finding of this study was that body shape (waist to hip ratio) was associated with 
cognitive decline to a greater extent than total body fat (body mass index) in people with type 2 
diabetes, and that inflammation did not influence this relationship. Another finding was that, a 
specific inflammation marker called IL6 was shown to be associated with cognitive decline. Level 
of exercise was also shown to be related to cognitive ability.  Surprisingly, dementia appears to 
be associated with a lower body mass index and lower levels of exercise. This may be due to the 
slow progression of dementia, and that many people that had developed dementia after 10 
years may already have had symptoms such as weight loss at the start of the study. More work 
is needed to find out if any of these risk factors cause dementia or cognitive decline, as the 
results of the present study cannot be used to reveal causal relationships. This would be 
important as it may help in developing strategies to prevent dementia and cognitive decline in 
people with diabetes who are already at a higher risk than the general population. 
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Chapter 1: Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus, commonly referred to as diabetes, is one of the most important public 
health challenges faced in the 21st century (Zimmet et al., 2014). Globally, the number of 
people suffering from the disease has almost doubled in the last 20 years, with an 
estimated 451 million adults diagnosed and also suffering undiagnosed from the condition 
worldwide (Cho et al., 2018).  This equates to 1 in 11 adults having a diagnosis; however, it 
is understood that 1 in 2 adults with diabetes (around 224 million) are undiagnosed (Cho et 
al., 2018). In 2017, 9.9% of global all-cause mortality was attributable to diabetes (Cho et 
al., 2018). The global economic burden of diabetes is an estimated 850 billion USD and it is 
predicted that, by 2045, this figure will rise to 958 billion USD, when an estimated 693 
million people will be living with the disease (Cho et al., 2018). Diabetes prevalence in 
England is reported to be 6.7% of all adults aged above 17 in the period 2016- 2017 (QOF, 
2017), while in Scotland, the most recent figures from the Scottish Diabetes Survey (2016) 
indicate a prevalence of 5.4% and that diabetes accounts for 3.7% of all deaths (all age 
ranges) in the period 2015- 2016.  
Diabetes, characterised by high blood glucose levels, describes a number of metabolic 
disorders, of which type 2 diabetes is the most common (World Health Organization, 1999). 
In Scotland, 88.3% of people with diabetes are diagnosed as having type 2 diabetes 
(Scottish Diabetes Survey, 2016). Type 2 diabetes usually develops in adulthood, although 
incidence in childhood and adolescence is increasing (Pulgaron and Delamater, 2014), and 
occurs as a result of the hormone insulin, produced by beta cells of the pancreas, not being 
effectively utilised by fat, muscle and liver cells to absorb and store dietary glucose. Other 
less common forms of diabetes include type 1, often diagnosed in childhood where the 
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pancreas fails to produce adequate insulin (through an immune mediated response) and 
gestational diabetes occurring during pregnancy (American Diabetes Association, 2014). 
Genetic predisposition plays a role in all forms of diabetes, including type 2; however, this 
type is often associated with obesity and adopting a sedentary lifestyle (Chen et al., 2012). 
Patients can present with symptoms such as polyuria, polydipsia, fatigue, weight loss, 
increased appetite, blurred vision, loss of feeling in the fingers and toes and recurring 
infections. Patients can be asymptomatic for years, or symptoms might only be minimal or 
non-specific, which can make diagnosis difficult. Criteria for diagnosis include presenting 
with symptoms along with abnormal blood test results. These include having a fasting 
plasma glucose concentration greater than 7mmol/L (126mg/dL) (World Health 
Organization, 2006) or having a glycated haemoglobin (HbA1c) level of above 6.5% (World 
Health Organization, 2011). HbA1c is an approximate measure of average blood glucose in 
the previous 2-3 months. 
Once diagnosed, treatment aimed at relieving symptoms and preventing or delaying 
complications, can take the form of a prescribed diet (low in simple carbohydrates), oral 
medications that stimulate insulin production or reduce insulin sensitivity, or injectable 
medications such as insulin.  A combination of treatments may be prescribed depending on 
the severity of symptoms. Complications of diabetes include episodes of hyperglycaemia, 
small vessel disease, heart disease, stroke, neuropathy, nephropathy, retinopathy, cognitive 
impairment, and dementia (UK Prospective Diabetes Study Group, 1998). Dementia and 
cognitive decline as a complication of diabetes will be the focus of this thesis and the 




1.2 Intelligence and cognition 
Individual differences exist when testing human intelligence (also termed cognitive ability, 
cognitive function or IQ), and are measured using psychometric tests (Deary et al., 2010a). 
These tests measure different cognitive skills that contribute to a person’s overall 
intelligence and are almost universally positively correlated. These relatively separate skills, 
termed cognitive domains, are difficult to measure specifically and, although one specific 
test may in principal measure ability in one domain, e.g. memory, a different domain may 
also be required to succeed at the test e.g. processing speed, attention etc. For this reason, 
it is almost always found that many cognitive test results when administered to a number 
of individuals are positively correlated (Deary et al., 2010a, Carroll, 1993). General 
intelligence, or general cognitive ability, often referred to as ‘g’ describes this observed 
overlap in cognitive domains (Deary et al., 2010a), and is described formally as the “general 
mental capability that involves the ability to reason, plan, solve problems, think abstractly, 
comprehend complex ideas and learn quickly and learn from experience” (Gottfredson, 
1997a). First described by Spearman (1904), general intelligence, often a derived factor or 
component from a number of different cognitive test results using factor/principal 
component analysis, describes a latent/summary variable which accounts for around 40% 
of the total variance in test scores. For example, it tends to appear as relatively high 
loadings of all tests on the first un-rotated principal component on a principal component 
analysis. This factor ‘g’ is usually normally distributed, with males having a slightly wider 
distribution of scores (Johnson et al., 2008) and is shown to be relatively stable in rank 
order between individuals throughout life (Deary et al., 2000, Deary, 2014). General 
intelligence is also shown to be predictive of life outcomes such as school achievement 
(Deary et al., 2007), occupational achievement (Gottfredson, 1997b), and later life health 
status and age at death (Calvin et al., 2010, Deary et al., 2010b). 
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Neural correlates of ‘g’ are difficult to localise (Deary et al., 2010a); however through 
functional and structural Magnetic Resonance Imaging (fMRI) imaging studies it is 
recognised that the lateral prefrontal cortex and parietal regions are key brain regions 
associated with general intelligence (Gray et al., 2003) and that the white matter neural 
connections between these regions play a major role in ‘g’ (Gläscher et al., 2010). It is now 
also well established that genetic heritability of ‘g’ increases with age from about 30% in 
childhood to 80% in later life (Deary et al., 2010a, Plomin and Deary, 2015).   
Although ‘g’ is important, there are other sources of variance in cognitive tests, at the 
domain and test-specific levels (Deary, 2013). Therefore, a hierarchal approach is often 
used when modelling the concept of intelligence or cognition using large data sets that 
employ cognitive test batteries (Carroll, 1993). Carroll (1993) describes a three stratum 
model: at the bottom the test specific outcome stratum, at the intermediate level the 
cognitive domain stratum, and a top stratum represented by ‘g’ as a combination of the 
cognitive domains. Others have described that alternative hierarchal models with differing 
numbers of strata, e.g. Johnson and Bouchard Jr (2005) describe a four strata model; 
however, a common feature of all theories is that the general intelligence factor is always 
on top. General intelligence can also be described as fluid or crystallised, where the former 
describes the cognitive functions that are susceptible to age-related change, and the latter 
are the functions whose means are thought to remain more stable with age (Cattell, 1963). 
Fluid ability is thus a reflection of current cognitive ability or intelligence, while crystallised 
ability is thought to be an estimation of premorbid level of ability, or peak level of 
intelligence (Franzen et al., 1997). 
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1.3 Age related cognitive decline 
The process by which we age is complex, involving a progressive impairment of function 
which increases risk of disease and mortality (Kirkwood, 2005). Aging affects both the body 
as a whole, as well as the brain, and a number of cellular and molecular processes have 
been suggested to play a role. These include an altered cellular response to DNA damage, 
telomere loss impairing cell division, mitochondrial mutations resulting in decreased tissue 
bioenergenesis, reduced protein turnover resulting in an accumulation of damaged or 
redundant protein waste products, or a combination of all of these processes (Kirkwood, 
2005).  
Age related cognitive decline is used here to describe the ‘non-pathological’ (that is, not 
dementia or so-called mild cognitive impairment, which are clinical categories of cognitive 
decline), mean decline in cognitive ability from young to older adulthood (Salthouse, 2009). 
It affects the fluid cognitive abilities (e.g. memory, executive function, reasoning and 
processing speed), critical for independent living, to a greater extent than the crystallised 
abilities (Deary et al., 2009), and so can have great impact on the quality of life of older 
people (Lawton, 1997, Sloane et al., 2005).  
 
1.4 Cognitive Impairment and Dementia 
Differentiating between non-pathological and pathological cognitive decline can be 
challenging (Deary et al., 2009).  Individual differences exist when describing the point, on 
the cognitive decline continuum, which may be used to distinguish between clinically 
relevant impairment and normal cognitive ageing.  This cut point is also very much 
dependent on prior intelligence and cognitive reserve and so when exploring non-
pathological cognitive decline in a cohort, it should be acknowledged that not all individuals 
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classed as non- pathological are phenotypically the same (Deary et al., 2009); in other 
words, some people may be undiagnosed pathological or high functioning pathological and 
still be classed as non-pathological.  
 
Mild Cognitive Impairment  
Mild Cognitive Impairment (MCI) is a pathological cognitive impairment and describes the 
clinically relevant cognitive condition that can lead to an increased risk of progressive 
neurological disease. The clinical diagnostic criteria for MCI have evolved over the last 10 
years and are now widely accepted to include, self or carer reported cognitive impairment, 
objective cognitive impairment measured by neuropsychological testing, preserved 
independence in functional abilities, and no dementia diagnosed (Petersen, 2016). Often 
confused with the term pre-clinical dementia, where physiological features of disease are 
picked up in the absence of cognitive symptoms, MCI is a distinct syndrome that may occur 
before pre-clinical dementia or dementia (Petersen, 2016). The trajectory of pathological 
cognitive disease begins many years before the diagnosis of MCI or dementia (Sperling et 
al., 2011), and it is therefore important to explore all types of cognitive impairment or 
decline, not just when deemed clinically relevant.   
 
Dementia 
The World Health Organization reports dementia to be the 7th leading cause of death 
globally, and is the 3rd leading cause of death in high income countries in 2016 (World 
Health Organization, 2018). The global prevalence of dementia is currently estimated to be 
around 30 million and is expected to double by 2030 (Prince et al., 2013). In 2016, the 
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prevalence of dementia in Scotland and England was calculated to be 0.8% according to ISD 
Scotland and Public Health England. The economic burden of the disease is predicted to 
grow as the population ages. Currently estimated to cost the National Health Service more 
than 25 billion pounds per year, this figure is expected to rise to around 40 billion pounds 
per year in 2030 (Lewis et al., 2014). Dementia is an umbrella term for a number of 
cognitive diseases that all have in common a marked degree of cognitive impairment due to 
physical changes in the brain that are sufficient to impact on daily functioning. The 
Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria for 
dementia include a marked degree of cognitive decline that affects daily living, as reported 
by a clinician, carer or patient; and are not as a result of delirium or other mental disorder. 
Formal diagnosis is made upon referral to a neurologist, who makes a diagnosis of 
dementia, with reference to a subtype, based on the evidence provided from 
neuropsychological assessment and MRI imaging. Despite no treatment currently being 
available to slow, prevent or reverse dementia, pharmacological therapies are available 
that aim to reduce the symptoms of disease. These drugs do not slow overall disease 
progression, but do improve the quality of life for a limited period of time. The main 
medications are acetylcholinesterase inhibitors (Donepezil, Rivastigmine and Galantamine) 
which inhibit the breakdown of the neurotransmitter acetyl choline and Memantine which 
regulates the effects of the neurotransmitter glutamate.  
The most common subtype of dementia is Alzheimer’s disease, which has a community 
prevalence of around 31%. Other subtypes include vascular dementia (prevalence of 
around 22%), dementia with Lewy bodies (prevalence of around 11%) and fronto-temporal 
dementia (prevalence of around 8%). Mixed dementia is also a commonly used term, often 
describing dementia with Alzheimer’s-like and vascular-like pathology (Stevens et al., 2002). 
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1.5 Neural mechanisms of cognitive ageing and dementia 
The main risk factor for neurodegeneration and cognitive decline is the aging of the brain 
(Bishop et al., 2010). Through research on animal models, pathways and mechanisms 
involved in the general ageing process have been explored and have also been related to 
specific areas of the brain. The following sections will discuss the most recent theories for 
brain ageing and cognitive decline. As yet, it is still unclear how the role of these pathways 
contribute to neurological disorders such as dementia (Bishop et al., 2010). 
The neurovascular unit is a term which refers to the neurons, glia and supporting 
vasculature that is involved in the homeostasis and functioning of the cerebral micro 
environment. In dementia, the neurovascular unit is impaired, and this can occur as a result 
of disruption to a host of processes that lead to a reduction in neurotransmission and 
neuronal network activation (McGaugh, 2000). In dementia, cerebral changes are observed 
which are specific to the dementia subtype. Cerebral changes including atrophy and the 
presence of protein clumps are seen in the neurodegenerative dementias such as 
Alzheimer’s, Lewy body and fronto-temporal dementia where misfolded protein aggregates 
such as hyper-phosphorylated tau and amyloid beta accumulate and lead to neuronal cell 
death (Pievani et al., 2011).  Neuronal atrophy has been shown to follow functional 
networks, as opposed to regions close in proximity to each other, suggesting that atrophy in 
dementia follows pre-existing neuronal networks (Raj et al., 2012). 
Cerebral changes observed in vascular dementia also lead to neuronal atrophy but are 
thought to occur due to cerebral ischaemia. This is understood to occur as a result from 
both microvascular and macrovascular disease that leads to poor oxygenation of regions of 
brain (Jellinger, 2002). These vascular pathologies lead to alterations of the blood-brain 
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barrier, vascular inflammation, oxidative stress and are all believed to have direct impact on 
neurons and their supporting cells (Iadecola, 2010).  
In mixed forms of dementia, it is thought that the vascular pathologies and toxic protein 
aggregates act together with additive effect on cognition or that one pathology promotes 
and exacerbates the other (Iadecola, 2010). Although the exact neuronal mechanism is yet 
to be fully understood, evidence from animal and imaging studies provides evidence to 
support the notion that the different pathological pathways all culminate in neural atrophy, 
which has a direct impact on cognitive decline and impairment. 
 
1.6 Diabetes related dementia and cognitive decline 
People with diabetes have a 50% increased risk of developing dementia when compared to 
the general population (Biessels et al., 2006).  For Alzheimer’s disease, this relative risk is 
1.46 while for vascular dementia this is as much as 2.48 (Cheng et al., 2012). The population 
attributable risk of Alzheimer’s disease for people with diabetes is 2.4%, equating to 
826,000 cases of Alzheimer’s disease being attributable to diabetes worldwide (Barnes and 
Yaffe, 2011).  
Cognitive impairment, short of dementia, has also been shown to be associated with 
diabetes (Van den Berg et al., 2009). Moreover, the rate of decline has been found to be 
worse than that of the general population during normal age related cognitive decline 
(Yaffe et al., 2012). It has been suggested that an increased risk of dementia in people with 
diabetes translates in practice to an earlier age of onset of clinically relevant impairment by 
2.5 years and the effect of accelerated age-related cognitive decline, short of dementia, 
exacerbates this by lowering the age of diagnosis, as an additive effect (Biessels et al., 
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2014). This is suggestive of two distinct processes occurring with a cumulative effect on the 
point at which clinically relevant cognitive impairment is diagnosed (Biessels et al., 2014). 
Because it is relatively rare for an individual diagnosed with dementia to only have one pure 
subtype, and that often neurodegenerative processes occur alongside other comorbidities 
and a background of age related cognitive change (Schneider et al., 2007), it is difficult to 
elucidate the underlying mechanisms of cognitive decline and dementia in diabetes. 
Experimental studies using rat models have found that cerebral insulin levels may play a 
role in Alzheimer-like pathologies (Ho et al., 2004), while clinical studies using autopsy data 
show that people with diabetes related dementia are more likely to have vascular dementia 
pathology (Ahtiluoto et al., 2010). It is predicted that diabetes related cognitive decline is 
likely the result of the cumulative effect of multiple processes including vascular lesions, 
loss of white matter and general brain atrophy (Biessels et al., 2014).  
Diabetes related mechanisms proposed include small vessel disease leading to neuronal 
ischaemia and white matter lesions and cognitive decline (Pantoni, 2010), microvascular 
disease which leads to alterations in the blood-brain barrier and cognitive decline (Janelidze 
et al., 2017) and hyperglycaemia where it is predicted that cerebral blood flow and osmotic 
effects may play a role in cognitive decline (Sommerfield et al., 2004). It has also been 
suggested that insulin resistance itself may have a direct effect on cognitive decline. Insulin 
can cross the blood-brain barrier, where it may compete for binding sites on insulin 
degrading enzymes present in the brain that also play a role in the clearance of amyloid 
beta plaques found in Alzheimer’s disease (Craft et al., 2013). This state of brain specific 
insulin resistance, which has been suggested to occur even in the absence of global insulin 
resistance, has been termed by some as ‘type 3 diabetes’, indicating that this is a distinct 
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form of diabetes (de la Monte, 2014). Despite some agreement on this, a general consensus 
is yet to be reached on the appropriateness of this terminology (Kandimalla et al., 2017).  
 
1.7 Risk factors 
1.7.1 Risk factors for cognitive decline in the general population 
One issue common to cognitive epidemiology is the notion of reverse causality. This 
describes the concept that early life intelligence traits can impact on later health outcomes 
and also cognitive health outcomes. This can have an impact on the interpretation of 
analyses that look at the associations between risk factors and health outcomes where it is 
often assumed that as a result of the risk factor, the eventual health outcome is realised 
(Deary et al., 2009).  Gow et al. (2012a), illustrate this when investigating the association 
between physical activity and cognition in older people; where despite finding an 
association, it could not be determined whether physical activity predicts cognitive status, 
or whether cognitive status predicts level of physical activity. Commenting on temporal 
relationships in observational research in general is problematic, especially in studies that 
investigate cognitive outcomes, as it may be that a superior cognitive ability in early 
adulthood directly impacts on healthier lifestyle choices throughout the course of an 
individual’s life, and in turn, may affect later life cognitive health outcomes. In these kinds 
of studies it is therefore advantageous to investigate, not only cross-sectionally but also 
longitudinally, where cognitive ability in late life takes into account the previous, childhood 
or peak cognitive ability. This approach provides support for a temporal relationship 
between a previous exposure and a later health outcome.  
Up to half of cases of Alzheimer’s disease are thought to be potentially attributable to 
modifiable risk factors (such as obesity, physical inactivity, hypertension, depression, 
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smoking, cognitive inactivity and diabetes), and it is predicted that this figure may be 
similar for all cause dementia (Barnes and Yaffe, 2011). In terms of cognitive decline, the 
Lothian Birth Cohort 1936, a general population cohort study of older people in Scotland, 
found that the main risk factors for declining cognitive ability across a 6 year period 
included age, male sex, childhood IQ and education level. They also found that general 
fitness, as measured by a composite of different physical activity measures, was associated 
with cognitive decline (Ritchie et al., 2016). The Edinburgh Artery Study, identified systemic 
markers of inflammation to be associated with decline in specific cognitive abilities 
(Rafnsson et al., 2007b), and also cardiovascular disease including stroke and myocardial 
infarction to be associated with cognitive decline (Rafnsson et al., 2007a) .  Other risk 
factors for cognitive decline often discussed in the literature include hypertension, hyper 
lipidaemia, smoking, depression, physical inactivity and obesity (Barnes and Yaffe, 2011, 
Plassman et al., 2010, Cooper et al., 2015, Beydoun et al., 2008, Anstey et al., 2011, Sofi et 
al., 2011, Blondell et al., 2014). 
 
1.7.2 Risk factors for cognitive decline in people with diabetes 
As people with type 2 diabetes are at increased risk of developing cognitive decline or 
dementia, a number of key risk factors have been identified in this high risk population. It is 
now fairly well established that the severity of diabetes in terms of impaired fasting glucose 
and insulin resistance are associated with  increased risk of dementia (Luchsinger, 2008, 
Cooper et al., 2015). Hypertension and heart disease has also be been identified as a risk 
factor for cognitive decline and dementia in people with type 2 diabetes (Xu et al., 2004, 
Cukierman-Yaffe et al., 2009). Depression was found be associated with dementia in people 
with diabetes by some (Katon et al., 2012); however, others found no association 
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(Koekkoek et al., 2013). It has been suggested that for depression and cognitive decline in 
diabetes bidirectional associations may exist (Biessels et al., 2014), for example depression 
may occur as a result of cognitive symptoms or vice versa.  
Elevated levels of systemic inflammatory markers have been identified as potential 
mediators of cognitive decline and dementia in people with diabetes (Mittal and Katare, 
2016). In particular, interleukin 6 (IL-6) and C reactive protein have been found to be 
associated with type 2 diabetes, whereby increased inflammation leads to insulin resistance 
(Hotamisligil, 2003). As Alzheimer’s disease is associated with insulin resistance, 
inflammation may be involved in diabetes related cognitive decline. 
Obesity has also been suggested to play a role in this inflammatory pathway as obesity is 
characterised as a chronic state of low level inflammation (Hotamisligil, 2003, Matarese et 
al., 2016), suggesting that obesity itself may be a key component of diabetes related 
cognitive impairment. Highlighted as an area of research that is as yet not fully understood, 
it has been suggested that obesity induced insulin resistance, hypertension, increased 
systemic inflammation, oxidative stress, and hypercholesterolaemia may all contribute to 
the association between obesity and cognitive decline in diabetes (Mittal and Katare, 2016).  
Obesity as a modifiable risk factor for diabetes related cognitive decline warrants further 
exploration (Biessels et al., 2014).   
Similar to obesity, physical activity levels have also been shown to influence levels of 
systemic inflammation (Edwards and Loprinzi, 2018), which in turn may affect cognitive 
processes. In the general population, the association between physical activity level and 
cognitive decline is not clear and some report that any observed protective effect of 
increased activity may be a result of reverse causation (Sabia et al., 2017), where preclinical 
dementia in the cohort results in lower physical activity. The effect of physical activity on 
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cognition in people with diabetes is not well understood. Studies are beginning to emerge 
that explore this topic which indicate that physical activity may be a protective factor for 
cognitive decline in this high risk population (Shih et al., 2018). This relatively new area of 
research provides a potential new avenue for finding alternative modifiable risk factors that 
may have influence on cognitive decline and dementia in diabetes (Callisaya and Nosaka, 
2017). 
The risk factors for cognitive impairments in people with diabetes are multifaceted and 
likely to be inter-related whereby one factor is influenced by another and may be related in 
varying degrees to either diabetes status or cognitive outcome (Strachan et al., 2011), and 
it is therefore important to explore possible associations in real world, large scale 
epidemiological studies that can look at individual as well as combinations of risk factors. 
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Chapter 2: Aims and Objectives 
2.1 Aims  
The aim of this thesis was to explore lifestyle-related, modifiable risk factors for cognitive 
decline and dementia in people with type 2 diabetes, focusing on obesity and physical 
inactivity and possible mediation of any association between these factors and cognitive 
outcomes by systemic inflammation. The main analyses aimed to determine whether 
systemic inflammation and/or obesity were associated with cognitive decline or incident 
dementia in older people with type 2 diabetes over a follow up period of 10 years and the 
independence of these associations. Additional analyses aimed to determine the 
association between physical inactivity and cognitive ability, both measured at the same 
time point.  
 
To meet these aims, a systematic review of the literature was carried out, presented in 
chapter 3. Following this, data were used from the Edinburgh Type 2 Diabetes Study, a 
representative cohort of community-dwelling, older people with type 2 diabetes.  
Longitudinal risk factor associations for cognitive decline and dementia over 10 years as 
well as cross-sectional associations as measured at baseline and at year 10 were assessed. 
The main outcome of interest was general cognitive change between baseline and year 10, 
which was further explored by the outcome of specific cognitive tests. Other outcomes of 
interest were incident dementia (recorded over 10 years), prevalent dementia (at year 10) 
and cognitive ability (measured at baseline and at year 10).  
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The analysis is presented in the thesis in three main sections in chapter 5.  The first section 
explores the longitudinal association between measures of obesity and cognitive decline, 
followed by the association between inflammation markers and cognitive decline. The 
second section explores the association between obesity, inflammation and dementia over 
time. The final section explores cross-sectional associations between physical inactivity and 
cognitive decline and dementia.  
 
2.2 Objectives 
1. To determine the longitudinal association of specific circulating markers of systemic 
inflammation with cognitive change and incident dementia over 10 years in older people 
with type 2 diabetes. 
2. To determine the longitudinal association of measures of obesity with cognitive change 
and incident dementia over 10 years in older people with type 2 diabetes, and to assess the 
possible role of inflammatory markers in any association . 
3. To determine the cross-sectional association between measures of physical inactivity and 
cognitive change and prevalent dementia in older people with type 2 diabetes. 
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Chapter 3: A systematic literature review on physical inactivity, 
sedentary behaviour and obesity as risk factors for cognitive 
decline in people with type 2 diabetes. 
In this chapter, the motivation for investigating the risk factors obesity and physical (in) 
activity and their association with cognitive dysfunction is explored. This is presented in the 




Several key risk factors have been shown to be associated with cognitive decline and 
dementia (Middleton and Yaffe, 2009). The association between diabetes and cognitive 
decline is now fairly well established based on both clinical and epidemiological evidence 
(Alafuzoff et al., 2009, Feinkohl et al., 2015) as well as experimental research (Bitel et al., 
2012).  A recent review provided an overview of the main risk factors thought to be 
associated with diabetes related cognitive impairment, highlighting glycaemic control, 
cerebral blood flow and inflammation as key contributing factors (Riederer et al., 2017). 
Another recent narrative review explored the association between modifiable risk factors 
and diabetes related cognitive decline, in which obesity and low levels of exercise were 
highlighted as key risk factors for cognitive decline in people with type 2 diabetes (Callisaya 
and Nosaka, 2017).  
To date, a comprehensive systematic literature review exploring the evidence for an 
association of obesity and physical (in) activity with cognitive decline and cognitive ability in 
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people with diabetes is lacking. Ideally, such a review would systematically evaluate the 
published and unpublished evidence linking measures of obesity and/or physical (in) 
activity with change in cognition, poorer cognitive ability at older age and the development 
of dementia over time and potentially inform strategies for introducing exercise and diet 
related health interventions aimed at improving cognitive health.  This chapter describes 
the systematic reviews I undertook as part of my doctoral work, although because of time 
and resource constraints, I was not able to consider unpublished data or to include 
independent data extraction by a second reviewer. 
 
3.2 Aim 
The aim was to determine whether there is an association of physical activity, sedentary 
behaviour or obesity with poorer cognitive ability, accelerated age related cognitive decline 
or the development of dementia in older people, aged 65 or more, with type 2 diabetes.  
 
3.3 Methods 
3.3.1 Eligibility criteria 
The following inclusion and exclusion criteria were developed in order to best address the 
review’s objectives.  
 
Types of studies 
All observational cross-sectional and longitudinal cohort studies investigating physical 
activity, sedentary time and body weight or size as risk factors associated with cognitive 
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status, cognitive decline, MCI or dementia in both males and females, aged 65 and over, 
living in the community with type 2 diabetes were included. Cross-sectional studies were 
included to capture studies investigating associations of the risk factors of interest with 
dementia prevalence or cognitive status in a diabetes cohort. Longitudinal studies were 
included to capture studies investigating associations of the risk factors of interest with 
dementia incidence or cognitive change in a diabetes cohort.  All other observational 
studies such as case control were excluded.  Randomised controlled trials (RCTs) were only 
included if the trial contained relevant cross-sectional/baseline data on (in) activity levels 
and cognitive status or the intervention was exercise based and carried out over a period of 
1 year or more, with relevant measurement of cognitive status.  All other RCTs were 
excluded.  
 
Types of participants 
 All adults diagnosed with type 2 diabetes aged 65 and over at baseline and/or follow-up 
(i.e. when cognitive status was measured) were included. For longitudinal studies, this cut-
off was applied because this is when age related cognitive change would likely start to 
appear. For cross-sectional studies, this cut-off was also applied, as the main interest of this 
review was to investigate cognitive health in later life. Predictor variables could be 
measured at any age, as I wanted to capture studies looking at premorbid lifestyle factors 
and how this affects cognitive outcomes later in life.  Community based studies as well as 
those based in a residential care setting were included.  
Studies that did not report a formal cognitive assessment or an assessment for clinical 
diagnosis of dementia or MCI in line with the Diagnostic and Statistical Manual (DSM) IV or 
V were excluded. Studies were also excluded if the study population was recruited on the 
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basis of possible mental health comorbidities (e.g. depression), as these may affect 
cognitive status or change. If a study was solely recruited on the basis of a specific physical 
health concern (e.g. heart disease) but included people with diabetes (e.g. as a sub group), 
the study was included, as were studies investigating other health comorbidities within a 
main diabetic cohort. If a study contained a mix of participants where only some met the 
inclusion criteria, it was included only if the publication had sufficient information on the 
study sub-population meeting the inclusion criteria. No restrictions were placed on 
ethnicity, region or other demographics relating to the study population. 
 
Report/publication characteristics 
All studies published up to and including 2018 were included. The search was limited to 
human studies. No restrictions were placed on publication status or language and when 
required, a translation was sought. 
 
3.3.2 Search strategy 
An electronic search was carried out on the 11th of January 2018, which was designed to 
capture all literature that met the eligibility criteria up until this date. The final search terms 
applied to the Ovid Medline database are shown in Figure 1. Similar searches were carried 
out on the same day in the databases PsychInfo, Embase, SportDiscuss. Manual searches of 
reference lists were carried out as were online searches of the journals: American Journal 
of Epidemiology, PLOS One, The Journal of Diabetes Research, Diabetes Care, 
Diabetologica, and International Journal of Epidemiology. This was done in order to capture 
articles that may have been incorrectly indexed or indexed with alternative key words or 
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spellings. This search was done using the following independent search terms: dementia, 
cognition, memory and intelligence.  These searches of the literature included both journal 
articles and conference proceedings. 
1 exp exercise/ or exp physical endurance/ or physical exertion/ or exp physical 
fitness/ or physical activity.mp. 
2 exp Sedentary Lifestyle/ or posture/ or sedentary.mp.  
3 sitting.mp. 
4 inactivity.mp. 
5 2 or 3 or 4 
6 body fat distribution/ or adipose/ or body mass index/ or body weight/ or 
overweight/ or obesity/ or waist circumference/ or skin fold thickness/ or waist-hip 
ratio/ 
7 exp cognition/ or intelligence/ or exp executive function/ or exp memory/ or exp 
problem solving/ or exp Cognitive Ageing/ or exp cognitive dysfunction/ or exp 
dementia/ or cognitive decline.mp. 
8 1 or 5 or 6 
9 7 and 8 
10 diabetes mellitus/ or exp diabetes mellitus, type 2/  
11 9 and 10 
12 limit 11 to (humans and "all adult (19 plus years)") 
Figure 1. Search terms for systematic review. Terms applied to Ovid Medline, 
11/01/2018. exp; explode term, mp.; multipurpose field. 
 
3.3.3 Selection of studies 
All abstracts from electronic searches were downloaded and checked for duplicates. Titles 
and abstracts were screened for eligibility and only the studies matching the pre-defined 
selection criteria were shortlisted. Articles meeting the selection criteria were then 
downloaded and assessed for eligibility by myself. Ideally a second independent researcher 
would have been consulted to verify if inclusion criteria was met, as per Cochrane 
guidelines (Higgins, 2011), however for the purposes of my thesis, this was not practical. 
Studies using the same data sets were linked to prevent duplication of data. 
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3.3.4 Data extraction and management 
Data were extracted from the final studies that matched the eligibility criteria using a data 
extraction form developed for this review. 
All literature searches and publications retrieved were stored using Endnote and saved on 
secure and frequently backed up servers. The data extraction form was electronic and 
created on Microsoft Excel. 
 
3.3.5 Risk of bias tool 
As no tool exactly meeting the needs of this review could be identified, a modified risk of 
bias tool, adapted from the Cochrane Tool to Assess Risk of Bias in Cohort Studies (The 
Cochrane Collaboration, 2012), was used to assess quality of each study that met the 
eligibility criteria. This quantified how reliable the results reported by the authors were. 
Two versions of the tool were developed for cross-sectional and longitudinal studies. The 
cross-sectional version of the modified tool is shown in Figure 2. Additional questions were 
incorporated for the longitudinal version of the tool which included; “Can we be confident 
that the outcome of interest was not present at the start of study?”, and “Was the follow-
up of cohorts adequate?”, which were scored in a similar way. Maximum scores differ per 
version where the cross-sectional version is out of 16 and the longitudinal version out of 20.  














No    
(-1) 
1 Was the population representative of the local 
diabetic population? 
    
2 Can we be confident in the assessment of 
exposure? 
    
3 Did the statistical analysis adjust for confounding 
variables? 
    
4 Can we be confident in the assessment of diabetes 
in the cohort? 
    
5 Was the study blinded?     
6a How well was cognition measured? I.e. Was a 
cognitive test battery used? 
    
6b Was a general cognitive variable calculated?     
7 Was effect size adequately reported?     
Figure 2. The modified risk of bias tool adapted from The Cochrane Collaboration (2012), 




3.4.1 Studies identified 
The systematic review search returned a total of 617 results which were exported to 
Endnote. A duplication check was run, which identified 78 duplicates leaving 539 articles 
which were screened by title and abstract. The systematic selection process is detailed in 
Figure 3. The title and abstract screening phase identified a further 10 duplicates, 78 review 
articles, 4 animal studies and 356 not relevant articles. This resulted in 91 articles being 
identified for full text screening. After examination of the article in full, 8 articles were 
rejected due to the outcome measure not being relevant, 44 were rejected due to the 
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predictor not being relevant, 2 were rejected as they were protocols for future studies that 
had not yet come to completion and 18 were rejected as they were either case control 
studies or trials where the authors failed to report any baseline analysis on the cohort. This 
resulted in a total of 23 publications that met the selection criteria. Four papers reported 
analysis on physical activity, 11 papers reported analysis on obesity and a further 4 
reported analysis of both physical activity and obesity.  
Of the articles identified, a total of 13 studies provide data on the association between 
obesity and cognitive ability in people with diabetes, 4 studies provide data on the 
association between obesity and cognitive decline in people with diabetes, 8 studies 
provide data on the association between physical activity and cognitive ability in people 
with diabetes and 1 study provided data on the association between physical activity and 




Figure 3. The systematic selection process used to identify publications included in this review after the removal of all duplicates.
  
3.4.2 Characteristics, risk of bias and findings of studies 
Specific characteristics and outcomes of each study are summarised in Tables 1 to 4. Risk of 
bias is summarised in Table 5. Table 1 summaries the characteristics and results of cross-
sectional studies identified by this search strategy exploring the association between 
obesity and cognitive ability. Table 2 summarises the characteristics and results of 
longitudinal studies exploring the association between obesity and cognitive decline. Table 
3 shows the characteristics and results of cross-sectional studies identified to be exploring 
the association between physical activity and cognitive ability and Table 4 shows the 
characteristics and result of the one longitudinal study identified that explored the 
association between physical activity and cognitive decline. No studies were found that 
investigated the association between sedentary behaviour and cognitive ability or decline. 
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Cognitive tests Result§ p-value 
Abbatecola et 
al. 




analysis of a 
prospective cohort 
Glucose 











not shown NS 









b=-0.326  0.013 

















mg/dl on two 
examinations 






















BMI Factor: all test 
scores 
















not shown NS 
Table 1. Studies exploring the cross-sectional association between obesity and cognitive ability 
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Cognitive tests Result§ p-value 
T2DM (ICD-9 
code) by a 
healthcare 
professional , 




within 6 months  
Factor: Immediate 
and delayed recall/ 
Recognition 
not shown NS 





























and delayed recall/ 
Recognition 
not shown NS 
Kim et al.  2008 60 Korean 
hospital 
outpatients 




None BMI Elderly verbal  
learning test 
not shown NS 
Simplified Rey 
figure test 
not shown NS 
Korean-Boston 
naming test (short) 
not shown NS 
Digit span forward not shown NS 
Digit span backward not shown NS 
Choice Reaction 
Time  
not shown NS 
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Cognitive tests Result§ p-value 
Cognitive Reaction 
Time 
r = 0.23 NS 
None WC Elderly verbal  
learning test 
r = -0.23 NS 
Simplified Rey 
figure test 
not shown NS 
Korean-Boston 
naming test (short) 
not shown NS 
Digit span forward r = -0.32 0.01 
Digit span backward not shown NS 
Choice Reaction 
Time  
r = 0.29 0.03 
Cognitive Reaction 
Time 







WC Digit span forward R2= 0.11 0.02 
Choice Reaction 
Time  
R2= 0.08 0.04 
Cognitive Reaction 
Time 
R2= 0.07 <0.05 







analysis of BL data 
in an RCT 
Medical 
diagnosis (5 
years or more) 








F (1,61) =9.17 
(ηp² = 0.13) 
0.004 
Self-efficacy test not shown NS 
Brief Self-control 
Scale 
F= 4.65  NS 
Greenwood et 
al. 
2003 22 Canadian trial 
participants 
Cross sectional 
analysis of BL data 







HDL, LDL, BP, 
Urea, 
Creatinine, 
BMI Logical Memory not shown NS 
TMTB not shown NS 
(presumed) 








Cognitive tests Result§ p-value 
Fasting Glucose, 
HbA1c. 










analysis of BL data 
in an RCT 





BMI Digit span forward not shown NS 
Digit span backward not shown NS 
Inspection time not shown NS 
Digit Symbol 
Substitution Test 
not shown NS 
TMTA not shown NS 
TMTB not shown NS 
Valiente-
Barroso et al. 
2015 59 Spanish 
hospital out-
patients 












BMI Stoop Word reading B= -0.197 <0.05 
Stroop Colour 
reading 
B= -0.217 <0.05 
Stroop Word-colour 
reading 
not shown NS 
Stroop Interference not shown NS 
Digits forward not shown NS 
Digits backwards not shown NS 
LNS not shown NS 
TMTA not shown NS 
MMSE not shown NS 
Lehtisalo et 
al. 























BMI CERAD b= -0.23  (95% CI 
-0.41, -0.04) 
0.011 
TMTA not shown NS 
WC CERAD b= -0.09  (95% CI 
-0.16, -0.02) 
0.012 
TMTA not shown NS 
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take place after 
13 years when 




Ciebiada et al. 
2014 276 Polish 
Hospital 
outpatients 
Cross sectional Medical 
diagnosis (1 


















BMI  MoCA not shown NS 
Rizzo et al. 2010 121 Italian 
hospital 
outpatients 
Cross sectional Medical 
diagnosis (1 





HbA1c, PPG, BG 
BMI MMSE B= -0.160  0.004 
Composite score B= -0.038 NS 
WHR MMSE B= -0.083  NS 
Composite score B= -0.102 NS 
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Cognitive tests Result§ p-value 
Espeland et 
al. 
2017 3802 American trial 
participants 
(BMI =/> 25 
kg/m2) 
Cross sectional 
analysis of BL data 
in an RCT, Action 










not shown NS 









None reported BMI MoCA not shown NS 
Trento et al. 2015 249 Italian trial 
participants 
Cross sectional 
analysis of BL and 










BMI MMSE not shown NS 
§ All associations are in the direction of higher BMI/WC/WHR/body fat associated with poorer cognition. B; standardised beta (regression analysis), b; unstandardised beta (regression 
analysis), r; coefficient of correlation (regression analysis), R2; squared correlation coefficient, F; F value (ANOVA), OR; Odds Ratio (regression analysis), T2DM; Type 2 Diabetes, BMI; Body 
Mass Index, WHR; Wait to Hip Ratio, WC; Waist Circumference, PA; Physical activity, MMSE; Mini Mental State Exam, MoCA; Montreal Cognitive Assessment, CERAD; Consortium to 
Establish Registry of Alzheimer’s Disease Assessment, TMT; Trail Making Task, LNS; Letter Number Sequencing, MCI; Mild Cognitive Impairment, HbA1c; Glycated haemoglobin, BG; Blood 
Glucose, BP; Blood Pressure, HBP; Hypertension, SBP; Systolic Blood Pressure, DBP; Diastolic Blood Pressure, LDL; Low Density Lipoprotein, HDL; High Density Lipoprotein, CRP; C Reactive 
Protein, IL-6; Interleukin 6, APOE 4;  Apolipoprotein E 4, MAGE; mean amplitude of glycaemic excursions, PPG; Postprandial glycaemia, RCT; Randomised Controlled Trial, BL; Baseline, FU; 
Follow-Up, ICD-9; International Classification for Disease 9, NS; Non-significant. It should be noted that p-values are reproduced according to how they were reported in original 
publications. 
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Author Year N at 
baseline 


















data on T2DM 
2 Glucose 
tolerance 















b= -0.021 (SE 
0.022) 
NS 








b= -2.264 (SE 
0.955) 
0.042 








b= -0.020 (SE 
0.010 
0.02 








b= -1.085 (SE 
0.295) 
0.002 
Table 2. Studies exploring the longitudinal association between obesity and cognitive decline 
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Author Year N at 
baseline 























































BMI CDT b= -0.53 (-
1.03- -0.04)  
<0.05 
MMSE not shown NS 













BMI MMSE not shown NS 
§ All associations are in the direction of higher BMI/WC/WHR/body fat associated with poorer cognition. B; standardised beta (regression analysis), b; unstandardised beta (regression 
analysis), r; coefficient of correlation (regression analysis), F; F value (ANOVA), OR; Odds Ratio (regression analysis), HR; Hazard Ratio, T2DM; Type 2 Diabetes, BMI; Body Mass Index, WHR; 
Wait to Hip Ratio, WC; Waist Circumference, PA; Physical activity, MMSE; Mini Mental State Exam, CDT; Clock Drawing Test, HbA1c; Glycated haemoglobin, BP; Blood Pressure, HBP; 
Hypertension, SBP; Systolic Blood Pressure , LDL; Low Density Lipoprotein, HDL; eGRF; Estimated Glomerular Filtration Rate, NS; Non-significant. It should be noted that p-values are 
reproduced according to how they were reported in original publications. 
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Author Year N Population Study 
design 
Diabetes criteria Adjustments Physical activity 
measure 
Cognitive tests Result§ p-value 
Devore et 
al. 







check of a 
sample) 
Age, education, use of 
antidepressants, 
alcohol, smoking, 
duration of diabetes, 
diabetic medication, 
BMI, BP, cholesterol, 
MI, coronary bypass , 





balance problems, body 


















fluency, TICS 10 
word list immediate 














delayed recalls, TICS 
























and fasting BG 
(>200 mg/dL) 









Medical diagnosis Age, sex, education, 
diabetes type, duration 




Word reading B= 0.346  <0.01 
Colour reading B= 0.311 <0.01 
Word-colour 
reading 
B= 0.305 <0.01 
Table 3. Studies exploring the cross-sectional association between physical activity and cognitive ability 
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Author Year N Population Study 
design 
Diabetes criteria Adjustments Physical activity 
measure 
Cognitive tests Result§ p-value 
hypercholesterolemia, 
depression. 
Interference NS NS 
Digits forward B= 0.367 <0.001 
Inverse backwards B= 0.394 <0.001 
LNS B= 0.330 <0.001 
TMTA B= 0.274 <0.01 
MMSE B= 0.400 <0.01 
Lehtisalo 
et al. 
















does not exclude 
non- diabetics as 
originally a 
prevention study 




take place after 
13 years when 
46% are now 
classed as 
diabetic) 
Age, education, sex, 






CERAD b= 0.26 (-
0.05- 0.57) 
0.04 
TMTA not shown NS 
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Author Year N Population Study 
design 
Diabetes criteria Adjustments Physical activity 
measure 









(1 year or more) 
Age, sex, education, 
marital status, smoking, 
duration of diabetes, 







Lack of physical 
activity question 
MoCA not shown NS 





(1 year or more) 
Age, sex, Medication, 
PA, MAGE (glucose), 




MMSE not shown NS 
Composite score not shown NS 








(1 year or more) 
Sex, ethnicity, age, 
health literacy, self-
efficacy for exercise, 
health care support 
level 
CHAMPS Positive Transfer of 
Past Experience 
from the Diabetes 
Problem-Solving 
Scale of Hill Briggs 
not shown NS 









Medical diagnosis Not reported LLFDI Frequency Keep Track not shown NS 
N-back not shown NS 
TMTA not shown NS 
Local Global not shown NS 
Stroop not shown NS 
Hayling not shown NS 
Rey Osterrieth Copy not shown NS 
Rey Osterrieth 
Recall 
r= 0.32 0.04 
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Author Year N Population Study 
design 
Diabetes criteria Adjustments Physical activity 
measure 
Cognitive tests Result§ p-value 
Wechler Immediate not shown NS 
Wechler Delayed not shown NS 
§ All associations are in the direction of lower physical activity associated with poorer cognition. B; standardised beta (regression analysis), b; unstandardised beta (regression analysis), r; 
coefficient of correlation (regression analysis), F; F value (ANOVA), OR; Odds Ratio (regression analysis), BMI; Body Mass Index, LTPA; Leisure Time Physical activity, CHAMPS; Community 
Healthy Activities Model Program for Seniors questionnaire, MMSE; Mini Mental State Exam, TICS; Telephone Interview for Cognitive Status,  MoCA; Montreal Cognitive Assessment, 
CERAD; Consortium to Establish Registry of Alzheimer’s Disease Assessment, TMT; Trail Making Task, LNS; Letter Number Sequencing, HbA1c; Glycated haemoglobin, BG; Blood Glucose, 
BP; Blood Pressure, HBP; Hypertension, SBP; Systolic Blood Pressure, DBP; Diastolic Blood Pressure, APOE 4;  Apolipoprotein E 4, MAGE; mean amplitude of glycaemic excursions, PPG; 
Postprandial glycaemia, MI; Myocardial Infarction, TIA; Transient Ischaemic Attack, RCT; Randomised Controlled Trial, TUG; Timed Up and Go Test, LLFDI; Late Life Function and Disability 
Index, KIHD; Kuopio Ischemic Heart Disease questionnaire, NS; Non-significant. It should be noted that p-values are reproduced according to how they were reported in original 
publications. 
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Author Year N at 
baseline 






























BP, cholesterol, MI, 
coronary bypass, 








walking ability.  














fluency, TICS 10 word 
list immediate and 









LTPA  Verbal memory (East 
Boston Memory Test 
immediate and 
delayed recalls, TICS 










§ All associations are in the direction of lower physical activity associated with poorer cognition. B; standardised beta (regression analysis), r; coefficient of correlation (regression analysis), 
F; F value (ANOVA), OR, Odds Ratio (regression analysis), BMI; Body Mass Index,  LTPA; Leisure Time Physical activity questionnaire, BP; Blood Pressure, MI; Myocardial Infarction, TIA; 
Transient Ischaemic Attack, TICS; Telephone Interview for Cognitive Status, NS; Non-significant. It should be noted that p-values are reproduced according to how they were reported in 
original publications. 
Table 4. Studies exploring the longitudinal association between physical activity and cognitive decline 
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Table 5. (a) Risk of bias in reporting in the cross -sectional studies 
Study Year 1 2 3 4 5 6a 6b 7 TOTAL 
Abbatecola et al. 2010 1 2 1 2 1 1 1 1 10 
Espeland et al. 2017 -1 2 0 2 1 1 0 1 6 
Greenwood et al. 2003 0 2 2 2 1 1 0 1 9 
Kim et al. 2008 2 2 2 2 0 2 1 0 11 
Kroes et al. 2012 2 2 2 2 0 1 0 1 10 
Niu et al. 2013 -1 2 -1 2 0 0 0 0 2 
Pearce et al. 2012 1 2 1 2 0 1 0 1 8 
Trento et al. 2015 1 2 1 2 0 0 0 1 7 
West et al. 2016 2 2 2 2 0 2 1 0 11 
Devore et al. 2009 1 2 1 1 0 2 1 1 9 
Ferreira et al. 2014 2 2 -1 2 0 0 0 0 5 
King et al. 2010 1 2 1 1 0 0 0 0 5 
Rucker 2014 0 2 -1 1 0 2 0 0 4 
Gorska-Ciebiada et al. 2014 2 1 2 2 0 0 0 0 7 
Lehtisalo et al. 2016 1 2 1 2 0 2 1 1 10 
Rizzo et al. 2010 2 1 1 2 0 1 1 0 8 
Valiente-Barroso et al. 2015 2 1 1 1 0 2 0 0 7 
1 Was the population representative of the local diabetic population? 
2 Can we be confident in the assessment of exposure? 
3 Did the statistical analysis adjust for confounding variables? 
4 Can we be confident in the assessment of diabetes in the cohort? 
5 Was the study blinded? 
6a How well was cognition measured? I.e. Was a cognitive test battery used? 
6b Was a general cognitive variable calculated? 
7 Was effect size adequately reported? 
Values are scaled; 2, yes; 1, probably yes; 0, probably no; -1, definitely no. Total score is 
out of 16. 
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Table 5. (b) Risk of bias in reporting in the longitudinal studies 
Study Year 1 2 3 4 5 6 7a 7b 8 9 TOTAL 
Abbatecola et al. 2010 1 2 1 1 2 1 1 1 2 1 13 
Herghelegiu et al. 2016 -1 2 2 1 2 0 0 0 2 2 10 
Hu et al. 2012 2 2 1 1 1 0 2 1 2 1 13 
Trento et al. 2015 1 2 1 1 2 0 0 0 0 1 8 
Devore et al. 2009 1 2 1 1 1 0 2 1 2 1 12 
1 Was the population representative of the local diabetic population? 
2 Can we be confident in the assessment of exposure? 
3 Can we be confident that the outcome of interest was not present at the start of 
study? 
4 Did the statistical analysis adjust for confounding variables? 
5 Can we be confident in the assessment of diabetes?  
6 Was the study blinded? 
7a How well was cognition measured? I.e. Was a cognitive test battery used? 
7b Was a general cognitive variable calculated? 
8 Was effect size adequately reported? 
9 Was the follow-up of cohorts adequate? 
Values are scaled; 2, yes; 1, probably yes; 0, probably no; -1, definitely no. Total score is 
out of 20. 
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Characteristics of studies 
The studies included were mostly observational cohort studies, recruiting from hospital 
clinics from all over the world. A number were studies that reported baseline cross-
sectional data from a randomised controlled trial. Most studies report cross-sectional 
analyses, however a number also report analysis on longitudinal data. Of these studies the 
majority were analyses using prospective cohorts. There was a wide range of sample sizes, 
ranging from 22 (Greenwood et al., 2003)  to 44660 (Hu et al., 2012). Predictor variables 
varied with BMI being the most common measure of obesity and physical activity measured 
by some form of questionnaire based assessment. Outcome variables also varied with a 
large proportion of studies measuring cognitive ability using the MMSE. The majority of 
studies made effort to make adjustments to their models for age and sex, and some 
adjusted further to include vascular and diabetes covariates. Some studies did not make 
any adjustments to their models. 
 
Risk of Bias 
Most studies were selected from the local diabetic population, with a number of studies 
using trial participants or making no mention of how or if a random sample was used. All 
studies used validated obesity measures and most used validated physical activity 
measures, with the exception of a few who made no mention or created their own measure 
of physical activity (Gorska-Ciebiada et al., 2014, Valiente-Barroso et al., 2015). The 
majority of longitudinal studies had specific exclusion criteria that ensured cognitive 
impairment or dementia was not present at baseline, however one study actively recruited 
people with MCI (Niu et al., 2013) and some failed to mention what steps had been taken. 
Most studies made basic adjustments in their statistical models while some did not adjust 
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or made no mention (Ferreira et al., 2014, Niu et al., 2013, Rucker, 2014). Many of the 
studies fully adjusted for many covariates in their statistical models. All studies made 
appropriate efforts to ensure that the population had diabetes. Few of the studies 
mentioned blinding and a relatively small number of studies used a comprehensive 
cognitive test battery to assess cognitive status, some opting to use a dementia screening 
tool. This in turn limited the number of studies that used a general cognition variable (for 
example derived though principal component analysis (PCA)) to determine overall cognitive 
ability. Longitudinal studies had a range of follow-up time with some studies having as 
much as 10 years and some at little as 18 months. 
 
3.4.2.1 Findings: Obesity and cognitive ability 
Of 13 studies that explored the association between obesity and cognitive ability, all 13 
measured obesity using BMI, 4 also measured waist circumference (WC), 2 measured waist 
hip ratio (WHR) and 1 measured body fat. A variety of cognitive tests were used to assess 
cognitive ability in different cognitive domains and also to measure general cognitive 
function.   
 
BMI and cognitive ability 
Five studies showed an association between increased BMI and poorer cognitive ability as 
measured by at least one of a number of cognitive tests and 8 studies showed no 
association. Between these studies there was little difference in risk of bias scoring (range 2 
to 11 out of maximum score of 16), though some studies had limited sample size (e.g. 
(Greenwood et al., 2003, Pearce et al., 2012)). Greenwood et al. (2003) showed an 
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association between increased BMI and poorer cognitive ability when using the Rey 
Auditory Verbal Learning test (p=0.03), in 22 men and women from a Canadian trial of the 
effect of diet on cognitive performance. A similar result was seen by Valiente-Barroso et al. 
(2015) who showed an association between increased BMI and poorer cognitive ability as 
measured by both the Stroop Word and Colour reading tasks (both p<0.05), in 59 male and 
female Spanish outpatients. Lehtisalo et al. (2016) showed an association between 
increased BMI and poorer cognitive ability, as measured by the Consortium to Establish 
Registry of Alzheimer’s (CERAD) test battery (p=0.01), in 364 men and women enrolled in 
the Finnish Diabetes Prevention Study. Rizzo et al. (2010) also showed an association 
between increased BMI and poorer cognitive ability, as measured by the MMSE (p<0.01), in 
121 Italian male and female outpatients. Lastly, Kroese et al. (2013) showed an association 
between increased BMI and poorer cognitive status (p=0.004), as measured by a subtest of 
the Utrecht Proactive Coping Competence Scale, in 64 men and women enrolled in the 
Dutch Good Intentions trial. Kroese et al. (2013) reported that they used this test as a way 
to measure cognitive status, however this test is not a conventional way to measure 
cognition. After deliberation, the article was included in the results because proactive 
coping, defined as anticipating and understanding a future negative event, may be 
considered a quantifiable cognitive task (Tielemans et al., 2014), as cognitive processes 
such as problem solving and executive functioning are likely to be involved in this. 
Furthermore, this study, despite having a small sample size, scored well in the risk of bias 
assessment.  
Despite these significant associations between BMI and cognitive ability, 8 studies found no 
statistically significant BMI-cognitive ability association and 3 found mixed results 
depending on the cognitive test battery used. The majority of these studies finding non-
significant and/or inconsistent results scored equally highly on the risk of bias assessment. 
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Waist circumference (WC) and cognitive ability 
All 4 studies which used WC as a measure of obesity showed an association between 
increased WC and poorer cognitive ability as measured by at least one of a number of 
cognitive tests. Between these studies there was little difference in risk of bias scoring 
(range 10 to 11 out of a maximum of 16), though one study had small sample size (Kim et 
al., 2008) compared to that of the others. West et al. (2016) showed an association 
between increased WC and lower cognitive ability (p=0.003) in women but not in men, as 
measured by a factor score derived from a number of cognitive tests capturing multiple 
cognitive domains, in 897 participants in the Israel Diabetes and Cognitive Decline Study. 
Abbatecola et al. (2010), showed an association between increased WC and poorer 
cognitive ability (p=0.013) when using a composite score of multiple cognitive tests as well 
as when using the MMSE dementia screen (p=0.041), in 253 male and female Italian 
outpatients. Similarly, Lehtisalo et al. (2016) showed an association between increased WC 
and poorer cognitive ability (p=0.012), in 364 men and women enrolled in the Finnish 
Diabetes Prevention Study, as measured by the CERAD test battery and Kim et al. (2008) 
showed an association between increased WC and poorer cognitive ability when using the 
Digit span forward, Choice Reaction Time and Cognitive Reaction time tests (all p<0.05), in 
both unadjusted and fully adjusted models of Korean male and female outpatients. It 
should be noted that 3 out of the 4 studies exploring the associations between WC and 
cognition also found non-significant associations when employing different cognitive tests 
to measure cognitive ability, namely TMTA and Digits span tests were shown to be non-
significantly associated with the predictor WC (Lehtisalo et al., 2016, West et al., 2016, Kim 
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et al., 2008). All of the studies exploring the association between WC and cognitive ability 
scored highly on the risk of bias assessment.   
 
WHR and cognitive ability 
One study showed an association between increased WHR and poorer cognitive ability as 
measured by at least one of a number of cognitive tests and 1 study showed no association. 
Both studies scored similarly in the risk of bias assessment (8 and 10 out of a maximum of 
16), with one (Abbatecola et al., 2010) having a slightly larger sample size. In the latter 
study, Abbatecola et al. (2010) showed an association between WHR and cognitive ability in 
both a general cognitive ability composite score and the MMSE (both p=0.04), in 253 male 
and female Italian outpatients. In contrast to this, Rizzo et al. (2010) in a similar study did 
not find a statistically significant association between WHR and either their general 
cognitive ability composite score or MMSE, in 121 Italian male and female outpatients.   
 
Body fat and cognitive ability 
Only 1 study showed an association between increased body fat and poorer cognitive 
ability, as measured by at least one of the cognitive tests and this study scored relatively 
highly in the risk of bias assessment (10 out of 16). No other studies were identified that 
explored this association. Abbatecola et al. (2010), found an association between increased 
body fat and poorer cognitive ability as measured by their general cognitive ability 
composite score (p=0.033), in 253 male and female Italian outpatients. However they did 
not find an association between body fat and cognitive ability as measured by the MMSE.  
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3.4.2.2 Findings: Obesity and cognitive decline 
Of 4 studies that explored the association between obesity measures and cognitive decline, 
all four measured obesity using BMI, and 1 study used BMI alongside WHR, WC and body 
fat to measure obesity.  
Two studies showed an association between increased BMI and cognitive decline as 
measured by at least one of a number of cognitive tests and 2 studies showed no 
association. Between these studies there was some difference in risk of bias scores (range 8 
to 13 out of a maximum of 20) and all studies had reasonable sample sizes. Herghelegiu et 
al. (2016) showed an association between increased BMI and a decline in ability in 
completing the clock drawing test (p<0.05) in 360 Romanian male and female geriatric/ 
gerontology inpatients over an 18 month follow-up period. Hu et al. (2012) measured 
cognitive decline by recording dementia diagnoses and found a positive association 
between BMI and incident dementia diagnosis (p<0.001), in a cohort of 44660 American 
male and female outpatients, over a 10 year follow-up period. In contrast to these results, 
Abbatecola et al. (2010) and Trento et al. (2015), both found there to be no statistically 
significant association between BMI and cognitive decline in different studies (n=253 and 
n=249, respectively) on male and female Italian outpatients. In assessing cognitive decline, 
both authors used MMSE as an indication of cognitive ability and, in addition, Abbatecola et 
al. (2010) also used a composite score of the results of cognitive tests measuring executive 
functioning and attention. This non-significant association between BMI and decline in 
MMSE score was also found by Herghelegiu et al. (2016).  Of these studies, Abbatecola et 
al. (2010) and Hu et al. (2012) both scored highly in the risk of bias assessment, in contrast 
to the studies by Herghelegiu et al. (2016) and Trento et al. (2015) who both scored lower 
on the assessment. It should be noted that the paper by Abbatecola et al. (2010), contained 
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an error in the reporting of their results, and after contacting the authors and journal I was 
provided with comment on the issue and correct data were provided, which is reported in 
the results table in this thesis chapter. 
Only 1 study was identified that explored the association between WHR, WC and body fat 
and cognitive decline in 253 Italian men and women (Abbatecola et al., 2010). This study 
scored relatively high on the risk of bias assessment (13 out of 20) and showed an 
association between increased WHR and cognitive decline in both the MMSE and 
composite score (both p=0.04), an association between increased WC and cognitive decline 
in both the MMSE and composite score (p=0.04 and p=0.02, respectively) and also an 
association between increased body fat and cognitive decline in both the MMSE and 
composite score (p=0.04 and p=0.002, respectively). No other studies were identified that 
measured obesity using WHR, WC or body fat in people with type 2 diabetes. 
 
3.4.2.3 Findings: Physical activity and cognitive ability 
Six studies showed an association between lower physical activity and poorer cognitive 
ability as measured by at least one of a number of cognitive tests and 3 studies showed no 
association. Between these studies there was a range of scores in the risk of bias 
assessment outcome (3 to 10 out of a maximum of 16), and some studies had very small 
sample sizes.  Devore et al. (2009) scoring relatively highly on the risk of bias assessment, 
showed an association between lower leisure time physical activity level and poorer 
cognitive ability as measured by the Telephone Interview for Cognitive Status (TICS), a 
screening tool for dementia (p=0.03), in 1550 American female nurses. Valiente-Barroso et 
al. (2015) also showed an association between lower score on their exercise questionnaire 
and lower MMSE score (p<0.01), along with the rest of their test battery (all p<0.01) in a 
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Spanish cohort of male and female outpatients. Rucker (2014), showed an association 
between physical activity as measured by the Late Life Function and Disability Index (LLFDI) 
and the Rey Osterrieth Recall test (p=0.04), in a different group of 40 American outpatients. 
All of these studies scored considerably lower on the risk of bias assessment, compared to 
Devore et al. (2009). 
Despite these statistically significant associations, 5 of these authors had mixed results 
where some analyses were significant while others were not depending on the predictor or 
outcome variables used, and a further 3 found no associations between physical activity 
and cognitive ability in any of their analyses. These studies also had wide range of scores on 
the risk of bias assessment, suggesting that not all findings are equally reliable. 
 
3.4.2.4 Findings: Physical activity and cognitive decline 
Only one study, by Devore et al. (2009), was identified that looked at the effect of physical 
activity on cognitive decline in people with type 2 diabetes. This study scored 12 out of 20 
in the risk of bias assessment and had a large sample size, although only of women.  No 
statistically significant association was found between leisure time physical activity level 
(LTPA) and cognitive decline in a cohort of 1550 American female nurses with type 2 
diabetes. The authors used three different cognitive test batteries to assess cognitive 
ability, namely the Telephone Interview for Cognitive Status (TICS), a verbal memory 
battery that included the East Boston Memory Test immediate and delayed recalls and the 
immediate and delayed recall word lists of the TICS, and a global cognitive functioning score 
that included the immediate and delayed recalls and category fluency of the East Boston 
Memory Test and the immediate and delayed word lists and digit span backwards from the 
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TICS. There was no statistically significant association between LTPA and any of the 3 test 
batteries, TICS, verbal memory and global scores, over a period of 2 year follow-up.  
It should be noted that no studies were identified that investigated the effect of sedentary 
behaviour or sitting on cognitive decline. 
 
3.5. Discussion 
In general, findings from studies exploring the association between obesity and cognitive 
ability and/or decline in people with type 2 diabetes were inconsistent.  Although some 
studies did find a statistically significant association between increased BMI and poorer 
cognition cross-sectionally in people with type 2 diabetes, a majority of studies failed to 
show any association, or had inconsistent results depending on which cognitive test was 
used to assess cognition.  Similarly inconsistent results were found for studies investigating 
BMI and cognitive decline over time. Only a limited number of studies were identified that 
explored the association between other obesity measures such as WC, WHR and body fat 
and cognitive ability and/or decline in people with type 2 diabetes. Generally, these studies 
were more consistent in suggesting an association between these measures and cognitive 
ability, although there was still a reasonable degree of variability in findings between 
studies. For example, the two studies which explored the association between WHR and 
cognitive ability had opposing results, despite relatively similarly methodology and study 
populations.  Only one study explored the association between obesity measures other 
than BMI and cognitive decline longitudinally. This study found that an increased WHR, WC 
and body fat were associated with cognitive decline. 
Overall, given that there are so few studies, with a range of different obesity and cognitive 
measures used, it is difficult to assess the likelihood of a true association between obesity 
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and cognitive deficits and further work is needed before any firm conclusions on any such 
association can be drawn. 
The outcomes of studies exploring the association between physical activity level and 
cognitive ability and/or decline in people with type 2 diabetes were also mixed. Some 
associations were found by authors exploring associations of physical activity level with 
cognitive ability however most authors found mixed results when using different cognitive 
measures. No association was found between physical activity level and cognitive decline 
longitudinally, however as only one study explored this association, more work is needed to 
confirm this finding. It should also be noted that no studies were identified that 
investigated the effect of sedentary behaviour or sitting on cognitive ability or cognitive 
decline over time. 
 
3.5.1 Notable features of the studies 
A notable feature of all studies is that the cognitive test batteries used were all very 
different and also that many studies only measured cognition with one test. When only 
relying on one cognitive test to reflect an individual’s general cognitive ability, this test 
needs to have been shown to correlate highly with general cognition, often by indicating 
that it has a high factor loading onto a latent cognitive variable (Spearman, 1904). Such 
tests include trail making tasks, digit symbol coding and letter number sequencing which a 
number of authors included in this review have used. However, others failed to use tests 
commonly known to contribute to general cognition and a number of studies failed to 
justify their selection of cognitive test (Herghelegiu et al., 2016, King et al., 2010, Rizzo et 
al., 2010, Trento et al., 2015).   
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Another notable feature was that the number and type of adjustments made in each 
cognitive model were different for each study. The majority adjusted for age and sex 
amongst others, however some made no mention of adjustments (Ferreira et al., 2014, Kim 
et al., 2008, Niu et al., 2013, Rucker, 2014). This impacts the ability to compare results 
across different studies with confidence. 
In general, the vast majority of studies exploring associations between obesity and 
cognitive ability or decline used only BMI as their measure of obesity and other measures 
such as WHR and WC were neglected. This observation is of particular importance as the 
one study that was of relatively high quality, and also explored the association of multiple 
obesity variables found that it was WHR, WC and body fat that were significantly associated 
with cognitive decline, as opposed to BMI, where no association was found (Abbatecola et 
al., 2010). These results should be further explored as they indicate that all these different 
measures of obesity may not be measuring the same phenotype. 
One study also used a population of patients with MCI with diabetes, and explored the 
association between BMI and cognitive ability in this group (Niu et al., 2013). This study 
showed a non-significant result, which should be interpreted with caution as the cognitive 
ability range in this group is very limited, if they all have MCI or pre-dementia, and so it is 
not surprising that no significant associations were found.   
Caution should also be exercised when interpreting the result from the study exploring the 
association of BMI and WC on cognitive ability in people with diabetes and prediabetes 
(Lehtisalo et al., 2016). This study initially recruited people with prediabetes, while data 
collection took place 13 years after initial recruitment with 46% of the population at this 
stage formally diagnosed with diabetes. Although no subgroup analysis was carried out on 
the people with confirmed diabetes, the study was included in the final results table. The 
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reason for inclusion was that as this population did have blood glucose impairments, albeit 
mild (5.6-7.0mmol/l), it could be argued that any associations found in this population 
would likely be exacerbated in a fully diabetic population.  
Caution should also be taken when interpreting the results presented by studies with very 
small numbers of study participants. One study included in this review only had 22 
participants (Greenwood et al., 2003), which is problematic when considering the role of 
chance. This was a cross-sectional analysis of the baseline characteristics of participants 
who were involved in an RCT which gave information on the association between physical 
activity and cognitive ability. In order to find variation in a sample, where the effect size is 
likely to be small, the number of participants needs to be large enough to be able to 
identify if any differences are statistically significant and likely not due to random variation 
or chance alone (Hackshaw, 2008). The study by Greenwood et al. (2003), was included in 
this review despite its small sample size after some consideration. The review set out to 
identify all studies that investigated activity or obesity related risk factors on cognition and 
for completeness this study was identified though the search strategy, as small sample size 
was not part of the exclusion criteria. Furthermore, by including this study, it was 
highlighted that there were not many publications on this specific risk factor and outcome 
in people with diabetes and showed that of those identified an even more limited number 
were of a robust sample size to be useful, placing the results of others in some form of 






3.5.2 Strengths and limitations of this review  
The search strategy used in this review was developed to capture all studies that 
investigated the role of obesity and physical activity measures on cognitive outcomes. 
Despite efforts made to include a variety of search terms and the use of MeSH terms when 
possible, studies may have been missed due to multiple or incorrect spellings or other 
phrasings of terminology used by authors. It should also be noted that not all possible 
cognitive outcomes, specifically the names of individual cognitive tests, were entered as 
search terms. The latter may have improved the sensitivity of the search but was not done 
due to the vast numbers of possible cognitive tests in existence, which made developing 
this sort of comprehensive search impractical. Another limitation of the search strategy 
may have been the use of “dementia” as an umbrella term instead of the different 
dementia sub-types such as Alzheimer’s disease, vascular dementia and others, as authors 
may have used these more specific terms.  A variety of databases were searched along with 
hand searching of selected journals, in the hope of finding additional articles to those 
retrieved by the principal Medline database search. Although the majority of relevant 
studies will be identified though Medline and other search methods, articles that are 
unpublished or only internally published, are incorrectly indexed, or where the abstract is 
not translated to English would be missed by this search strategy. 
The main conclusion of this review is that there appears to be a general lack of studies that 
explore obesity and physical activity as risk factors for cognitive decline in people with 
diabetes, demonstrating that this topic is under-researched and that further work is needed 
before any robust conclusions can be drawn. Similarly, the observation that no results were 
found on the association between sedentary behaviour and cognitive ability or change in 
cognitive ability in people with type 2 diabetes was surprising.  This indicates that either the 
71 
search strategy (despite employing search terms such as “sitting” and “sedentary”) may not 
have been sufficient to capture all possible studies on this topic or that there is a lack of 
research in this area. 
When comparing the results of the individual studies identified by this review, the main 
observation is that the lack in comparable methodology makes carrying out a meta-analysis 
impossible. The studies all measured their outcome of cognitive ability or change in 
cognitive ability in different ways. A relatively large number used the MMSE test as one 
outcome, but as this is only a dementia screen and not a comprehensive test of cognitive 
ability, meta-analysis on this selected outcome would not necessarily be helpful in 
addressing the aims of this review. Two studies used dementia diagnosis as a cognitive 
outcome. Caution must be taken when interpreting these results grouped with results of 
other cognitive outcomes because cognitive decline occurs as part of the natural aging 
process, while dementia is a clinical disease state and the two definitions of cognitive 
impairment need not capture the same outcome. In this review, if the study design was 
longitudinal, dementia as an outcome was grouped with other studies of cognitive decline, 
and if the study design was cross-sectional, dementia as an outcome was grouped with 
other studies of cognitive status. 
Physical activity was also measured in many different ways by the studies identified, and so 
a need for comparable physical activity measures to be adopted by authors is also 
highlighted by this review.  For the purposes of this review, the data extraction was carried 
out by one researcher, which can lead to biases in reporting and selection of results. Having 
a second independent researcher carry out parallel data extraction would have helped to 
address this problem and would have improved the overall quality of this review. 
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3.5.3 Future research 
The field of diabetes-related cognitive decline in terms of the modifiable risk factors obesity 
and physical activity, is under-researched. In general, more high-quality, longitudinal 
studies are needed to address whether associations exist or not. More specifically, future 
research needs to focus on the effect of different obesity variables, such as WHR and WC as 
well as BMI, on cognitive outcomes. In order to explore the mixed nature of the results 
presented in this review, future research also needs to explore both global cognitive 
outcomes as well as domain specific analysis, to determine whether risk factors affect 
overall cognition or whether certain abilities are affected more so than others.  
Additionally, future research should also be carried out on sedentary behaviour in addition 
to physical activity, as this area seems to have been identified as a new field of research as 
yet unexplored. 
Lastly, it should be noted that as in all observational studies, the results of the studies 
shown here only provide information on possible biological associations, and, while 
longitudinal studies provide some indication of temporal associations,  these cannot be 
used to infer causal relationships. Clinical trials, carried out over a reasonable period of 




This systematic literature review presents current epidemiological evidence on the 
association of obesity and physical activity with cognitive ability and cognitive decline in 
older people with type 2 diabetes. I found limited evidence for an association of obesity 
with both cognitive ability and cognitive decline and for an association of physical activity 
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with the same outcomes in people with type 2 diabetes. Due to inconsistencies in 
methodology, reporting and findings, it is not possible to draw any definite conclusions on 
the validity or strength of these associations. In particular, methods of measuring cognition 
varied widely between studies and it is possible that different cognitive domains, as 
measured by the variety of different individual cognitive tests used, are associated with 
either obesity or physical activity to different extents. Good quality, large scale 
epidemiological studies that test cognitive ability and change in cognitive ability over time 
by means of a comprehensive cognitive test battery that can be used to create a general 
cognitive ability variable alongside individual domain analysis are therefore needed in order 
to determine associations with confidence.  
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Chapter 4: Methods 
This chapter describes the design and methodology of the Edinburgh Type 2 Diabetes Study 
(ET2DS). This includes details of the data collection relevant to this thesis, especially the 10 
year follow-up phase which I undertook myself.  The statistical methodology used to 
analyse the data is also described.  
 
4.1 The Edinburgh Type 2 Diabetes study 
The ET2DS is a population-based prospective cohort study set up in 2006/2007 of 1066 men 
and women aged between 60 and 75 years at baseline with type 2 diabetes, living in the 
Lothian region in Scotland. The primary objective of the ET2DS was to explore associations 
between potentially modifiable risk factors and cognitive decline in people with type 2 
diabetes (Price et al., 2008). The majority of other large prospective cohort studies of 
cognitive ageing recruit from the general population. The ET2DS provides a rare and 
valuable opportunity to investigate risk factors for cognitive decline, exclusively in people 
with diabetes, thereby allowing for in-depth analysis on specific potential underlying causes 
of cognitive decline in this high risk population. The ET2DS has had 4 main phases of data 
collection to date: a baseline clinic (2006/2007), a liver sub-study clinic (2007/2008), a year 
4 clinic (2010/2011), and a cardiovascular events record linkage update (2015/2016).  For 
the purposes of this thesis, I undertook a further follow-up phase, including year 10 clinic 
(2016/2017) and the focus of this chapter and my subsequent analysis is on this latest data 
collection phase. The study protocol by Price et al. (2008), provides a detailed description of 
the early phases of the ET2DS and this is used below along with other publications to 
describe the aspects of those study phases relevant to this thesis. 
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4.2 The ET2DS population 
Participants for the ET2DS were recruited at random from the Lothian Diabetes Register 
(LDR), a database established in 2001 containing information on around 20,000 people 
diagnosed with diabetes according to WHO criteria living in the Lothian region, UK. 5454 
participants, selected at random by sex and 5 year age bands from the LDR, were contacted 
by post, of whom 1252 replied. 1077 participants attended the baseline clinic in 2006/ 
2007. Non- native speakers of English and individuals with poor visual acuity (those unable 
to read large print text or distance vision <6/36) were excluded from the study as these 
requirements would impact performance during the paper based or verbal-language centric 
cognitive testing. Diabetic status was assessed at baseline by assessing medical records to 
exclude participants who were incorrectly recorded as having type 2 diabetes on the LDR. 
Only individuals treated with oral and/or injection anti-diabetic medications, or individuals 
managing their diabetes through diet and with an HbA1c >6.5% were included in the study 
at baseline. Individuals not on a medication (diet controlled) and with an HbA1c <6.5% had 
their diabetic status reviewed by a consultant diabetologist to confirm their diagnosis. 
Individuals with pancreatic disease and those on insulin within one year of diagnosis or 
those on insulin before the age of 35 were also reviewed. Those where clinical information 
on diabetic history or status could not be obtained, were excluded. Individuals unwilling or 
unable to provide informed consent were also excluded. This resulted in a total baseline 
population of 1066 participants. This baseline population allows for 90% power at the two 
sided 5% significance level to detect correlation of ≥ 0.1 of two continuous variables. At 
baseline, participants underwent detailed physiological and cognitive testing and 
completed a questionnaire on past medical history.  These data were used, along with 
linkage to hospital discharge records, to derive the baseline variables subsequently 
incorporated into the analyses for this thesis. The cognitive test battery and much of the 
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physiological data collected was the same as collected at the 10-year follow-up clinic (see 
below).  Other details of all the baseline testing done and variables derived have been 
described previously (Price et al., 2008). 
 
4.3 Ethical approvals 
At baseline, the study had full ethical approval from the Lothian Medical Research Ethics 
Committee and complied with the Declaration of Helsinki. I submitted a new application for 
the year 10 follow up phase of the study to the Research Ethics Committee and to NHS 
Lothian R&D, sponsored by The Academic and Clinical Central Office for Research and 
Development (ACCORD), which was granted. This application was written and submitted 
through the Integrated Research Application System (IRAS) (See Appendix C). 
Documentation approved by the REC and NHS Lothian R&D included the application form, 
protocol, participant information sheet, informed consent form, letters of invitation to the 
participants, GP letters and amended versions of the various clinical questionnaires and 
other clinical documentation. Written informed consent was obtained from all subjects on 
attendance at each clinical phase of the study. 
 
4.4 Participant follow-up at year 10 
One year prior to commencing with the year 10 follow up clinics I contacted participants via 
a newsletter, thanking them for their prior contribution to the ET2DS, informing them of 
recent developments and disseminating key results of the study (Appendix D). The 
newsletter also informed them of the intention of holding another phase of clinical data 
collection and provided contact details of the study, should they wish to opt out or have 
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questions. The newsletter was followed by a formal invitation to attend the research clinic 
with a specified appointment date and time. The invitation contained a tear off reply slip 
(and a stamped self-addressed envelope) to provide opportunity for the participants to 
indicate their willingness to attend the 10-year follow-up clinic.  Upon receiving reply from 
the participant, I or another member of the study team phoned the participant to confirm 
their appointment, reschedule an alternative appointment, or record the reason for not 
taking part in this phase of the study. Participants failing to respond to the written 
invitation were contacted by telephone to confirm address and future participation. 
Through telephone contact it was evident that both clinic visit and home visits were 
appropriate in this phase of the study, due to the age and comorbidities experienced by the 
cohort. Telephone contact was also key in addressing specific participant concerns that 
otherwise would have resulted in reduced attendance rates of this phase of the study. 
Examples of this included medical, mobility, confidentiality, and cognitive concerns that 
were addressed though organising transport to and from the clinic, organising a home visit 
or explaining and clarifying the clinical procedures. Considerable effort was made by myself 
and/or other members of the ET2DS team to contact each participant personally and an 
updated list of non-contactable participants was kept throughout the data collection year. 
 
4.5 Clinical data collection 
Data collection took place at the Wellcome Trust Clinical Research Facility (CRF) at the 
Western General Hospital, Edinburgh at each clinical phase of the study. In order for the 
data collection to commence for the year 10 phase, I applied for, and was granted an NHS 
Lothian Honorary Research Contract and wrote detailed Standard Operating Procedures 
(SOP) for each aspect of the clinic. I also compiled a CRF site file, detailing ethical approvals, 
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SOPs, contact details of study personnel and study protocol.  Reserved parking spaces were 
available to participants as was a taxi service, and I ensured participants were reimbursed 
for travel expenses. Appointments were scheduled at times convenient to participants at 
08:45 and 12:45 and were rescheduled should the appointment have been missed for any 
reason. Participants were instructed to bring an early morning urine sample with them. I 
and one other ET2DS team member undertook all the physical and cognitive examinations.  
A maximum of 6 appointments were made per day and the order of clinical examinations 
varied depending on the time of arrival, as the clinic appointments were staggered. This 
enabled one participant per time slot (AM or PM) being given self-administered 
questionnaires to complete while the other two were seen by the researchers in roughly 
equal share. This enabled a ratio of 3 participants to 2 researchers, and a maximum use of 
research clinic time. The clinic was wheelchair accessible, nursing and medical staff were 
available to assist if necessary, and refreshments were offered to all participants upon 
arrival. The following sections describe the data collected, procedures for which were the 
same as used at baseline unless specifically stated. 
 
4.5.1 Demographics 
The participant questionnaire completed at baseline (See Appendix E) included questions 
on date of birth, sex and ethnicity and postcode information from 2006 was used to 
calculate the Scottish Index of Multiple Deprivation (SIMD) score to assess level of 
deprivation (grouped by quintile). The SIMD is a composite index which combines 38 
indicators across seven domains, covering income; employment; health; education, skills 
and training; housing; geographic access to services; and crime levels provided by The 
Scottish Government (2006). Lothian quintiles of SIMD are also often used to describe 
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levels of deprivation in Lothian, which result in a more detailed representation of socio 
economic status in Lothian. The use of Scottish SIMD may therefore result in a skew in the 
data and imply that the ET2DS population have a very low level of deprivation. Despite this, 
Scottish quintiles, as opposed to Lothian quintiles are used in this thesis to describe the 
ET2DS population as this measure is more commonly used and can also be used to place 
this population in context of Scotland as a whole. At year 10 follow-up participants 
completed a similar questionnaire as at baseline in which they were asked to provide 
updated information on address, marital and employment status. 
 
4.5.2 Medical history and diabetes 
As at baseline, the 10-year participant questionnaire contained questions on medical 
history, prescriptions, alcohol intake, and smoking status and history was given to 
participants. This questionnaire included specific questions on diabetes status, duration, 
and medication, and also questions from the WHO Chest Pain and Edinburgh Claudication 
Questionnaire.  
 
4.5.3 Physiological examination 
Consistent with the physiological examination at baseline, systolic and diastolic blood 
pressure was taken from the right arm manually using a sphygmomanometer and 
stethoscope. A Doppler scan was used to obtain Ankle Brachial Pressure Index ABPI 
readings from the left and right brachial, posterior tibial and posterior pedis arteries in 
supine position. Height (to the nearest 1 mm) hip, waist (to the nearest 0.5 cm) and weight 
(to the nearest 0.1 kg) measurements were taken. Near vision was assessed using a 
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standard near vision eye chart. In addition, at baseline the percentage of body fat was 
assessed using an OMRON BF306 Body Fat Monitor (to the nearest 0.1%), by taking an 
average of three measures. 
 
4.5.4 Blood and urine samples 
At baseline, fasting blood samples were processed at the research clinic, for immediate 
measurement of vascular risk factors, including those used in this thesis such as low-density 
lipoprotein (LDL), high-density lipoprotein (HDL), serum triglycerides, inflammatory markers 
(c-reactive protein, CRP; interleukin-6, IL-6; tumor necrosis factor-alpha, TNF-α, fibrinogen) 
and HbA1c and plasma was stored at 40°C. Assays for plasma CRP, IL-6, and TNF-α were 
performed in the University Department of Medicine, Glasgow Royal Infirmary. CRP was 
assayed using a high-sensitivity immunonephelometric assay. TNF-α and IL-6 antigen levels 
were determined using high-sensitivity ELISA kits. At year 10 follow-up, blood and urine 
samples were taken and stored for later analysis (plasma frozen and stored at -80oC, urine 
samples collected and stored at -20oC. 
 
4.5.5 Physical activity questionnaire 
For the first time in the ET2DS, the long version of the International Physical Activity 
Questionnaire (IPAQ) (Craig et al., 2003) was given to participants at the 10-year clinic.  This 
took the form of an interview. The IPAQ was used to collect detailed information on level of 
activity within the different domains of daily activity. These domains included indoor and 
outdoor household activities, occupational activity, self-powered transport, and leisure-
time physical activity as well as sedentary time. The data were collected and scored in the 
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form of minutes of activity per week and was used to generate a physical activity score by 
weighing scores using predefined Metabolic Equivalent Units (METs). This resulted in a 
physical activity unit of MET minutes per week (MET-1 minutes-1 week-1), which gives an 
estimate of frequency and intensity of activity per week. Sedentary time data were 
gathered by asking the participant to recall in detail a ‘typical’ day, and sedentary time, in 
minutes, was recoded. An additional question per physical activity domain was asked to 
gather information on change in the past 10 years, scored as; (1) lower, (2) no change, or 
(3) increased. A mean of this score was taken to reflect overall change in physical activity. A 
similar change score was recorded for sedentary time. According to the scoring guidelines, 
scores above 3000 MET minutes per week are considered high, scores below 600 MET 
minutes per week are considered low. For healthy adults aged 40- 64 years, a typical score 
of 4780 has been reported and for adults aged ≥65 years, a typical score of 5692 has been 
reported in a Swiss general population cohort (Wanner et al., 2016). A recent validation 
study of the long version of the IPAQ in older people with diabetes, who had a BMI of ≥30 
kg/m2, indicated that a typical score was 1845 (Minetto et al., 2018). 
 
4.5.6 Cognitive examination 
As at baseline, a neuropsychological test battery consisting of 7 tests for cognitive ability, 
one test which screened for dementia, one test which assessed predicted peak cognitive 
ability, one test which measured reaction time, and one test that assessed depression and 
anxiety were administered to all participants.  The 7 tests of the main test battery was 
developed in order to capture the principal cognitive domains thought to be susceptible to 
decline in people with diabetes, that were commonly used in the literature. The cognitive 
examination lasted approximately one hour and was administered in the same order 
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(consistent with the order of the following sub-sections, describing the individual tests).  
Testing was only carried out after close reading ability was confirmed to be sufficient to 
read small text, and blood glucose level was above 4 mmol/L. If blood glucose was below 
this, participants were given the opportunity to consume some food and were then later re-
assessed for fitness to be tested. Participants were instructed to bring and wear reading 
glasses and/or hearing aids if required. Those unable or unwilling to partake in the cognitive 
examination were excluded if this was apparent at baseline only.  
 
Hospital Anxiety and Depression Scale (HADS) 
The Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983) measured self-
reported symptoms of depression and anxiety on separate scales. The maximum score for 
each was 21 and minimum was zero, with higher scores indicating increased number of 
symptoms. The scores were used as continuous measures; however, scores above 8 can 
indicate suspected clinical depression and anxiety. If participants scored above 10, their GP 
was notified of their score. 
 
Mill Hill Vocabulary Scale (MHVS) 
The multiple choice section of the combined junior and senior versions of the Mill Hill 
Vocabulary Scale (Raven et al., 1998) was used to provide an estimate of premorbid 
crystallised-type intelligence. This test involved identifying the correct synonym of a given 
word from a choice of 6 options. The groups of words were arranged in ascending order of 
difficulty and one score was given for each correct answer. The maximum score was 43 and 
minimum score was zero, with higher scores indicating increased ability.  It should be noted 
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that despite evidence that scores reflect peak premorbid cognitive ability, this test score 
can only be assumed reflect an estimate of the true level of ability. A more common test for 
crystallised-type intelligence is the National Adult Reading Test, which correlates highly 
with the MHVS (r=0.69) (O'Carroll and Gilleard, 1986). The MHVS was used as opposed to 
the NART as it takes less time to complete and ease of administration as it can be carried 
out independently, without the need for a tester being present. 
 
Mini Mental State Exam (MMSE) 
The Mini Mental State Exam (Folstein et al., 1975), often used as a screening tool for 
dementia by clinicians, provided an estimate of global cognitive functioning with respect to 
likelihood of cognitive impairment. The test evaluates cognition though a host of different 
exercises to assess domains such as memory, attention, praxis, and orientation. The 
maximum score is 30 and minimum is zero, where a score of <24 would provide a clinician 
grounds for referral for fuller cognitive assessment. This test is often used in research for its 
relative brevity and ease of administration as a measure of overall cognitive ability; 
however, this test is only intended for use as a brief screening tool and does not provide a 
full cognitive assessment. For this reason, this test was only administered as a screening 
tool for cognitive impairment and a comprehensive test battery was used to provide a more 






Logical Memory (LM) 
Logical memory, a subtest of the Wechsler Memory Scale 3rd Edition UK version (WMS-III), 
developed by Wechsler in 1987. This test provided a measure of verbal declarative 
memory, where participants were asked to recall a short story of 25 units of detail. The test 
required immediate recall and then again after approximately 30 minutes. As immediate 
and delayed scores are highly correlated (Tulsky et al., 2003), the scores were summed to 
provide a measure of overall global verbal memory.  The maximum and minimum scores of 
summed recall were 50 and zero, respectively. 
 
Faces 
The Faces test is also a subtest of the WMS-III. This test provided a measure of non-verbal 
declarative memory, where participants were firstly exposed to set of 24 photographs of 
different faces, and then asked to identify familiar faces from a second set of 48 faces, of 
which the original 24 were included at random. Recall was assessed immediately after 
initial exposure and again after around 30 minutes. Each recall has a maximum score of 48, 
and minimum score of zero. The test scores were summed to provide a measure of overall 
non-verbal memory (maximum score 96). 
 
Trail Making Task B (TMTB) 
The Trail Making Task B, developed in 1944 as part of the Army Individual Test for General 
Ability (Tombaugh, 2004), was used to measure the cognitive processes of mental 
flexibility, processing speed, attention, and executive functioning. The task involved 
presenting the participants with a sheet of A4 paper with encircled numbers, 1- 13, and 
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letters, A-L, provided randomly on the page. The task is then to draw a continuous line 
connecting the circles in alternating order (e.g. 1- A- 2- B- 3- C...) in as short a time as 
possible; the numbers and letter are set on the page so that the connecting lines do not 
cross. This test involved 26 connections and used time in seconds as a unit of 
measurement. A low score is indicative of a superior ability to perform at the task. 
Participants were given a short practice test to allow them to fully comprehend the 
instructions given before formal testing, and if a participant made a mistake in the test, this 
was pointed out immediately and the participant was instructed to continue from the point 
at which the mistake occurred. The time added to the total time to complete the task is 
indicative of a poorer performance.   
 
Matrix Reasoning (MR) 
The Matrix Reasoning subtest of the Wechsler Adult Intelligence Scale 3rd Edition (WAIS-III), 
developed by Wechsler in 1997, was used to measure non-verbal reasoning ability. The 
participants were presented with a series of geometric pictures, with 5 options below each 
main image to select from. Participants were instructed to choose the one that best 
completes the sequence, without time pressure. Each correct answer contributes one mark 
to the overall score, and the test was stopped after 4 consecutive wrong answers were 
given or 4 wrong answers out of 5 consecutive answers were given. The test had a 





Digit Symbol Test (DST) 
The Digit Symbol Test, also a subtest of the WAIS-III, was used to provide a measure of 
processing speed. The participant is presented with an A4 sheet of paper with a grid of 
symbols and blank boxes.  At the top of the page is a key with the symbols and 
corresponding digits 1-9. After a short practice section, the participants were instructed to 
fill in as many boxes as possible within 120 seconds. The total test score is based on the 
number of correct symbols achieved in the time limit. The maximum score is 133 and 
minimum is zero.  
 
Letter Number Sequencing (LNS) 
The Letter number sequencing task is also a subtest from the WAIS-III. This test assessed 
working memory by requiring participants to listen to sequences of letters and numbers in 
a random order, and then asking participants to recall the digits sorted firstly by number 
and then by letter in numerical and alphabetical order. This required the participants to 
firstly listen, then mentally manipulate the original order and then recall the new order. 
This began with only one letter and one number, and after every third trial, a new digit 
(number or letter) was added.  This continued up until a maximum of 8 digits and so 
allowed for a maximum score of 21 and a minimum of zero. In the case of three consecutive 
wrong order manipulations in a given difficulty block, the test was stopped. 
 
Borkowski Verbal Fluency Task (BVFT) 
The Verbal Fluency task developed by Borkowski et al. (1967), provided a measure of 
executive function and semantic memory. Participants were asked to name as many words 
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as possible, excluding proper nouns, with a seemingly random letter given to them. This 
was repeated 3 times and the letters used were always C, F and L. Participants were give a 
practice opportunity with a different letter (S) and, once confident in the instructions of 
task, formal testing was initiated. Each time the participant was given 60 seconds to think 
of words, so was given a maximum time of 180 seconds to complete the task. The task was 
scored by summing the number of non-repeated, correct words recalled. There was no set 
maximum for the test, however the minimum was zero. 
 
Deary-Liewald reaction time task 
Reaction time was measured using the Deary-Liewald reaction time task (Deary et al., 
2011b), which measures processing speed. This task involved the use of a computer where 
the screen was set up to depict a number of blank boxes on a blue background. The task 
required participants to press keys corresponding to where an ‘X’ symbol appeared on the 
screen, in as short a time as possible. The first part of the task involved only one box and 
the second part of the task involved 4 boxes. Scores reflect the response times, i.e. the 
speed of cognitive processing, and the speed of physical movement. Participants are given 
a short practice opportunity before each part of the task. A mean latency for each part was 
calculated, and is used to score the two parts of the task.  
 
4.6 Record linkage and Events 
4.6.1 Vascular events 
At baseline, year 4 and at year 8 (2014/2015), hospital discharge data and death codes 
were obtained from Information and Services Division of NHS Lothian. At year 10, hospital 
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discharge and deaths data were updated by consulting TRAK and the National Records of 
Scotland. Information on diagnoses, prescriptions, admissions and events were obtained in 
order to build evidence, along with information gathered at the clinics, for cerebrovascular 
and cardiovascular events. Prevalent cerebrovascular and cardiovascular event variables 
(stroke, TIA, myocardial infarct or angina) were used as binary variables defined as having 
either has a stroke or TIA prior to the baseline clinic or either having had a heart attack or 
angina diagnosis prior to the baseline clinic. These events were all determined by use of a 
set of criteria developed by members of the study team. For cerebrovascular disease, the 
criteria were met if 2 out of the 3 following statements applied: (i) self- report, (ii) hospital 
discharge code, (iii) review of clinical notes. For cardiovascular disease, the criteria were 
met if 2 out of the 3 following statements applied: (i) self-report, (ii) WHO Chest Pain 
Questionnaire indication, (iii) ECG indication. Alternative criteria for cardiovascular disease 
were if a hospital discharge code was found in combination with a self-report. 
 
4.6.2 Incident dementia events 
At baseline the majority of participants of the ET2DS were assumed to not have dementia 
as a written response to the invitation, a scheduling of an appointment and a subsequent 
clinical attendance was required by the participant, although each participant was not 
formally assessed. Evidence for prevalent or incident dementia was collected periodically 
throughout the 10 years of follow-up, with the majority collected at year 10. These included 
hospital records (TRAK), hospital discharge codes, death certificate codes, GP reporting, 
prescription for dementia medication, self or carer reporting and MMSE score. The gold 
standard for dementia diagnosis is through a clinical neuropsychological assessment which 
in accordance to the DSM V often includes a CT or MRI scan. This diagnostic procedure was 
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used as primary evidence for the classification of dementia events in the ET2DS, and the 
basis of the following criteria for probable cases of dementia in the cohort. Primary sources 
of information include hospital records (TRAK and discharge data), death certificates, and 
prescription data. These sources all are presumed to provide information on dementia after 
a formal diagnosis has been made according to DSM V criteria. Other information on 
dementia diagnosis through self, carer or GP report are considered secondary sources of 
information as the primary source of diagnosis was consulted to generate this ‘second 
hand’ information. Similarly the MMSE dementia screen, often used by GPs prior to formal 
assessment provides indication of cognitive impairment but alone does not provide 
information on dementia status. The following criteria were developed by me and clinical 
experts in the field of diabetes and cognitive aging to classify participants as probable 
sufferers of dementia and probable not a sufferer of dementia. It should be noted that 
these criteria are not equivalent to a clinical diagnosis of dementia and thus is termed 
‘probable’ dementia.  
‘Probable dementia’ is at least one of A and at least one of B 
Or 
Two or more of A  
 
A: Primary medical record of diagnosis 
TRAK diagnosis or hospital discharge code or death code or prescription of 
dementia medication 
B: Secondary source of a medical diagnosis 
Self/ carer report or GP report or MMSE<24/ missing at year 10 
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On the basis of these criteria, participants were classed as having probable dementia at 
year 10 or no dementia at year 10. A number of participants did not meet the formal 
criteria but had one source of primary medical evidence (criteria part A) for dementia. 
These cases had their clinical notes reviewed by a committee and a consensus was reached 
that, in light of the evidence, they are to be included in the probable dementia category.  It 
should be noted that some participants had a formal MCI diagnosis on TRAK, however 
these were not included in the final probable dementia group. Date of diagnosis was not 
available for all reports of dementia, and as disease onset precedes diagnosis no distinction 
was made at baseline between incident and prevalent events, as such differentiation would 
be arbitrary and misleading. It should be noted that ‘missing at year 10’ was incorporated 
into part B of the criteria, as it would allow participants who did not attend due to 
dementia to be classed accordingly. 
 
4.6.3 Diabetic Retinopathy 
At baseline, participants had digital retinal photography carried out at a separate clinic 
following initial appointment. A detailed description of procedures is describes by Ding et 
al. (2010), but in brief, seven field non stereoscopic colour photographs were taken of both 
eyes and independently graded by two ophthalmologists according to the Early Treatment 
Diabetic Retinopathy Study Group (1991) scoring system. Scores above 10 were classed as 
retinopathy and others as no retinopathy present. At year 10 follow-up, routinely collected 
image data, which was pre- graded by a clinician was collected from SCI Diabetes. Grades 
R1 and above were classed as retinopathy and others as no retinopathy. For participants 
known to still be alive at year 10, image data obtained in, or if missing, closest to 2016/17 
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was used for classification purposes. Diabetic retinopathy was used as a binary variable in 
all analysis as a proxy for micro vascular disease.  
 
4.7 Data management and cleaning 
All participant data were recorded and kept in hard copy in secure, locked filing cabinets in 
a secured, restricted access room at The University of Edinburgh. At each phase of data 
collection, all questionnaire, clinical, laboratory and cognitive data were entered manually 
into a master database using Microsoft Access 2003/2010 software. Data were entered in 
batches by members of the research team after the clinics finished. This database was 
backed up on a dedicated university server that required both electronic authorisation and 
password access. At baseline, double data entry was carried out for all participants which 
identified an error rate around 0.02%, when omitting easily identifiable typographical 
errors (e.g. hospital names/abbreviations). At year 4 a random 10% sample group of 
participants was selected for double data entry. Similarly at year 10, a random 10% sample 
was selected for double data entry. Data were entered into a separate Microsoft Access 
database, and this was checked against the original entry. At year 4 this identified an error 
rate of 0.017% and at year 10 this identified a similar error rate of 0.018%. Any 
discrepancies were resolved by firstly consulting the original paper file, and then if still 
unresolved, secondly by committee consensus. Alongside this, all data were checked for 
outliers and impossible values. For continuous data, outliers were defined as cases ± 2 
standard deviations of the mean of that variable. Impossible values, identical to original 
paper copy were recoded as missing and errors recoded. All other outlier values were 
retained in the database. These checks were carried out by me and other members of the 
92 
current research team at year 10, and by other research team members following the 
previous phases of data collection. 
 
4.8 Missing HbA1c data 
Baseline variables included in this thesis were checked for missing data and it was found 
that despite previous checks, the variable HbA1c contained relatively high missing data. 
HbA1c contained 38 cases of missing data (3.56%) at baseline. After checking paper files for 
laboratory blood results, a number of cases were identified that did have a baseline HbA1c 
value. If missing data persisted, often due to a blood tube failing, or not able to obtain 
blood on the day of the clinic, routinely collected data were consulted. The value closest to 
the day of the participant’s baseline clinic date was taken, provided it was within 6 months 
of the baseline clinic. This approach allowed the overall missing HbA1c data to be reduced 
to 9 (0.84%) and, as HbA1c level is representative of a 3 month mean value of blood 
glucose, it is expected to remain relatively stable with in the 6 months either side of the 
clinic date (Ohde et al., 2018). 
 
4.9 Data analysis 
All longitudinal analyses were carried out on predictor variables collected at baseline and 
outcome variables collected at year 10 follow-up. Cross-sectional analyses were carried out 




4.9.1 Clinical and physiological variables 
The obesity variable BMI was calculated from height (cm) and weight (kg) using the 
standard formula: weight (kg) / [height (m)] 2, and WHR was calculated by dividing waist 
circumference by hip circumference (cm). Hypertension was used as a binary variable 
derived from systolic and diastolic blood pressures (mmHg), and was defined as having a 
systolic blood pressure > 140 mmHg or a diastolic blood pressure of > 90 mmHg. This 
derived variable used in this thesis captures the most common type of hypertension; 
isolated systolic hypertension (>140/<90 mmHg), and the less common; systolic–diastolic 
hypertension (>140/>90 mmHg) and diastolic hypertension (<140/>90 mmHg) (Tsimploulis 
et al., 2017). For the purposes of this thesis the variable hypertension does not include 
participants on anti-hypertensive medication, and should be understood to reflect cases of 
uncontrolled hypertension only. Care should be taken when interpreting findings, as 
individuals on an anti-hypertensive medication may still be suffering or have suffered from 
clinically relevant hypertension in the past and this may still present as a risk factor for 
various vascular outcomes. Unadjusted measures are used in this thesis as it was reasoned 
that, untreated hypertension at baseline was likely to be a more accurate and clinically 
important risk factor for the study outcomes, than those who may have had hypertension 
in the past or who are medically controlled and thus have a considerably lower risk of 
vascular disease.  At baseline only self-reported prescription data was available, which is 
notoriously unreliable. At year 10 full prescription data was obtained from SCI- Diabetes, 
however for the purposes of this thesis it was not possible to trace back every anti-
hypertensive medication for each participant and so the variable reported in this thesis 
should be interpreted only as untreated hypertension. 
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4.9.2 Preparation of cognitive variables prior to analyses 
Derived scores 
Cognitive data from baseline and year 10 follow-up were used in this thesis. Cognitive tests 
with immediate and delayed components (Logical Memory test and the Faces test) were 
summed, at each time point, prior to analysis as temporal scores were highly correlated (for 
baseline Logical Memory; 0.87 and Faces; 0.55, both p<0.001). The terms in this thesis 
‘Logical Memory’ or ‘Faces’ describe the summed scores, unless otherwise stated. 
 
General cognitive function variable 
Latent variables, suggested early on by Spearman (1904), are theoretical constructs that are 
inferred on the basis of a number of observations, and are not directly quantifiable though 
one measurement or test alone. These underlying constructs are often used in 
psychological testing, where one test may not capture the full ability of an individual. This 
can be the case when aiming to capture a cognitive domain, such as executive functioning 
or when aiming to capture an individual’s general cognitive ability, often termed general 
intelligence. Factor analysis (FA) is a common data reduction method used in psychological 
analyses to derive a latent variables. Principal component analysis (PCA), is another data 
reduction method commonly used when generating a summary, though not strictly latent, 
variable. The two methods vary as latent variables derived using FA only take into account 
the shared variance between the data, whereas summary variables derived using PCA use 
all the variance in the data to generate variables (Gaskin and Happell, 2014). This is 
important as while FA is often preferred by researchers, as it takes into account testing 
error and so is deemed more accurate, it generates novel variables that are not purely a 
summary of the original tests. PCA merely summarises the cognitive test data and so in the 
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context of this thesis, was the preferred data reduction technique. Associations found using 
this summary variable can be explored further by the results of the individual cognitive 
tests, which in the context of multiple testing, is beneficial.  A PCA was run using imputed 
(described in the following section) age adjusted cognitive data from the 7 cognitive tests at 
baseline (LM, Faces, TMTB, MR, DST, BVFT and LNS) and Eigenvalues of <1 were extracted. 
The approach was based on that of Gow et al. (2008), where all cognitive data at all time 
points were stacked into seven columns and a single PCA was carried out. Regression scores 
of the first component were then saved according to time point and were termed general 
cognitive function or ‘g’. This approach allowed baseline ‘g’ values to be centred on zero 
with a standard deviation of 1 and allowed follow-up ‘g’ values to be relative to baseline 
scores. This means that a person’s ‘g’ score can be directly compared to their baseline ‘g’ 
score. If the PCA was carried out separately on baseline scores and then again on follow-up 
scores, both variables would be have means of zero and could not be used in a cognitive 
change analysis. It should be noted that, although the assumption of independent samples 
is violated, this does not bias the factor loadings. It does however over-estimate the 
variation in the factors. The PCA scree plot indicates that 1 component adequately 
describes the data, accounting for 48.06% of the variation in the data. The loadings of the 
cognitive tests on this un-rotated component are described in Table 6. 
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Cognitive test First Un-rotated Principal Component  
Loading score 
Logical Memory 0.603 
Trail Making Task B -0.827 
Faces 0.489 
Matrix Reasoning 0.691 
Digit Symbol Task 0.790 
Borkowski Verbal Fluency Task 0.644 
Letter Number Sequencing task 0.749 
The log transformed variable for Trail Making Task B was used for analysis. Imputed 
data were used to generate components and loading scores. 
 
Imputations 
Cognitive data at baseline or at follow-up was not always complete for each participant 
(common reasons being disability, fatigue, time constrains etc.) and so prior to generating 
the general cognitive function component, the cognitive data sets were imputed separately 
at baseline and at follow-up. This is because this component can only be produced for cases 
with complete cognitive data. This technique, commonly used in cognitive aging 
epidemiology (Van Beijsterveldt et al., 2002) termed multiple imputation, allows for missing 
values to be predicted by means of generating a number of likely values based on other 
variables on a case by case basis. A mean of these imputed values is then taken as a 
substitute for the missing value. This is a superior method of imputation to other more 
simple methods of imputation such as imputing the sample mean (Sterne et al., 2009). This 
technique generates a specific value for a missing variable based on the age, sex and other 
cognitive test results of the participant. Care should be taken when interpreting results 
using imputed data as it may be the case that a test score higher than the true ability of the 
participant is generated, especially if the reason for not completing the task is due to poor 
cognition. To overcome this, extra care was taken when preparing the data set for 
Table 6. The loading scores of the cognitive tests on the un-rotated component ‘g’. 
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imputation by checking if missing values were not in fact true zero scores. Every participant 
had notes taken regarding their ability and willingness to carry out cognitive testing and on 
a cases by case basis these were consulted to determine if scored were missing or true zero 
scores. Furthermore, imputations were only carried out on data where there was less than 
3 out of 7 cognitive tests missing and remaining missing data were kept as missing. 
Imputation was deemed necessary, despite its limitations, as the power of analyses of the 
variable ‘g’ was increased considerably.  All data described and analysed in this thesis, 
except for the latent general cognitive function variable ‘g’, is on non-imputed raw data.  
 
4.9.3 Statistical analysis 
Descriptive Statistics 
Histograms and Q-Q plots were visually inspected to check if data were normally 
distributed for all data used in this thesis (see Appendix A and B). Any variables found to 
have skewed distributions were natural log-transformed prior to analysis and median 
values were reported, with respective interquartile ranges. Log transformations are used to 
convert skewed data to fit a more normal distribution in order to meet the assumption of 
normality when carrying out specific parametric analyses. It should be noted that other 
transformations were carried out (e.g. square root), however, the log transformation was 
used as it allowed the data to fit a normal bell–shaped distribution upon visual inspection. 
It should also be noted that predictor variables in regression analysis need not be normally 
distributed, and so if the data were not fully normalised this would have little effect on the 
outcome of the various analyses.  Mean values and standard deviations were reported for 





The statistical cut point p<0.05 was used to reject the null-hypothesis, which reflects a <5% 
probability of incorrectly rejecting the null-hypothesis (a type 1 error). This error rate 
increases with the number of comparisons made, and so often post hoc corrections (e.g. 
Bonferroni corrections) are applied to analyses of multiple comparisons. However, this 
approach leads to an increased level of type 2 errors, where the null-hypothesis is 
incorrectly accepted. For the purposes of this thesis, a specific hypothesis is tested using 
the outcome summary variable ‘g’, as derived though PCA, and then further explored by 
the same model using the individual cognitive test scores as outcome variables to find if 
one or multiple tests drive the association with ‘g’.  The main analysis is on ‘g’ and is only 
illustrated further by the other cognitive tests, and so for this reason, it was not appropriate 
to correct further for multiple comparisons. In light of this, caution should be taken when 
interpreting results close to the p<0.05 cut point, and results equal to or above this point 
should be assumed as not significant.  
 
Cognitive outcomes 
The main outcomes described in this thesis are general cognitive ability, change in general 
cognitive function and incidence of dementia at follow-up. These outcomes are described in 
relation to key risk factors measured at baseline. 
Cognitive ability was measured at baseline and at follow-up by individual cognitive test 
performance and by general cognitive function score. The scores obtained at follow-up 
99 
represent the outcome of cross-sectional analysis between risk factors and cognitive ability 
at year 10. 
 
Change in cognition was measured by adjusting cognitive ability scores at follow-up, by 
scores obtained at baseline. This approach, known as the Adjustment Method, models 
change over time and is commonly used in the literature of cognitive aging (Gow et al., 
2008). Another approach to obtaining a change in cognition variable, is by calculation a 
difference variable. This approach is affected by regression to the mean (Reynolds et al., 
2002), whereby random errors in measurements distort the true mean of the sample 
(Barnett et al., 2004). When measurements are repeated at follow-up, cases with extreme 
baseline scores tend to have scores closer to the mean at follow-up, resulting in the 
observation that people with high scores perform relatively less well and people with low 
scores perform relatively better than before (Gow et al., 2012b). Both methods typically 
yield identical results (Willett and Sayer, 1994), and so because of the downfalls of the 
difference method, the adjustment method was adopted in this thesis to describe and 
analyse change in cognitive ability. It should be noted that this was carried out for both the 
individual cognitive tests and for the general cognitive ability score.   
 
Incident dementia, described previously (see section 4.5.7), was determined at follow-up by 
fulfilling predefined criteria. This is a categorical outcome variable where risk factors 
measured at baseline or at follow-up are modelled against the binary outcome variable of 
probable dementia vs the remaining study population. 
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Principal Analysis  
Univariate analysis 
Differences between year 10 follow-up attenders vs non attending population in terms of 
risk factors, demographics and cognitive scores was described by means of chi-squared 
tests and t-tests in order to show how representative the follow-up population was of the 
original cohort. In order to justify the use of the summary variable, Pearson’s correlations 
coefficients were used to describe cognitive scores and predictor variables thought to be 
inter-correlated. All analyses were two-tailed. 
 
Multivariable analysis 
Linear regression analyses (multivariable) were employed to determine the longitudinal 
associations between baseline risk factors and cognitive outcomes and the cross-sectional 
associations between year 10 risk factors and cognitive ability. For analyses on categorical 
outcome data on dementia status, multivariable binary logistic regression was used.  For 
both types of model, a hierarchal approach, whereby blocks of related risk factors were 
sequentially added to the models was used to describe how the association of each 
predictor risk factor and cognitive outcome was modified by the addition of other 
covariates to the model. This approach was utilised in addition to the adjustment method 
to determine the association of a risk factor on cognitive change over time. All analyses 
were carried out in SPSS version 21 (IBM Corporation, New York). 
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Chapter 5: Results 
This chapter describes the baseline and 10 year follow-up characteristics of the ET2DS 
population. Also presented are the analyses of key risk factor inter-correlations and 
associations of obesity and systemic inflammation markers with other variables. This is 
followed by the main analysis on the associations of obesity with cognitive change, 
considering adjustment for other variables and for inflammation.  
The distribution of variables used in this thesis are shown in Appendix A and B. Most 
variables met the assumption for normality and those skewed were natural log 
transformed. The variables transformed are reported in the tables with the prefix ‘ln’, and 
in the text reported without reference to the transformation, unless specified. 
 
5.1 CHARACTERISTICS OF BASELINE STUDY POPULATION AND 10-YEAR FOLLOW-UP 
5.1.1 Baseline characteristics  
Baseline characteristics of the ET2DS population (n=1066) are presented in Table 7.  The 
population had an average age of 67.9 years, 51.3 % were male and the majority of 
participants were retired (n=864; 81%).  The highest percentage of participants belonged to 
the 5th quintile of the Scottish Index of Multiple Deprivation (SIMD), indicating that 32.7% of 
the study population was considered to be least deprived when compared to that of the 
rest of Scotland while only 11.9% belonged to the most deprived quintile. This was 
reflected by the observation that further education was achieved by 44.8% (n=478) of the 
study population and 54.4% (n=581) secondary level education.  
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The median duration of diabetes was 6 years (range 0 to 43 years). The majority of 
participants were on an oral diabetes medication alone (without insulin) (63.9%), 17.4% 
were on insulin and/or an oral medication and the rest controlled their diabetes through 
diet alone (18.7%).  The population had a median HbA1c of 7.20 %, which ranged from 5.0 
to 14.9%. 
The population had a mean systolic blood pressure of 1.33±16.44 mmHg and a mean 
diastolic blood pressure of 69.06±9.01. When adopting the definition of hypertension as 
having a systolic blood pressure of >140mmHg or a diastolic blood pressure of >90mmHg, 
367 (34.4%) were classed as hypertensive. 172 (16.1%) of participants had high levels of 
cholesterol as defined as having more than 5 mmol/l of total cholesterol.  Diabetic 
retinopathy was prevalent in 32.5% of the study population, the majority of whom had only 
mild retinopathy (86%). The prevalence of macrovascular disease, defined as having had 
one or more macrovascular event (MI, angina, stroke or TIA), was 35.1% (n=374), of which 
angina and MI were most common (28.0% and 14.1%, respectively). 
Most of the study population were non-smokers (n=912; 85.6%), consisting of those who 
had never smoked (n=498; 46.7%) or those having quit smoking (n=414; 38.8%) and on 
average 9 units of alcohol were consumed per week. 
The mean BMI was 31.42±5.69 kg/m2, with a minimum of 18.39 kg/m2 and maximum of 
55.44 kg/m2, with 55.3% of participants being classed as obese (BMI >30 kg/m2). The other 
obesity variables reflect this as WC was on average 107.00±12.82 cm, WHR was on average 
0.96±0.76 and body fat was 38.09±7.55 %. 
Mean clinical anxiety and depression levels as measured by the Hospital Anxiety and 
Depression Scale were 5.72 and 3.85, respectively. One hundred and eighty nine 
participants (17.7%) had mild anxiety, 103 (9.7%) had moderate anxiety and 29 (2.7%) had 
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severe anxiety, when screened using this tool. Ninety eight participants (9.2%) had mild 
depression, 24 (2.3%) had moderate depression and 4 (0.4%) had severe depression, when 
screened using this tool. Clinical cases of anxiety or depression, as indicated by a score of 
11 or more (Snaith, 2003), were 132 (12.4%) and 28 (2.6%), respectively. 
Characteristic Population Mean 
± SD or n (%) 
Minimum Maximum N Missing 
data % 





Age (years)  67.91 ± 4.20 60.14 76.1 1066 0 
Sex males (n %) 547 (51.3)  -  - 1066 0 
SIMD rank:   
 
  1066 0 
1st quintile  127 (11.9) -  - -  - 
2nd quintile  208 (19.5) -  - -  - 
3rd quintile  188 (17.6) -  - -  - 
4th quintile  194 (18.2) - -  -  - 
5th quintile 349 (32.7) - - - - 
Educational attainment:   
 
  1066 0 
University/ college 171 (16.0) - - - - 
Professional/ technical 307 (28.8) - - - - 
Secondary school 581 (54.4) - - - - 
Primary School 7 (0.7) - - - - 
Employment status:   
 
  1066 0 
Full-time 75 (7.0) - - - - 
Part-time 77 (7.2) - - - - 
Unemployed 9 (0.8) - - - - 
Retired 864 (81.1) - - - - 
Homemaker 19 (1.8) - - - - 
Other 22 (2.1) - - - - 
Vascular related:           
Systolic blood pressure 
(mmHg) 
 133.30 ± 16.44 90 210  1064 0.19  
Diastolic blood pressure 
(mmHg) 
 69.06 ± 9.01 20  110 1064  0.19 
Hypertension (n)  367 (34.4) - -  1064 0.19  
Total cholesterol 
(mmol/l) 
 4.31 ± 0.90 2.3 9.40  1057 0.84  
High density lipoprotein 
(mmol/l) 
 1.29 ± 0.36 0.39  3.34 1057  0.84 




 1.70 ± 0.65 0.64 5.89  1058 0.75  
Retinopathy (n) 339 (32.5)  - -  1044 2.06  
Any macro vascular 
disease (n)a 
374 (35.1) - - 1066 0 
- MI (n)a 150 (14.1) - - 1066 0 
- Angina (n)a 298 (28.0) - - 1066 0 
- Stroke (n)a  62 (5.8) - -  1066 0  
- TIA (n)a  31 (2.9) - -  1066 0 
Smoking status   
 
  1066 0 
- Current 154 (14.4) - - - - 
- Former  414 (38.8) -  - -  - 
- Never  498 (46.7) -  - -  - 
Total cigarettes per day  2.34 ± 6.94 0 60 1061 0.47 
Alcohol units per week  9.01 (14.48) 0 112 1066 0 






(median years (IQR)) 
 6 (2-10) 0 43 1053 1.21 
HbA1c (%) (median 
(IQR)) 
7.20 (6.6-7.8) 5 14.9 1056 0.94 
Plasma Glucose 
(mmol/l) 
 7.56 ± 2.10 2.1 22.2 1049 1.59 
Medication status (n)   
 
  1066 0 
- Insulin ± oral  186 (17.4) - -  - -  
- Oral  681 (63.9) -  - -  - 
- Diet controlled  199 (18.7) -  - -  - 





Body mass index 
(kg/m2) 
 31.42 ± 5.69 18.39 55.44 1065 0.09 
Underweight BMI (<18.5 
kg/m2) 
1 (0.1) - - - - 
Normal BMI (18.5- 24.9 
kg/m2) 
108 (10.1) - - - - 
Overweight BMI (25-29 
kg/m2) 
366 (34.3) - - - - 
Obese BMI ( >30 kg/m2) 590 (55.3) - - - - 
Waist circumference 
(cm) 
 107.00 ± 12.82 73  159.00 1061  0.47 
Waist to hip ratio  0.96 ± 0.76 0.74  1.21 1061 0.47  
Body fat (%)  38.09 ± 7.55 15.5  50.00 1052  1.31 
Inflammatory related:           
Fibrinogen (median 
ng/ml) 
 3.60 (0.97) 0.7 7.14  1063 0.28  
CRP (median mg/ml)  1.86 (3.50) 0.1 47.10  1042 2.25  
IL-6 (median pg/ml)  2.86 (2.54) 0.49 34.18 1064 0.19 
TNFα (median pg/ml)  1.07 (0.93) 0.1 28 1063 0.28 
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MMSE <24  47(4.4) - - 1063 0.28 
HADS A  5.72 ± 3.91 0 20 1065 0.09 
HADS D  3.85 ± 2.89 0 16 1065 0.09 
Total n=1066. Values are means ± SD, median (interquartile range) or n (%). SIMD, 
Scottish Index of Multiple Deprivation; HbA1c, haemoglobin A1c; CRP, c-reactive protein; 
IL-6, interleukin-6; TNFα, tumour necrosis factor α; MI, Myocardial Infarct; TIA, transient 
ischaemic attack; BMI, Body Mass Index, MMSE, Mini Mental State Exam; HADS A, 
Hospital Anxiety and Depression Scale-Anxiety subscale; Hospital HADS D, Hospital 
Anxiety and Depression Scale- Depression subscale. a These data are not cumulative. 
 
5.1.2 Missing data 
The majority of the variables, collected at baseline, had zero or few missing data (Table 7). 
Binary disease variables were sourced from NHS discharge data. These variables are all 
complete as only those with a diagnosis were recorded, and so it is possible some missing 
data are present in these variables if they have suffered the condition without it being 
recorded.  Variables with the highest percentage missing include, CRP (n=24; 2.25%) and 
retinopathy (n=28; 2.06%). Retinopathy was determined by photographs taken by the study 
team at a separate appointment and so this may account for the relatively high percent of 
missing data. 
It should be noted that HbA1c also had a high percentage of missing data (n=28; 2.63%), 
however, after looking at NHS routine haematology data, levels from blood samples taken 
within a period of 6 months on either side of the original clinic appointment date were used  
in analysis reducing the missing data by 10 cases to 0.94%.  
 
5.1.3 Representativeness 
The representativeness of the recruited sample compared to the true population of older 
people with type 2 diabetes living in Lothian was determined at baseline by the ET2DS 
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research team by comparing the socio-demographic and clinical characteristics of the study 
population to that of the total population included on Lothian Diabetes Register (Marioni et 
al., 2010). On average, the ET2DS population was found to have similar, age, duration of 
diabetes, HbA1c, medication type, and SIMD quintile to the non- responders (n=4386), 
while some differences were observed in sex (n=547, 51.3% male versus n=1839, 41.9% 
male; p<0.001), systolic blood pressure (137.2 mmHg ± 18.2 versus 133.3 mmHg ± 16.4; 
p<0.01) and total cholesterol (4.2 mmol/l ± 0.96 versus 4.3 mmol/l ± 0.90; p<0.001) 
(Marioni et al., 2010). 
 
5.1.4 Ten year follow-up attendance and attrition  
A total of 581 participants attended for cognitive re-testing at the year 10 follow-up clinic. A 
flow chart of attendance over the 10 years of the ET2DS study is shown in Figure 3. Table 8 
describes the reasons given by either the participant or participant’s representative for 
non-attendance and the levels of attrition since baseline. The attrition rate over the full 10 
years of the study was 45.5% (n=485). The most common reason for non-attendance was 
death of participant (n=310) accounting for 63.9% of the total non-attending population 
(n=485), and 29.1% of the total study population (n=1066). The second highest reason given 
for non-attendance was health concerns that resulted in the participant not being fit to 
attend an appointment (n=80) accounting for 16.5% of the total non-attending population 
(n=485) and 7.5% of the total study population (n=1066). Of the total study population, we 
were not able to obtain a reason for non-attendance for 24 participants accounting for 




















Figure 4. Attenders of the year 10 follow up of the ET2DS
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medical report)  
Attrition at year 10 
follow-up (n) 
% of non-attenders 
(n=485) 
Health concerns  80 16.49 
Full-time carer  10 2.06 
Relocation  8 1.65 
Withdrawn  53 10.93 
Non-contactable  24 4.95 
Deceased 310 63.92 
Total baseline n = 1066. Total invited back at year 10 follow-up n = 845. 
Total attenders at year 10 follow-up = 581. Total non-attenders at year 
10 follow-up = 485. 
 
5.1.5 Baseline characteristics of 10-year follow-up population versus non-attenders 
Table 9 compares the baseline characteristics of the 10-year follow-up population (n=581) 
with those who did not attend for cognitive re-testing (n=485). The attending population 
was significantly different in age (p<0.001), deprivation status (p=0.005) and education 
(p=0.041) with participants who attended tending to be younger, less deprived and having 
achieved a higher level of education at baseline. 
The attending population had a lower systolic blood pressure (p=0.008), a higher 
prevalence of hypertension (p=0.004) and a lower prevalence of stroke (p=0.010).  There 
was also a statistically significant difference in smoking status (p=0.009), with less of the 
attenders being current smokers, and on average smoking less cigarettes (p<0.001). 
Conversely, the attending population consumed more units of alcohol than the non-
attending population at baseline (p=0.038).  
Table 8. Reasons for non-attendance at year 10 follow-up  
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The status of diabetes was less severe in the attending population, with differences seen in 
duration of diabetes (p=0.004), and type of medication (p=0.005) - more of the attenders 
managed their diabetes with diet alone. 
Obesity variables BMI (p=0.023), WC (p=0.014), and body fat (p=0.045) were lower in the 
attending population at baseline, except for waist to hip ratio, where no difference 
between the groups was observed. Markers of systemic inflammation were also 
significantly lower in the attending population (Fibrinogen; p<0.001, CRP; p<0.001, IL-6; 
p<0.001, TNF alpha; p=0.029). 
The attending population also scored less on levels of anxiety or depression (both, 
p<0.001), and fewer people had a score of <24 on their MMSE test (p=0.022), 24 being the 




T or X2 (p-value) 
N 
Mean ± SD, median (IQR) or n 
(%) 
N 
Mean ± SD, median (IQR) or n 
(%) 
Demographic:          
Age (years) 581 67.31 ± 4.2 485 68.62 ± 4.2 -5.077 (<0.001) 
Sex males (n %) 581 296 (50.9) 485 251 (51.8) 0.069 (0.793) 
SIMD rank: 581   485   14.725 (0.005) 
1st quintile   56 (9.6)  71 (14.6)   
2nd quintile   116 (20.0)  92 (19.0)   
3rd quintile   92 (15.8)  96 (19.8)   
4th quintile   103 (17.7)  91 (18.8)   
5th quintile   214 (36.8)   135 (27.8)   
Educational attainment: 581   485   8.234 (0.041) 
University/ college   109 (18.8)   62 (12.8)   
Professional/ technical   169 (29.1)   138 (28.5)   
Secondary school   300 (51.6)   281 (57.9)   
Primary School   3 (0.5)   4 (0.8)   
Employment status: 581   485   21.438 (0.001) 
Full-time   47 (8.1)  28 (5.8)   
Part-time   54 (9.3)  23 (4.7)   
Unemployed   7 (1.2)  2 (0.4)   
Retired   443 (76.2)  421 (86.8)   
Homemaker   15 (2.6)  4 (0.8)   
Other   15 (2.6)   7 (1.4)   
Table 9. Baseline characteristics of attenders and non-attenders of the ET2DS at Year 10 
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Vascular related:          
Systolic blood pressure (mmHg) 580 132.06 ± 14.7 484 134.79 ± 18.2 -2.651 (0.008) 
Diastolic blood pressure (mmHg) 580 69.36 ± 8.5 484 68.69 ± 9.6 1.198 (0.231) 
Hypertension (n) 580 178 (30.7) 484 189 (39.0) 8.161 (0.004) 
Total cholesterol (mmol/l) 578 4.33 ± 0.9 479 4.29 ± 0.9 0.739 (0.462) 
High density lipoprotein (mmol/l) 578 1.31 ± 0.4 479 1.27 ± 0.4 1.975 (0.049) 
Serum triglycerides (mmol/l) 581 5.13 ± 58.5 485 14.04 ± 110.4 -1.601 (0.110) 
Retinopathy (n) 575 173 (30.1) 469 166 (35.4) 3.318 (0.069) 
Stroke (n) 581 24 (4.1) 485 38 (7.8) 6.621 (0.010) 
TIA (n) 581 20 (3.4) 485 11 (2.3) 1.291 (0.256) 
Smoking status (n) 581   485   9.456 (0.009) 
-          Current   70 (12.0)  84 (17.3)   
-          Former   246 (42.3)  168 (34.6)   
-          Never   265 (45.6)  233 (48.0)   
Total cigarettes smoked 577 1.66 ± 5.81 484 3.14 ± 8.02 6.874 (<0.001) 
Alcohol units 581 9.85 ± 14.5 485 8.00 ± 14.5 2.081 (0.038) 
Diabetes related:          
Duration (median years (IQR)) 581 8.19 ± 9.8 485 10.33 ± 13.9 -2.857 (0.004) 
HbA1c (median (IQR)) 578 7.37 ± 1.1 479 7.45 ± 1.2 -1.133 (0.258) 
Plasma Glucose (mmol/L) 574 7.48 ± 1.9 475 7.66 ± 2.3 -1.406 (0.160) 
Medication status (n) 581   485   10.511 (0.005) 
- Insulin ± oral   89 (15.3)  97 (20.0)   
- Oral   365 (62.8)  316 (65.2)   
- Diet controlled   127 (21.9)   72 (14.8)   
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Obesity related:          
Body mass index (kg/m2) 581 31.06 ± 5.5 484 31.86 ± 5.9 -2.273 (0.023) 
Waist circumference (cm) 580 106.01 ± 12.7 481 107.95 ± 12.9 -2.463 (0.014) 
Waist to hip ratio 580 0.96 ± 0.1 481 0.96 ± 0.1 -1.004 (0.315) 
Body fat (%) 574 37.67 ± 7.7 478 38.60 ± 7.4 -2.010 (0.045) 
Inflammatory related:          
Fibrinogen (median ng/ml) 580 3.57 ± 0.7 483 3.74 ± 0.8 -3.677 (<0.001) 
CRP (median mg/ml) 569 3.15 ± 4.5 473 4.77 ± 7.4 -4.161 (<0.001) 
IL-6 (median pg/ml) 580 3.45 ± 3.2 484 4.49 ± 3.8 -4.771 (<0.001) 
TNFα (median pg/ml) 579 1.26 ± 1.7 484 1.47 ± 1.3 -2.184 (0.029) 
Psychological:          
MMSE <24 581 18 (3.1) 485 29 (6.0) 5.247 (0.022) 
HADS A 581 5.29 ± 3.7 484 6.24 ± 4.1 -3.922 (<0.001) 
HADS D 581 3.47 ± 2.7 484 4.32 ± 3.0 -4.785 (<0.001) 
Total attenders n = 581 (max). Total non-attenders n = 485 (max). Analysis is a two-tailed independent t-test or Pearson’s chi squared. 
Values are means ± SD, median (interquartile range) or n (%). SIMD, Scottish Index of Multiple Deprivation; HbA1c, haemoglobin A1c; 
CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α; TIA, transient ischaemic attack; MMSE, Mini Mental State 
Exam; HADS A, Hospital Anxiety and Depression Scale-Anxiety subscale; Hospital HADS B, Hospital Anxiety and Depression Scale- 
Depression subscale. 
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5.1.6 Baseline cognitive status of total study population and those attending 10-year follow-
up 
The correlations between the individual cognitive tests are shown in Table 10a and 10b. 
The cognitive tests at baseline were all highly correlated (p<0.001), and this was also 
observed at follow-up (p<0.001). Note that for TMTB, the correlations are all negative as for 
this test a higher score represents a worse performance.  
Table 11 presents the cognitive ability of the total study population at baseline (n=1066).  It 
also compares the baseline cognitive ability of the population who attended the follow-up 
clinic (n=581) with those who did not attend (n=485).  
At baseline, the general cognition, as measured by ‘g’, of the total population was 
arbitrarily centred on 0 with a standard deviation of 1. The population who went on to 
attend the 10-year follow-up had a higher mean ‘g’ score than those who did not attend 
(0.21±0.95 versus -0.26±1.00; R 0.25). Similarly, when looking at the constituent cognitive 
tests the attending population consistently had a superior score when compared with those 
of the non-attending population.   
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  MHVS LM Faces MR DST InTMTB LNS BVFT 
MHVS - 0.38 0.28 0.45 0.37 -0.37 0.40 0.44 
LM  - 0.24 0.28 0.27 -0.28 0.31 0.25 
Faces   - 0.24 0.29 -0.26 0.20 0.22 
MR    - 0.38 -0.46 0.40 0.36 
DST     - -0.63 0.40 0.40 
InTMTB      - -0.50 -0.39 
LNS       - 0.46 
BVFT        - 
Cognitive tests are non-imputed.  Values for all individual cognitive tests are correlation 
coefficients from two-tailed Pearson correlations. All p<0.001. MHVS, Mill Hill Vocabulary 
Scale; LM, Logical Memory; MR, Matrix Reasoning; DST, Digit Symbol Test; lnTMTB, Trail 
Making Test B (Natural log transformed); LNS, Letter Number Sequencing; BVFT, 
Borkowski Verbal Fluency Test.  
 
  MHVS LM Faces MR DST InTMTB LNS BVFT 
MHVS - -0.42 0.33 0.46 0.43 -0.37 0.44 0.45 
LM  - 0.35 0.38 0.45 -0.46 0.44 0.29 
Faces   - 0.33 0.41 -0.36 0.31 0.33 
MR    - 0.49 -0.52 0.52 0.40 
DST     - -0.74 0.52 0.45 
InTMTB      - -0.57 -0.40 
LNS       - 0.46 
BVFT        - 
Cognitive tests are non-imputed.  Values for all individual cognitive tests are correlation 
coefficients from two-tailed Pearson correlations. All p<0.001. MHVS, Mill Hill Vocabulary 
Scale; LM, Logical Memory; MR, Matrix Reasoning; DST, Digit Symbol Test; lnTMTB, Trail 
Making Test B (Natural log transformed); LNS, Letter Number Sequencing; BVFT, 
Borkowski Verbal Fluency Test.  
 
Table 10. (a) Inter-correlations of cognitive test scores at baseline 
Table 10. (b) Inter-correlations of cognitive test scores at year 10 
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Table 11. Baseline cognitive test scores for total population and for 10 year follow-up population 
Cognitive 
test 
Total Population                         
(maximum n=1066) 
Population attending follow-up  
(maximum n = 581) 
Population not attending follow-up  
(maximum n = 485  ) 
N mean ± SD Min Max N mean ± SD Min Max N mean ± SD Min Max 
g 1061 0.00 ± 1.00 -3.37 3.08 581  0.21 ± 0.95 -2.65 3.08 480 -0.26 ± 1.00 -3.37 2.26 
MMSE 1063 28.30 ± 1.89 14 30 580  28.51 ± 1.62 21 30 483 28.06 ± 2.14 14 30 
MHVS 1049 30.93 ± 5.23 9 43 574 31.59 ± 5.23 11 43 475 30.13 ± 5.11 9 43 
LM 1050 25.24 ± 8.17 0 46 577  25.83 ± 8.06 4 46 473 24.52 ± 8.26 0 45 
TMTB 1052 119.00 ± 59.63 38 570 578 109.63 ± 51.09 38 570 474 130.43 ± 66.93 40 498 
Faces 1059 65.82 ± 7.88 40 88 580  66.89 ± 7.84 40 88 479 64.52 ± 7.75 42 84 
MR 1052 12.81 ± 5.28 3 25 575  13.74 ± 5.32 4 25 477 11.69 ± 5.01 3 25 
DST 1057 49.21 ± 14.77 9 99 579  51.78 ± 4.56 9 99 478 46.09 ± 14.43 10 93 
BVFT 1060 36.93 ± 12.83 5 79 580  38.28 ± 12.65 8 79 480 35.29 ± 12.87 5 76 
LNS 1048 9.67 ± 2.75 0 19 575  10.07 ± 2.70 2 19 473 9.19 ±2.74 0 17 
Values are mean ± SD. Data for g has been imputed; for remaining cognitive tests are non-imputed. G was arbitrarily standardised 
through principal components analysis, resulting in mean = 0 and SD = 1. Data for TMTB was log transformed prior to analysis. 
MMSE, Mini-Mental-State Examination; MHVS, Mill Hill Vocabulary Scale; LM, Logical Memory; TMTB, Trail-Making Test-B; MR, 
Matrix Reasoning; DST, Digit Symbol Test; BVFT, Borkowski Verbal Fluency Test; LNS, Letter Number Sequencing. 
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5.1.7 Change in cognitive scores from baseline to year 10 in those attending follow-up 
Table 12 describes the cognitive test scores of the population attending follow-up at 
baseline and at year 10. General cognition, ‘g’ was 0.34±0.85 at baseline in the attending 
population which fell to -0.10±0.90 at year 10. This was reflected by the other cognitive 
tests, where performance in all cognitive tests worsened at follow-up, except for the Faces 
test where performance improved slightly at follow-up (66.99±7.83 versus 67.86±8.75). 
Mean performance in the MHVS was poorer at follow-up, despite being used as a measure 
of crystallised intelligence that was predicted to remain relatively stable over time. 
 
5.1.8 Baseline characteristics of people with incident dementia by year 10  
Table 13 compares the baseline characteristics of the people classed as having probable 
dementia at year 10 (n=106) with those without dementia (n=960). 
The probable dementia group was significantly different in age (p<0.001). After adjusting 
for age and sex, the probable dementia group consumed on average significantly less 
alcohol at baseline (p=0.013), than those without dementia. Percentage of body fat was 
lower at baseline in the group with probable dementia (p=0.025) and psychological tests 
revealed that the probable dementia group had a higher percentage of people scoring less 
than 24 on their MMSE dementia screen test (p<0.001), 24 being the clinical cut-off used 
for referral, and this group had higher levels of anxiety and depression when compared to 
the remaining sample (p=0.001, p<0.001, respectively).
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Table 12. Cognitive test scores of attenders at follow-up at baseline and year 10 follow-up 
Cognitive test N 
Baseline score of population attending follow-up Year 10 follow-up score of population attending follow-up 
mean ± SD mean ±SD 
g 526  0.34 ± 0.85 -0.10 ± 0.90 
MMSE 580  28.51 ± 1.62  27.62 ± 3.16 
MHVS 550  31.45 ± 5.13  30.76 ± 5.59 
LM 577  25.83 ± 8.06  23.32 ± 9.21 
TMTB† 544  97.00 (76.00-124.00)†  127.00 (98.00-178.00)† 
Faces 563  66.99 ± 7.83  67.86 ± 8.75 
MR 568  13.77 ± 5.32  10.96 ± 5.32 
DST 553  52.37 ± 14.39  43.90 ± 14.28 
BVFT 576  38.37 ± 12.62  35.50 ± 13.29 
LNS 567  10.09 ± 2.69  7.73 ± 3.31 
Maximum n = 581. Values are mean ± SD (unless indicated†). Data for g have been imputed; for remaining cognitive tests are non-imputed. G was 
arbitrarily standardised through principal components analysis, resulting in mean = 0 and SD = 1. MMSE, Mini-Mental-State Examination; MHVS, 
Mill Hill Vocabulary Scale; LM, Logical Memory; TMTB, Trail Making Test B; MR, Matrix Reasoning; DST, Digit Symbol Test; BVFT, Borkowski Verbal 




(total n = 106) 
Remaining 
sample (total 
n = 960) B (SE) OR (95% CI) 
Demographic:   
 
   
















1st quintile  13 (12.3) 114 (11.9)    
2nd quintile  17 (16.0) 191 (19.9)    
3rd quintile  20 (18.9) 168 (17.5)    
4th quintile  27 (25.5) 167 (17.4)    
5th quintile  29 (27.4) 320 (33.3)    
Educational 




 1.151 (0.872- 
1.519) 
University/ college 18 (17.0) 153 (15.9)   
Professional/ technical 21 (19.8) 286 (29.8)   
Secondary school 65 (61.3) 516 (53.8)   
Primary School 2 (1.9) 5 (0.5)   





Full-time 8 (7.5) 67 (7.0)   
Part-time 5 (4.7) 72 (7.5)   
Unemployed 0 9 (0.9)   
Retired 92 (86.8) 772 (80.4)   
Homemaker 1 (0.9) 18 (1.9)   
Other 0 22 (2.3)   
Vascular related:     
Systolic blood 





Table 13. Baseline demographic characteristics of dementia patients and sample without 
dementia at year 10 
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Diastolic blood 

















































10 (9.4) 144 (15.0)   
-  Former 
59 (55.7) 439 (45.7)   
- Never 
37 (34.9) 377 (39.3)   
Total cigarettes per 










Diabetes related:     
Diabetes duration 





HbA1c (median (IQR)) 
















- Insulin ± oral 22 (20.8) 164 (17.1)   
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- Oral 66 (62.3) 615 (64.1)   
- Diet controlled 18 (17.0) 181 (18.9)   
Obesity related:     
Body mass index 





















Inflammatory related:     
Fibrinogen (median 















TNFα (median pg/ml) 





Psychological:     















Total dementia cases n = 106. Total remaining sample n = 960. Analyses are logistic 
regression adjusting for age and sex. Values are means ± SD, median (interquartile range) 
or n (%), B; Unstandardised beta (Standard error), OR; Odds Ratio (95% Confidence 
interval). SIMD, Scottish Index of Multiple Deprivation; HbA1c, haemoglobin A1c; CRP, c-
reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α; TIA, transient 
ischaemic attack; MMSE, Mini Mental State Exam; HADS A, Hospital Anxiety and 
Depression Scale-Anxiety subscale; Hospital HADS B, Hospital Anxiety and Depression 




5.1.9 Baseline cognitive ability of people with incident dementia at year 10 
The baseline cognitive test scores of the people with probable incident dementia by year 10 
follow-up are shown in Table 14. All cognitive test scores in the dementia group were lower 
than those of the remaining sample at baseline. MHVS, providing a measure of crystallised 
cognitive ability was lower in the probable dementia group, despite this group not having 
been diagnosed with dementia at baseline and so was predicted to be the same. MMSE, 
used to screen for dementia, was lower at baseline in the probable incident dementia 
group than the remaining sample, which indicates that the sample at baseline who went on 




Table 14. Baseline cognitive test scores in dementia patients and sample without 
dementia at year 10 follow up  
Cognitive test 
Y10 Dementia group at BL (max 
n=106) 
Remaining Sample at BL (max n= 
960) 
Total (N) Mean ± SD Total (N) Mean ± SD 
g  105  -0.61 ± 1.10  956  0.08 ± 0.96 
MMSE  106  27.11 ± 2.77 957 28.43 ± 1.72  
MHVS  104  29.34 ± 5.89 945  31.11 ± 5.12 
LM  100 22.04 ± 8.57 950 25.58 ± 8.06 
Faces  105  63.55 ± 7.74 954 66.07 ± 7.86 
MR  105 11.27 ± 5.49 947 12.99 ± 5.23 
DST  104 42.74 ± 14.30 953 49.91 ± 14.66 
TMTB†  104 132.50 ± 96.00 948  102.00 ± 55.00  
LNS  106  8.22 ± 2.77 942  9.84  ± 2.70 
BVFT  106 32.97 ± 13.07 954 37.37 ± 12.74 
Values are mean ± SD (unless indicated†). Data for g has been imputed; for remaining 
cognitive tests are non-imputed. G was arbitrarily standardised through principal 
components analysis, resulting in mean = 0 and SD = 1. Data for TMTB was log 
transformed prior to analysis. MMSE, Mini-Mental-State Examination; MHVS, Mill Hill 
Vocabulary Scale; LM, Logical Memory; TMTB, Trail-Making Test-B; MR, Matrix 
Reasoning; DST, Digit Symbol Test; BVFT, Borkowski Verbal Fluency Test; LNS, Letter 
Number Sequencing. †TMTB values are median (IQR), as not normally distributed. 
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5.2 INTER-CORRELATIONS AND RISK FACTOR ASSOCIATIONS OF OBESITY AND SYSTEMIC 
INFLAMMATION MARKERS 
5.2.1 Inter-correlations of obesity measures and association with other risk factors at 
baseline 
Table 15a shows the correlations between all the obesity measures collected at baseline. All 
variables were significantly correlated with each other (all p<0.001), with correlation 
coefficients being larger for BMI with WC and BF (0.84 and 0.68), than WHR with WC and BF 
(0.49 and 0.19). BMI and WHR were significantly correlated at baseline but with a relatively 
low correlation coefficient of 0.10, indicating a weak effect. 
Table 15b shows the correlations between all obesity measures collected at follow-up. 
Again, all were significantly associated with each other (all p<0.001). Correlation 
coefficients between the variables reflected those seen at baseline, with smaller 
associations between BMI and WHR (0.18) than that seen with WC (0.81).  
Table 16 shows the association of BMI and WHR with the other baseline risk factors. To 
summarise, higher BMI was significantly associated with more intensive types of diabetic 
medication status (p =0.003) as was a higher WHR (p<0.001). Both higher BMI and higher 
WHR were also associated with male sex (both p<0.001), increased risk of angina (both 
p<0.001), lower level of HDL (both p<0.001), increased serum triglycerides (both p<0.001) 
and increased severity of depression (both p<0.001).  
Increased BMI was as also significantly associated with age (p<0.001), diastolic BP (p=0.024) 
and number of alcohol units consumed (p=0.025), while WHR was not. In contrast, 
Increased WHR was significantly associated with the duration of diabetes (p<0.001), HbA1c 
(p<0.001, plasma glucose (p=0.004), diabetic retinopathy (p=0.006), anxiety (p=0.005), 
smoking status (p=0.002) and number of cigarettes smoked (p=0.006), while BMI was not. 
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This highlights that while BMI and WHR are often used to measure the same clinical 
outcome (obesity), subtle differences are present when looking at risk factor associations.  
 
  BMI WHR WC BF (%) 
BMI -  0.099  0.843  0.682 
WHR   -  0.499  0.192 
WC    -  0.444 
BF (%)       - 
Values for all individual obesity measures are correlation coefficients from two-tailed 
Pearson correlations. All p<0.001. BMI, Body Mass Index; WHR, Waist to Hip Ratio; WC, 
Waist circumference; BF, Body fat. 
 
 BMI WHR WC 
BMI -  0.179 0.814 
WHR   -  0.571 
WC    -  
Values for all individual obesity measures are correlation coefficients from two-tailed 
Pearson correlations. All p<0.001. BMI, Body Mass Index; WHR, Waist to Hip Ratio; WC, 
Waist circumference. 
Table 15. (a) Inter-correlations of obesity measures at baseline 




r Beta (SE) P value r Beta (SE) P value 
Demographic:  
Age (years) 1066 -0.194  <0.001 -0.049  0.109 
Sex males  1066 
 2.218 (0.342) <0.001  -0.075 (0.004) <0.001 
Diabetes related:  
      
Diabetes duration (years)†  1053 0.050  0.109 0.115  <0.001 
HbA1c† 1057 0.047  0.132 0.161  <0.001 
Plasma Glucose (mmol/l) 1049 0.035  0.275 0.092  0.004 
Diabetic medication 1066  0.823 (0.279) 0.003  0.016 (0.003) <0.001 
Vascular related:  
Systolic BP (mmHg) 1064 0.057  0.076 -0.027  0.393 
Diastolic BP (mmHg) 1064 0.072  0.024 0.042  0.188 
Hypertension 1064  0.602 (0.353) 0.089  -0.001 (0.004) 0.822 
Stroke  1066  1.170 (0.726) 0.107  0.020 (0.009) 0.023 
TIA  1066  -0.873 (1.000) 0.383  0.003 (0.012) 0.775 
MI  1066  0.823 (0.496) 0.098  0.010 (0.006) 0.081 
Angina  1066  1.569 (0.377) <0.001  0.018 (0.005) <0.001 
Diabetic retinopathy 1044  0.162 (0.361) 0.653  0.012 (0.074) 0.006 
High density lipoprotein (mmol/l) 1057 -0.185  <0.001 -0.187  <0.001 
Table 16. Associations between BMI and WHR with baseline risk factors 
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Serum triglycerides (mmol/l) 1058 0.127  <0.001 0.128  <0.001 
Smoking status (current, ex, non-smoker) 1066  0.005 (0.251) 0.983  -0.009 (0.003) 0.002 
Total cigarettes per day 1061 -0.039  0.220 0.087  0.006 
Alcohol units 1066 -0.071  0.025 -0.025  0.425 
Psychological related:  
HADS A 1065 0.032  0.309 0.090  0.005 
HADS D 1065 0.183  <0.001 0.183  <0.001 
Analyses are two-tailed Pearson correlations, Spearman’s correlations (if indicated) or ANCOVA adjusted for age and sex (‘Demographic’, 
unadjusted). Values are Spearman’s correlation coefficients for duration of diabetes, HbA1c, smoking pack years, alcohol units. Values are Beta 
coefficients for sex, hypertension, stroke, TIA, MI, Angina, Diabetic Retinopathy, Smoking status.  BMI, Body Mass Index; WHR, Waist to Hip Ratio; 
HbA1c, haemoglobin A1c, TIA, Transient Ischaemic Attack; MI, Myocardial Infarction; HADS A, Hospital Anxiety and Depression Scale-Anxiety 
subscale; Hospital HADS B, Hospital Anxiety and Depression Scale- Depression subscale. †Spearman’s correlation analysis. 
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5.2.2 Inter-correlations of inflammatory markers and associations with obesity measures  
Table 17 shows the correlation between the individual markers for systemic inflammation 
at baseline. A significant but weak positive correlation between all markers (fibrinogen, 
CRP, IL-6 and TNF alpha) was observed (p<0.001).  The association of BMI and WHR with 
the inflammation markers (fibrinogen, CRP, IL-6 and TNF alpha) are shown in Table 18. Both 
increased BMI and increased WHR were significantly associated with each of the markers (r 




Table 17. Inter-correlations of inflammatory biomarkers at baseline 
  
Fibrinogen 




(ng/mol) -  0.533 0.338 0.128 
lnCRP (mg/mol)   - 0.426  0.119 
lnIL-6 (pg/mol)    -  0.314 
lnTNFα 
(pg/mol)       - 
Values for all individual inflammatory measures are correlation coefficients from two-
tailed Pearson correlations. All p<0.001. TNFα, Tumour Necrosis Factor Alpha; IL-6, 




5.2.3 The association between systemic inflammatory markers and cognitive ability at 
baseline 
Table 19 (re-analysed and adapted from Marioni et al. (2010)), shows the outcome of the 
regression models investigating the effect of inflammation on cognitive ability as measured 
at baseline.  
General cognitive ability was negatively associated with IL-6, both when adjusted for age 
and sex (standardised beta= -0.159; p<0.001), and in the fully adjusted model (standardised 
beta= -0.126; p<0.001). This result was mirrored by the majority individual cognitive tests 
where fully adjusted models for lnTMTB (standardised beta= 0.144; p<0.001), Faces 
(standardised beta= -0.078; p=0.017), MR (standardised beta= -0.105; p=0.002) and DST 
(standardised beta= -0.111; p<0.001) were associated with lower levels of IL-6 when 
adjusted for diabetes and vascular risk factors. General cognitive ability was also associated 
with TNF alpha (standardised beta= -0.085; p=0.007); however, in fully adjusted models this 
Table 18. Associations between BMI and WHR with potential mediating inflammatory risk 
factors at baseline 
Marker 
BMI WHR 
r p-value r p-value 
Fibrinogen  0.177 <0.001 0.071 0.023 
lnCRP  0.231 <0.001 0.118 <0.001 
lnIL-6  0.237 <0.001 0.124 <0.001 
lnTNFα  0.106 0.001 0.099 0.001 
Analyses are two-tailed Pearson correlations controlling for age and sex. Log-transformed 
variables were used for CRP, IL-6 and TNF-α. BMI, Body Mass Index; WHR, Waist to Hip 
Ratio; CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α. 
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association was no longer significant. The association between TNF alpha and cognitive 
tests TMTB and MR was however found to be statistically significant in fully adjusted 
models (standardised beta= 0.064; p= 0.042, standardised beta= -0.098; p= 0.002, 
respectively). 
Other inflammatory markers were associated with performance in a selection of the 
cognitive tests. Fibrinogen was associated with performance in TMTB (standardised beta= 
0.092; p=0.004) and MR (standardised beta= -0.029, p=0.030) when adjusted for age and 
sex; however, this association diminished in fully adjusted models. TNF alpha was found to 
be associated with performance in MR, when adjusted for age and sex but also in fully 
adjusted models (standardised beta= -0.097, p=0.002).  
It should be noted that for the analysis on CRP, cases with CRP level above 10 mg/ml were 
removed, as these are indicative of acute inflammation likely as a result of a temporary 
infection. Despite this, statistically significant associations with CRP were found. 
In summary, inflammatory markers TNF alpha and IL-6 were shown to be associated with 
cognitive ability in fully adjusted models, the latter marker being also significantly 
associated with the general cognitive ability as measured by ‘g’. 
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Table 19. The association between inflammatory markers and cognitive status as measured by individual cognitive tests and g at baseline 
Inflammation 
marker 
g LM ln TMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 
Fibrinogen 
+ age and sex 










-0.024    
(0.032) 




+ full adjustment of 
baseline covariates 








-0.037    
(0.032) 
0.024     
(0.032) 





+ age and sex 








-0.075    
(0.038) 






+ full adjustment of 
baseline covariates 








-0.032    
(0.039) 




























































+ full adjustment of 
baseline covariates 
















*p<0.05 **p<0.01 ***p<0.001. Baseline covariates: duration of diabetes (years), HbA1c (haemoglobin A1c), diabetic medication, hypertension, 
Cerebral Event (Stroke or TIA), Heart disease (Angina or MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), 
alcohol units, Diabetic retinopathy, anxiety, depression. Data for g have been imputed, for remaining cognitive tests are non-imputed. LM, Logical 
Memory; MR, Matrix Reasoning; DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency 
Test; CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α. 
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5.2.4 Associations between obesity measures and cognitive ability at baseline 
 The cross-sectional associations between obesity measures and cognitive ability at baseline 
are shown in Table 20. Higher BMI was significantly associated with poorer general 
cognition (r= -0.08; p=0.008), when adjusting for age and sex. Higher BMI was also 
significantly associated poorer scores in a number of the individual cognitive tests; MR (r=-
0.08; p=0.014), DST (r=-0.11; p=0.001) and BVFT (r=-0.07; p=0.027), when adjusting for age 
and sex. Higher WHR was also significantly associated with poorer general cognition (r=-
0.16; p<0.001), when adjusting for age and sex. Notably, this effect size was almost double 
that of BMI. Higher WHR was also significantly associated with poorer scores in the majority 
of the individual cognitive tests. WHR was associated with Faces (r=-0.09; p=0.006), MR (r=-
0.11; p= 0.001), DST (r=-0.14; p<0.001), lnTMTB (r=0.14; p<0.001), LNS (r=-0.09; p=0.007) 
and BVFT (r=-0.11; p=0.001). The effect sizes for the associations between cognitive ability 
and WHR were all greater than for those with BMI, with the greatest differences in effect 




r p-value r p-value 
g  -0.083 0.008 -0.161  <0.001 
LM   0.010  0.758 -0.052  0.100 
Faces  -0.037 0.245 -0.086  0.006 
MR  -0.077 0.014 -0.108  0.001 
DST  -0.109 0.001 -0.143 <0.001 
lnTMTB   0.057 0.068  0.144  <0.001 
LNS  -0.025 0.430 -0.085  0.007 
BVFT  -0.070 0.027 -0.107  0.001 
Analyses are two-tailed Pearson correlations controlling for age and sex. Data for g have 
been imputed, for remaining cognitive tests are non-imputed. BMI, Body Mass Index; 
WHR, Waist to Hip Ratio; LM, Logical Memory; lnTMTB, Trail Making Test B (Natural log 
transformed); MR, Matrix Reasoning; DST, Digit Symbol Test; BVFT, Borkowski Verbal 
Fluency Test; LNS, Letter Number Sequencing. 
 
 
5.3 OBESITY, INFLAMMATION AND COGNITIVE CHANGE 
5.3.1 The association between BMI and cognitive decline 
As BMI is often associated with cardiovascular outcomes in a non-linear or J-shaped 
manner, the main association of BMI with the cognitive outcome ‘g’ was investigated for 
linearity.  As the conventional clinical cut off scores, developed for cardiovascular outcomes 
did not generate equal categories in this data set, namely that only 1 person had a BMI of 
<18.5 kg/m2 and 590 had a BMI of >30 kg/m2 (see Table 7), quintile scores were derived 
which distributed the data equally among 5 groups. The cut-points of the quintiles along 
with the distribution of age and sex are described in Table 21. As there was slight variation 
in age and sex within the quintiles, analyses were adjusted for age and sex. When plotting 
Table 20. Cross-sectional associations between BMI and WHR and cognitive test scores at 
baseline 
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the 5 quintile BMI groups against the mean follow-up ‘g’ score per group there appeared to 
be no strong evidence for a non-linear association. Similarly, scatterplots of BMI as a 
continuous variable against follow-up ‘g’, indicated that there was also no evidence for a 




Quintile cut - point 







1 18.39 26.70 22.30 68.85 (3.79) 
2 26.72 29.17 24.00 68.3 (4.13) 
3 29.19 32.00 21.20 68.13 (4.15) 
4 32.02 35.49 19.20 67.44 (4.32) 
5 35.50 55.44 13.20 66.78 (4.32) 
 
 













1 2 3 4 5
g 
BMI Quintiles
Table 21.  The cut-points and distribution of age and sex per BMI quintile 
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Outcomes of the regression models investigating the association between BMI and change 
in cognition are shown in Table 22. After adjusting for age and sex, higher BMI was 
associated with poorer scores in follow-up ‘g’ (standardised beta= -0.093; p=0.033), MR 
(standardised beta= -0.107; p=0.016) and DST (standardised beta= -0.096; p=0.032). These 
initial associations did not remain after adjusting for baseline cognitive test score or any 
other subsequent adjustments for diabetes or vascular risk factors.  
A higher BMI was associated with a worse performance in LNS when adjusting for baseline 
cognitive test score. When adjusting for age, sex and baseline LNS score, an increased BMI 
was associated with a significantly poorer performance in LNS (standardised beta= -0.087; 
p=0.027) thereby indicating an association with a change in cognition. This association 
persisted after further adjusting for diabetes related risk factors (standardised beta= -0.082; 
p=0.039). However, in the fully adjusted model, which included vascular covariates, this 
association was no longer significant. All other associations between BMI and cognitive test 
at follow-up were not significant and remained so after each adjustment.  
In summary, despite observed associations between increased BMI and poorer follow-up 
cognitive ability, an increased BMI was only associated with worsened cognitive decline in 
the LNS subtest, where performance is related to working memory and processing speed. 
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BMI 
g LM ln TMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 






































































*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. BMI, Body Mass Index; LM, Logical Memory; MR, Matrix Reasoning; 
DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency Test.  
Table 22. The association between BMI and cognitive decline as measured by individual cognitive tests and g at year 10 follow-up 
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5.3.2 The association between WHR and cognitive decline 
Outcomes of the regression models investigating the effect of WHR on change in cognition 
are shown in Table 23. After adjusting for age and sex, increased WHR was associated with 
poorer follow-up ‘g’ (standardised beta= -0.265; p<0.001). This association was mirrored by 
the majority of the other cognitive tests.  
When adjusting for baseline cognitive performance associations persisted for ‘g’ 
(standardised beta= -0.105; p=0.001) and also for the majority of the individual cognitive 
tests. This indicates that higher WHR is associated with greater cognitive decline, in general 
cognition and also in several of the cognitive domains, over time. Furthermore, in the fully 
adjusted models, these significant associations remained for ‘g’ (standardised beta= -0.076; 
p=0.020), DST (standardised beta= -0.162; p<0.001), BVFT (standardised beta= -0.079; 
p=0.022) and LNS (standardised beta= -0.124; p=0.006). Despite these significant 
associations between increased WHR and cognitive decline in fully adjusted models, it 
should be noted that the effect sizes drop considerably, ranging from around 30% to 60% 
decrease in effect.  
These results indicate that an increased WHR at baseline is significantly associated with a 
greater decline in general cognition, as well as in the performance in DST, BVFT and LNS, 
where performance was related to processing speed, executive function, and working 
memory, respectively.  
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WHR 
g LM ln TMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 







































































*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. WHR, Waist to Hip Ratio; LM, Logical Memory; MR, Matrix 
Reasoning; DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency Test; CRP, c-reactive 
protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α. 
Table 23. The association between WHR and cognitive decline as measured by individual cognitive tests and g at year 10 follow-up 
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5.3.3 The association between systemic inflammatory markers and cognitive decline  
Outcomes of the regression models investigating the association between the individual 
inflammation markers and change in cognition are shown in Table 24. Similar to what was 
shown at baseline, cognitive ability at follow-up was associated with a number of the 
inflammatory markers measured at baseline. At follow-up the majority of associations were 
seen with IL-6, followed by Fibrinogen and CRP. In contrast to the associations observed at 
baseline, TNF alpha was not significantly associated with follow-up cognitive ability. 
In models that made further adjustment for baseline cognitive test performance, higher 
Fibrinogen (standardised beta= -0.059; p=0.032), CRP (standardised beta= -0.067; p=0.036) and 
IL-6 (standardised beta= -0.064; p=0.018) were found to be significantly associated with a 
decline in general cognitive ability. In fully adjusted models these associations observed 
between higher Fibrinogen, CRP and IL-6 and a decline in general cognitive ability were no 
longer significant. However, in the test MR, a significant association was observed, when fully 
adjusted for diabetic and vascular risk factors.  
Worsened performance in the DST test was shown to be associated with higher levels of a 
number of the inflammatory markers. In fully adjusted models, DST performance was 
associated with Fibrinogen (standardised beta= -0.087; p=0.008), CRP (standardised beta= -
0.091; p=0.022) and also TNF alpha (standardised beta= -0.086; p=0.005). This last association 
with TNF alpha is particularly striking as levels were shown to not be significantly associated 
with the ability to perform the test at either baseline or follow-up. Despite this, a clear 
association between this marker and a decline in performance over time is demonstrated in this 
analysis. 
It should be noted that for the analysis on CRP, cases with CRP level above 10 mg/ml were 
removed, as these are indicative of acute inflammation likely as a result of a temporary 
infection.
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Table 24. The association between inflammatory markers and cognitive decline as measured by individual cognitive tests and g at year 10 follow-
up 
Inflammation marker 
g LM lnTMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 
Fibrinogen 







































































+ baseline cognition 
score 















































































































































*p<0.05 **p<0.01 ***p<0.001. Baseline covariates: duration of diabetes (years), HbA1c (haemoglobin A1c), diabetic medication, hypertension, 
Cerebral Event (Stroke or TIA), Heart disease (Angina or MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), 
alcohol units, Diabetic retinopathy, anxiety, depression. Data for g have been imputed, for remaining cognitive tests are non-imputed. LM, Logical 
Memory; MR, Matrix Reasoning; DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency 
Test; CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α.  
141 
5.3.4 The association between BMI and cognitive decline when adjusting for inflammation 
The outcome of the fully adjusted regression model that explores the possible effect of 
inflammation on the association between BMI and cognitive decline is given in Table 25a.   
When adjusting for inflammation after other vascular covariates, there was no statistically 
significant association between BMI and cognitive decline (as measured by ‘g’ and also the 
other cognitive tests). 
Table 25b shows the result of a similar model in which inflammatory markers were entered 
into the model before the vascular covariates (rather than afterwards, as in Table 25a). The 
rationale for this was that the effect of adjusting for inflammation after vascular covariates 
may mask a very weak association between predictor on outcome, as inflammation is 
known to have an impact on vasculature. When inflammation was added to the model 
before vascular covariates (Table 25b), a larger effect was observed for the association 
between BMI and cognitive decline when compared to the models in Table 25a. Despite 
this, both variations of the regression model showed no significant association between 
BMI and cognitive decline, when adjusting for inflammation regardless of when 
inflammation is entered into the model. 
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BMI 
g LM lnTMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 
























































































*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. BMI, Body Mass Index; LM, Logical Memory; MR, Matrix Reasoning; 





Table 25. (a) The association between BMI and cognitive decline as measured by individual cognitive tests and g, adjusting for systemic 
inflammation after vascular covariates 
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BMI 
g LM lnTMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 
























































































*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. BMI, Body Mass Index; LM, Logical Memory; MR, Matrix Reasoning; 
DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency Test. 
 
Table 25. (b) The association between BMI and cognitive decline as measured by individual cognitive tests and g, adjusting for systemic 
inflammation before vascular covariates 
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5.3.5 The association between WHR and cognitive decline in total population and in men 
and women separately 
As WHR was shown to be associated with cognitive decline (‘g’, standardised beta= -0.105; 
p=0.001), a post hoc analysis to the results shown in Table 23 was carried out.  This aimed 
to address concerns that as body shape and fat distribution are known to vary between the 
sexes (Karastergiou et al., 2012), the observed significant association may be driven by sex, 
and that WHR is acting as a proxy to sex. In this analysis, a model adjusting for age and 
baseline cognitive score was applied to men and women in separate analyses. These 
models showed a significant association between WHR and cognitive decline in men 
(standardised beta= -0.109; p=0.004) and also in women (standardised beta= -0.101; 
p=0.008). This significant result for both sexes was also found for DST (men, standardised 
beta -0.158, p<0.001; women, standardised beta -0.162, p<0.016), MR (men, standardised 
beta= -0.118, p=0.12; women, standardised beta= -0.103, p=0.023) and LNS (men, 
standardised beta= -0.152, p=0.003; women, standardised beta= -0.163, p=0.002). In men, 
a decline in the BVFT test was also significantly associated with WHR (men, standardised 
beta= -0.137, p=0.003), as was TMTB (men, standardised beta= 0.120, p=0.011), however 
these associations were not significant in women. LM and Faces tests were also not 
significant, for men and for women, although this may also be due to a lack of power to 
detect an association.  
 
5.3.6 The association between WHR and cognitive decline when adjusting for inflammation 
The result of the fully adjusted model showing the association between WHR and cognitive 
decline when accounting for diabetes and vascular covariates (described in Table 23), and 
when also accounting for inflammation markers is given in Table 26. As shown previously, 
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the fully adjusted model, exploring the association between WHR and cognitive decline, 
showed a statistically significant association for ‘g’ (standardised beta= -0.076; p=0.020), 
DST (standardised beta= -0.162; p<0.001), BVFT (standardised beta= -0.079; p=0.022) and 
LNS (standardised beta= -0.124; p=0.006). When introducing the inflammation markers into 
the model, the standardised beta for the association between WHR and ‘g’ fell only slightly 
and remained statistically significant (standardised beta -0.074; p=0.023). Similarly, the 
association between WHR and the cognitive tests DST, BVFT and LNS also persisted after 
adjusting for inflammation (DST, standardised beta= -0.158, p=0.038; BVFT, standardised 
beta= -0.079, p=0.036; LNS, standardised beta -0.121, p= 0.048). 
As a final adjustment step, BMI was also included into the model. This made little difference 
to the model and after this final step, the significance level persisted for ‘g’ (standardised 
beta= -0.074; p=0.026), indicating that WHR is associated with cognitive decline, 
irrespective all previously mentioned adjustment covariates, and also irrespective of BMI. 
Again, this association was also found in the cognitive tests DST (standardised beta= -0.166; 




g LM lnTMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 


























































































-0.074*   
(0.035) 






-0.057   
(0.043) 
-0.166***   
(0.039) 




*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. WHR, Waist to Hip Ratio; BMI, Body Mass Index; LM, Logical 
Memory; MR, Matrix Reasoning; DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency 
Test; CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α.  
 
Table 26. The association between WHR and cognitive decline as measured by individual cognitive tests and g, adjusting for systemic inflammation 
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5.3.7 The association between waist circumference (WC) and cognitive decline when 
adjusting for inflammation 
As WHR is derived from WC, another post hoc analysis that aimed to explore if the WHR 
analyses could be driven purely by visceral fat as measured by WC was carried out. The 
outcome of the fully adjusted regression model that explores the possible effect of 
inflammation on the association between WC and cognitive decline is given in Table 27.  For 
the association between WC and decline in ‘g’, a significant association was found after 
adjusting for age, sex and baseline ‘g’ (standardised beta= 0.059; p= 0.032). This association 
did not persist after further adjustments to the model. This was reflected by findings for the 
cognitive tests DST and LNS (all p<0.05). The association between WC and decline in BVFT 
persisted after adjusting for vascular covariates, however this association diminished when 
making further adjustments for inflammation.  
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WC 
g LM lnTMTB Faces MR DST BVFT LNS 
Standardised Beta (SE) 





















































+ baseline vascular 
covariates 














-0.051   
(0.042) 
+ TNFα, IL-6, CRP, 
Fibrinogen 














-0.042   
(0.044) 
*p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (natural log transformed), HbA1c (haemoglobin A1c) 
(natural log transformed), diabetic medication. Baseline vascular covariates: hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or 
MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. 
Data for g have been imputed, for remaining cognitive tests are non-imputed. WC, Waist Circumference; LM, Logical Memory; MR, Matrix 
Reasoning; DST, Digit Symbol Test; lnTMTB, Trail Making Test B (Natural log transformed); BVFT, Borkowski Verbal Fluency Test; CRP, c-reactive 
protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α.  
 
Table 27. The association between WC and cognitive decline as measured by individual cognitive tests and g, adjusting for systemic inflammation 
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5.3.8 Summary of analysis 
To summarise, results indicated an association between measures of increased levels of 
obesity at baseline with reduced cognitive ability at follow-up and also with increased 
decline in cognitive ability over 10 years. This result was most pronounced in the 
association between higher WHR and more cognitive decline. In fully adjusted models this 
association between WHR and cognitive decline persisted, which was not the case for 
either BMI or WC.  
Results also indicated that the predominant inflammation marker associated with general 
cognitive ability and decline in cognitive ability was IL-6. However, when inflammation was 
incorporated into the regression model investigating the association between WHR and 
general cognitive decline, this latter association was not greatly affected, suggesting that 
inflammation may not have a major mediating effect. 
 
5.4 OBESITY, INFLAMMATION AND DEMENTIA 
5.4.1 The association between inflammation and Dementia 
The outcome of the regression models exploring the relationship between baseline 
inflammatory markers and incident dementia is shown in Table 28. Models were adjusted 
first for age and sex, then diabetes-related and vascular risk factors, followed by further 
adjustment of each model for the other inflammatory markers.   
For fibrinogen TNF alpha and CRP, there was little evidence of an association between 
raised levels of these inflammatory markers and incident dementia; ORs for dementia per 
unit increase in inflammatory marker ranged from 0.78 to 1.02 across age and sex adjusted 
and multi-adjusted models, and none of the models reached statistical significance at the 
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0.05 level. It should be noted that for the analysis on CRP, cases with CRP level above 10 
mg/ml were removed, as these are indicative of acute inflammation likely as a result of a 
temporary infection. 
For IL-6, the odds of dementia appeared to increase per unit increase in inflammatory 
marker (age and sex adjusted OR 1.24; 95% CI 0.91, 1.70), although again, this association 
did not reach statistical significance (p<0.05) until after adjustment for the other 
inflammation markers (Fibrinogen, CRP and TNF alpha); at this point the odds ratio rose to 
1.56 per unit increase in IL-6 (95% CI 1.08, 2.27, p<0.05). 
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Risk factor Fibrinogen lnCRP lnIL-6 lnTNF α 
OR (95% CI)  
+ age and sex 0.93 (0.69-1.25) 0.82 (0.70-1.01) 1.24 (0.91-1.70) 1.02 (0.76-1.36) 
+ baseline diabetes covariates 0.89 (0.66-1.21) 0.82 (0.66-1.02) 1.21  (0.88-1.66) 0.99 (0.74-1.33) 
+ baseline vascular covariates 0.86 (0.63-1.19) 0.84 (0.66-1.06) 1.31 (0.93-1.84) 0.99 (0.73-1.35) 
+ respective other inflammatory 
markers† 
0.94 (0.65-1.36) 0.78 (0.60-1.01)   1.56 (1.08-2.27)* 0.93 (0.68-1.28) 
Analyses are logistic regressions. *p<0.05 **p<0.01 ***p<0.001. Baseline diabetes covariates: duration of diabetes (years) (Natural log 
transformed), HbA1c (haemoglobin A1c) (Natural log transformed), diabetic medication. Baseline vascular covariates:  hypertension, Cerebral Event 
(Stroke or TIA), Heart disease (Angina or MI), HDL (mmol/l), serum triglycerides (mmol/l), smoking (current, ex, or non-smoker), alcohol units, 
Diabetic retinopathy, anxiety, depression. BMI, Body Mass Index. †For Fibrinogen analysis; adjusted for CRP, c-reactive protein; IL-6, interleukin-6; 
TNFα, tumour necrosis factor α. For CRP analysis; adjusted for Fibrinogen; IL-6, interleukin-6; TNFα, tumour necrosis factor α. For IL-6 analysis; 
adjusted for Fibrinogen, CRP, c-reactive protein; TNFα, tumour necrosis factor α. For TNFα analysis; adjusted for Fibrinogen, CRP, c-reactive protein; 
IL-6, interleukin-6. 
 
Table 28. The association between IL-6, TNF α, CRP and Fibrinogen at baseline and dementia at year 10 follow-up 
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5.4.2 The association between Obesity and Dementia 
The assumption of linearity between obesity measures and dementia was explored by 
means of plotting the main obesity measure BMI, as categorised by quintiles, against the 
percentage of individuals categorised as having dementia. This provided evidence for a 
linear relationship (see Figure 6).  
The outcome of the regression models exploring the relationship between obesity 
measures and incident dementia are shown in Table 29. Models were adjusted first for age 
and sex, then diabetes-related risk factors, vascular risk factors, followed by further 
adjustment of each model for the inflammatory markers.   
 
 




















BMI and Dementia 
For BMI, the odds of dementia appeared to decrease per unit increase of BMI (age, sex 
adjusted OR 0.97; 95% CI 0.93, 1.01), which remained unchanged when further adjusting 
for diabetes covariates. This association did not reach statistical significance (p<0.05) until 
after making further adjustment for vascular covariates; when at this point the OR 
decreased slightly to 0.95 per unit increase of WC (95% CI 0.90, 0.99, p=0.29), and this 
association persisted and remained unchanged after making further adjustment for 
inflammation (see Table 29). 
 
WHR and Dementia 
For WHR, there was little evidence of an association between WHR and incident dementia; 
ORs for dementia per unit increase of WHR ranged from 1.01 to 1.02 across age and sex 
adjusted and multi- adjusted models, and none of the models reached statistical 
significance at the 0.05 level (see Table 29).   
 
WC and Dementia 
For WC, the odds of dementia appeared to decrease per unit increase in WC (age and sex 
adjusted OR 0.99; 95% CI 0.97, 1.00), which remained unchanged when further adjusting 
for diabetes covariates. This association did not reach statistical significance (p<0.05) until 
after adjustment for vascular risk factors; when at this point the OR decreased slightly to 
0.98 per unit increase of WC (95% CI 0.96, 0.99, p<0.05), and this association persisted and 
remained unchanged after making further adjustment for inflammation (see Table 29).  
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Percentage body fat and Dementia 
For percentage body fat, the odds of dementia appeared to decrease per unit increase of 
body fat (age and sex adjusted OR 0.97; 95% CI 0.93, 1.00), which changed little when 
further adjusting for diabetes covariates (age and sex adjusted OR 0.96; 95% CI 0.92, 1.00). 
This association did not reach statistical significance (p<0.05) until after adjustment for 
vascular risk factors; when at this point the OR deceased to 0.94 per unit increase of body 
fat (95% CI 0.90, 0.98, p<0.01), and this association persisted and remained unchanged 
after further adjustment for inflammation (see Table 29). 
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Risk factor BMI WHR† WC % Body Fat 
OR (95% CI)  
+ age and sex 0.97 (0.93-1.01) 1.02 (0.99-1.05) 0.99 (0.97-1.00) 0.97 (0.93-1.00) 
+ baseline diabetes covariates 0.97 (0.93-1.01) 1.02 (0.99-1.06) 0.99 (0.97-1.00) 0.96 (0.92-1.00) 
+ baseline vascular covariates   0.95 (0.91-0.99)* 1.01 (0.98-1.05)   0.98 (0.96-0.99)*     0.94 (0.90-0.98)** 
+ TNFα, IL-6, CRP, Fibrinogen   0.95 (0.90-0.99)* 1.01 (0.98-1.05)   0.97 (0.96-0.99)*     0.94 (0.90-0.98)** 
Analyses are logistic regressions. *p<0.05 **p<0.01 ***p<0.001. †In analysis WHR is transformed so that 1 unit is 0.01. Baseline diabetes 
covariates: duration of diabetes (years) (Natural log transformed), HbA1c (haemoglobin A1c) (Natural log transformed), diabetic medication. 
Baseline vascular covariates:  hypertension, Cerebral Event (Stroke or TIA), Heart disease (Angina or MI), HDL (mmol/l), serum triglycerides 
(mmol/l), smoking (current, ex, or non-smoker), alcohol units, Diabetic retinopathy, anxiety, depression. BMI, Body Mass Index; WHR, Waist to Hip 
Ratio; WC, Waist Circumference; CRP, c-reactive protein; IL-6, interleukin-6; TNFα, tumour necrosis factor α. 
Table 29. The association between BMI, WHR, WC and % Body Fat at baseline and dementia at year 10 follow-up 
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5.4.3 Summary of dementia analyses 
To summarise, results provide evidence for an association between some inflammatory 
markers and risk of dementia. These results also indicate that the predominant 
inflammation marker associated with general dementia was IL-6. Whereby strong inter-
correlations with the other inflammatory markers, some of which not associated with 
dementia, may suppress the effect of IL-6 on the model. 
Evidence is also presented on the association between obesity and dementia, however the 
direction of these associations, whereby a reduced body mass, size or fat percentage is a 
risk factor for dementia, indicates that the effect of undiagnosed pre dementia in the 
cohort may play a role in this outcome. 
 
5.5 PHYSICAL ACTIVITY, SEDENTARY BEHAVIOUR, COGNITIVE CHANGE AND DEMENTIA 
5.5.1 Follow-up characteristics of the attending population  
Year 10 follow-up characteristics of the ET2DS population (n=581) are presented in Table 
30.  The population had an average age of 77.3 years and 50.9% were male. The median 
duration of diabetes was 16 years, mean HbA1c was 58.08 mmol/mol (International 
Federation of Clinical Chemistry units), which equates to an average of approximately 7.5%. 
Most participants were on an oral medication (58.7%), 28.2 % were on an oral plus injection 
based medication, and only 13.1% controlled their diabetes through diet alone. The mean 
systolic blood pressure was 144.23 and diastolic blood pressure was 68.39, with 52.3% of 
the population being classed as having a form of hypertension. Mean total cholesterol was 
4.15 mmol/l, ranging from 1.7 to 8.8 mmol/l. Cardiovascular events consisted mainly of 
angina, where 174 people (29.9 %) had been diagnosed with the disease. Eighty three 
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people (14.3%) had experienced at least one myocardial infarct, 60 people (10.3%) had 
experienced at least one stroke, and 44 people (7.6%) had been diagnosed as having had a 
transient ischaemic attack. Microvascular events in the form of having experienced any 
degree of diabetic retinopathy (grade 1-4) was found in 60.8% of the population (353 
cases). 
Mean anxiety and depression levels as measured by the Hospital Anxiety and Depression 
Scale were 4.96 and 4.39, respectively. Sixty five people (11.2%) had mild anxiety, 43 (7.4%) 
had moderate anxiety and 14 (2.4%) had severe anxiety, when screened using this tool. 
Seventy people (12.0 %) had mild depression, 23 (4.0%) had moderate depression and 3 
(4.5%) had severe depression, when screened using this tool. Clinical cases of anxiety or 
depression, as indicated by a score of 11 or more (Snaith, 2003), were 57 (9.8%) and 26 
(4.5%), respectively. 
Median physical activity score, as measured by the International Physical Activity 
Questionnaire (IPAQ), was 1690 MET-1 minutes-1 week-1, which ranged from 0 to 14024 
MET-1 minutes-1 week-1. Sedentary behaviour, was on average 4119 minutes per week, 
ranging from 420 to 8190. Both physical activity and sedentary behaviours reflecting a wide 
range in participant activity levels and abilities. The mean BMI was 30.1 ±5.70 kg/m2, with a 
minimum of 17.31 kg/m2 and maximum of 53.22 kg/m2, with 42.9% of participants being 
classed as obese (BMI >30 kg/m2).  
The majority of individuals had never smoked (47.2%), a similar proportion were former 
smokers (44.4%) and only 7.1% were current smokers. The population consumed on 




Mean ± SD or n 
(%) 
Minimum Maximum N 
Missing 
data % 
Demographic:         
Age (years) 77.31 ± 4.16 70.14 85.74 581 0 
Sex males (n %) 296 (50.9)      581 0 
Diabetes related:         
Duration of Diabetes (median years(IQR)) 16 (8) 10 53 577 0.69 
HbA1c (mmol/mol) 58.08 ± 13.48 28 119 551 5.45 
Diabetes medication:       581 0 
          - Diet controlled only 76 (13.1)         
           - Oral medication only 341 (58.7)         
           - Injection ± Oral 164 (28.2)         
Vascular related:         
Systolic blood pressure (mmHg) 144.23 ± 20.30 90 220 579 0.34 
Diastolic blood pressure (mmHg) 68.39 ± 11.53 30 112 579 0.34 
Total cholesterol (mmol/l) 4.15 ± 1.02 1.7 8.8 550 5.64 
Hypertension (n) 304 (52.3)    581 0 
Any macro vascular disease (n)a 240 (41.3)    581 0 
Angina (n)a 174 (29.9)    581 0 
Myocardial infarct (n)a 83 (14.3)    581 0 
Stroke (n)a 60 (10.3)    581 0 
TIA (n)a 44 (7.6)    581 0 
Diabetic Retinopathy (n)a 353 (60.8)    581 0 
Table 30. Characteristics of the ET2DS at follow-up and the percentage of missing data 
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Psychological:           
Anxiety 4.96 ± 3.71 0 18 580 0.17 
Depression 4.39 ± 3.17 0 18 580 0.17 
Lifestyle:         
Physical activity (MET-1 minutes-1 week-1) 1690 (2438) 0 14024 581 0 
Sedentary time (min/week) 4119 ± 1336 420 8190 581 0 
Body Mass Index (kg/m2) 30.07 ± 5.70 17.31 53.22 571 1.72 
Smoking      573 1.38 
             - Current 41 (7.1)       
             - Former 258 (44.4)       
            - Never 274 (47.2)       
Alcohol units 5.84 ± 10.9     581 0 
Total n=581. Values are means ± SD, median (interquartile range) or n (%). HbA1c, haemoglobin A1c; MI, Myocardial Infarct; TIA, transient 
ischaemic attack; HADS A, Hospital Anxiety and Depression Scale-Anxiety subscale; Hospital HADS D, Hospital Anxiety and Depression Scale- 
Depression subscale. a These data are not cumulative. 
 
160 
5.5.2 Follow-up characteristics of the clinic visit and home visit attending population 
Table 31 describes the characteristics of the year 10 follow-up population who attended a 
clinic visit (n=435) and who received a home visit (n=146). On average at follow-up, more 
women received a home visit than men (p=0.003). Those who were seen at home had both 
lower systolic (p=0.014) and diastolic (p<0.001) blood pressure and were less likely to suffer 
from untreated hypertension (p=0.018).  Home visit participants were more likely to suffer 
from Angina (p=0.001) or have had a macrovascular event (p=0.001). There were more 
people with probable dementia seen as a home visit (p <0.001), reflected by a lower ‘g’ 
score in the home visit population on average (p<0.001). Levels of anxiety and depression 
were higher in those seen at home (p= 0.026 and p=0.001, respectively) as were levels of 
sedentary behaviour (p<0.001) and inactivity (p<0.001), possibly as a result of higher 
numbers of dementia in this population. Other characteristics such as age and BMI did not 
differ between the home visit and clinic visit attending populations.  
These results reflect an important difference in these two attending populations that may 
introduce a systematic bias by means of mode effect, whereby different testing 
circumstances affect cognitive outcomes in individuals. For example it is possible that 
participants find it stressful having researchers enter their home, exacerbating anxiety and 
thus having a direct impact on cognitive test results. Alternatively, it may also be that 
people with dementia experience higher levels of anxiety and depression in general and are 
also known to be more likely to request a home visit. Similarly, the observation that 
participants seen at home have lower blood pressure and lower prevalence of 
hypertension, may be due to not having had to walk prior to the clinic. On the other hand, 
those seen at home are more likely to have medications prescribed in a daily pill box from 
their pharmacist or have a carer ensure medication are taken correctly and not forgotten. 
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In the home visit group both a lower cognition score for ‘g’, as measured during the 
clinic/home visit, and a higher number of people with dementia are recorded, as derived by 
criteria that take advantage of independent clinical diagnoses, are noted. This indicates that 
poorer cognitive test scores in the home visit group are likely as a direct result of dementia 
diagnoses and that specific mode effects introduced as a result of different testing 
circumstances do not have a strong effect on the findings. Despite this the possible effect of 




Clinic Visit Home Visit 
T or X2 (p-value) 
N 
Population Mean 
± SD or n (%) 
N 
Population Mean 
± SD or n (%) 
Demographic:          
Age (years) 435  77.20 ± 4.08 146 77.67 ± 4.37 -1.21 (0.229) 
Sex males (n %) 435 237 (54.5)  146 59 (40.4) 8.66 (0.003) 
Diabetes related:          
Duration of Diabetes (median years(IQR)) 432 16 (7) 145 17 (8) -1.96 (0.052) 
HbA1c (mmol/mol) 417 57.35 ± 12.29 134 60.34 ± 16.50 -1.94 (0.055) 
Diabetes medication: 435   146   6.20 (0.045) 
           - Diet controlled only   54 (12.4)   22 (15.1)   
           - Oral medication only   268 (61.6)   73 (50.0)   
           - Injection ± Oral   113 (26.0)   51 (34.9)   
Vascular related:          
Systolic blood pressure (mmHg) 435 145.43 ± 19.73 144 140.65 ± 21.62 2.46 (0.014) 
Diastolic blood pressure (mmHg) 435 69.71 ± 11.24 144 64.42 ± 11.49 4.86 (<0.001) 
Total cholesterol (mmol/l) 414 4.14 ± 1.03 136 4.19 ± 0.99 -0.45 (0.653) 
Hypertension (n) 435 240 (55.2) 146 64 (43.8) 5.63 (0.018) 
Any macro vascular disease (n)a 435 163 (37.5) 146 77 (52.7) 10.51 (0.001) 
Angina (n)a 435 114 (26.2) 146 60 (41.1) 11.55 (0.001) 
Myocardial infarct (n)a 435 63 (14.5) 146 20 (13.7) 0.05 (0.815) 
Stroke (n)a 435 39 (9.0) 146 21 (14.4) 3.47 (0.063) 
TIA (n)a 435 29 (6.7) 146 15 (10.3) 2.03 (0.154) 
Diabetic Retinopathy (n)a 435 257 (59.1) 416 85 (58.2) 0.03 (0.855) 
Table 31. Follow-up characteristics of the ET2DS at year 10 who received a clinic or home visit 
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Psychological:           
Anxiety 434 4.76 ± 3.62 146 5.55 ± 3.93 -2.23 (0.026) 
Depression 434 4.15 ± 3.05 146 5.12 ± 3.39 -3.25 (0.001) 
Probable dementia 435 17 (3.9) 146 18 (12.3) 13.69 (<0.001) 
‘g’ 433 -0.08 ± 0.94 142 -0.95 ± 1.17 8.05 (<0.001) 
Lifestyle:          
Physical activity (MET-1 minutes-1 week-1) 435 1952 (2564) 146 675 (1502) 6.92 (<0.001) 
Sedentary time (min/week) 435 3881 ± 1217 146 4826 ± 1427 -7.16 (<0.001) 
Body Mass Index (kg/m2) 430 30.20 ± 5.74 141 29.65 ± 5.59 1.00 (0.317) 
Smoking 435   146   0.26 (0.878) 
             - Current   22 (5.1)  19 (13.0)   
             - Former   202 (46.4)  56 (38.4)   
            - Never   203 (46.7)  71 (48.6)   
Alcohol units   6.11 ± 10.64 581 5.03 ± 11.65 1.04 (0.298) 
Total n=581, total clinic visit n=435, total home visit n=146. Values are means ± SD, median (interquartile range) or n 
(%). HbA1c, haemoglobin A1c; MI, Myocardial Infarct; TIA, transient ischaemic attack; HADS A, Hospital Anxiety and 
Depression Scale-Anxiety subscale; Hospital HADS D, Hospital Anxiety and Depression Scale- Depression subscale. a 
These data are not cumulative. 
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5.5.3 Inter-correlations of (in) activity measures 
Table 32 shows the correlations between all the (in) activity measures collected at year 10. 
All variables were significantly correlated with each other (all p<0.001), with correlation 
coefficients being strongest for physical activity with sedentary behaviour (-0.58). Increased 
BMI was significantly correlated with both lower levels of physical activity and increased 
sedentary behaviour but with a relatively low correlation coefficient of -0.18 and 0.23, 
respectively. BMI is often used in correlation analyses to aid in validating a new (in) activity 
measure (Hagströmer et al., 2006). These correlation coefficients are consistent with others 





5.5.4 Physical activity, sedentary behaviour and decline in general cognition 
Table 33 shows the outcome of the cross sectional linear regression models investigating 
the association of physical activity and sedentary behaviour with cognition.  
After adjusting for age and sex, increased physical activity was associated with improved ‘g’ 
(standardised beta= 0.301; p<0.001). This significant association was sustained after making 
Table 32. Inter-correlations of activity and obesity measures at follow-up 
  BMI Physical Activity Sedentary behaviour 
BMI -  -0.180   0.228 
Physical Activity   -  -0.584 
Sedentary behaviour    - 
Values are correlation coefficients from two-tailed Pearson correlations. All p<0.001. BMI, Body 
Mass Index; PA, Physical Activity (MET-1 minutes-1 week-1) (Log transformed); SB, Sedentary 
behaviour time (min/week). 
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further adjustments for diabetes and vascular risk factors (standardised beta= 0.290; 
p<0.001). 
A next step in the model adjusted for baseline ‘g’ as a measure of prior fluid-type cognitive 
ability. Despite a noticeable drop in standardised beta, a significant association persisted 
between increased physical activity level and a reduced decline in cognitive ability 
(standardised beta= 0.199; p<0.001). The last step in the model, included as a post hoc 
sensitivity analysis, aimed to find if this association between increased physical activity and 
reduced decline in cognitive ability level persisted even when taking into account people 
diagnosed with dementia. This analysis revealed that, when accounting for dementia, the 
association between physical activity and cognitive decline remained, albeit with a marked 
reduction in standardised beta (standardised beta= 0.171; p<0.001). 
Similarly, after adjusting for age and sex, increased sedentary time was associated with 
poorer ‘g’ (standardised beta= -0.273; p<0.001). This significant association persisted after 
making further adjustments for diabetes and vascular risk factors (standardised beta= -
0.257; p<0.001). When adjusting for baseline cognitive ability, increased sedentary time 
was shown to be associated with decline in ‘g’ (standardised beta= -0.162; p<0.001). This 
association remained significant even when taking into account those diagnosed with 
dementia (standardised beta= -0.135; p<0.001), although a noticeable drop in effect size 
was observed.  
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Risk factor Physical Activity (PA) Sedentary Behaviour (SB) 
Standardised beta (standard error) 
+ age and sex 0.301 (0.042)*** -0.273 (0.042)*** 
+ year 10 diabetes covariates 0.298 (0.042)*** -0.269 (0.042)*** 
+ year 10 vascular covariates 0.290 (0.044)*** -0.257 (0.044)*** 
+ Baseline g 0.199 (0.028)*** -0.162 (0.029)*** 
+ Dementia 0.171 (0.027)*** -0.135 (0.027)*** 
Analyses are multiple linear regressions. *p<0.05 **p<0.01 ***p<0.001. Physical activity (MET-1 minutes-1 week-1) (Natural log transformed), 
Sedentary behaviour (min/week), Year 10 diabetes covariates: HbA1c (mmol/l), Diabetes medication status, duration of diabetes (years) 
(Natural log transformed), Year 10 vascular covariates:  Systolic blood pressure (mmHg), hypertension, cerebrovascular disease (transient 
ischaemic attack or stroke), cardiovascular disease (myocardial infarct or angina), Diabetic retinopathy, Total cholesterol (mmol/l), smoking 
(current, ex, or non-smoker), alcohol units, anxiety, depression, BMI; Body Mass Index. 
 
Table 33. The cross-sectional association between physical activity and sedentary time score and g at year 10 follow-up 
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5.5.5 Association of physical activity and sedentary behaviour with prevalent dementia at 
year 10 
The outcomes of the analysis exploring the associations of physical activity and sedentary 
behaviour with prevalent dementia at year 10 are shown in Table 34. When adjusting for 
age and sex, lower physical activity levels were shown to be significantly associated with 
risk of dementia (OR 0.53; 95% CI 0.37, 0.76, p<0.001) per MET unit decrease in activity 
level. This association remained when making further adjustments for diabetes and 
vascular risk factors (OR 0.53; 95% CI 0.36, 0.78, p<0.001). 
For the association between sedentary behaviour and dementia, age and sex adjusted 
analyses showed an association between increased sedentary time and risk of dementia 
(OR 1.83; 95% CI 1.26, 2.65, p<0.001) per increase in minutes/week spent sedentary. This 
association persisted when further adjusting for diabetes and vascular covariates (OR 2.01; 
95% CI 1.31, 3.08, p<0.001).  
 
5.5.6 Summary of analysis 
In summary, these results indicate that there is evidence to suggest an association between 
physical activity and sedentary behaviour and either a decline in cognitive ability or 
dementia. However, no comment can be made about the direction of these associations. 
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Risk factor  Physical Activity (PA) Sedentary Behaviour (SB) 
OR (95% CI) 
+ age and sex 0.53 (0.37-0.76)*** 1.83 (1.26-2.65)*** 
+ year 10 diabetes covariates 0.53 (0.37-0.77)*** 1.84 (1.26-2.68)*** 
+ year 10 vascular covariates 0.53 (0.36-0.78)*** 2.01 (1.31-3.08)*** 
Analyses are logistic regressions. *p<0.05 **p<0.01 ***p<0.001. Physical activity (MET-1 minutes-1 week-1) (Natural log transformed) Sedentary 
behaviour (min/week), Year 10 diabetes covariates: HbA1c (mmol/l), Diabetes medication status, duration of diabetes (years) (Natural log 
transformed), Year 10 vascular covariates:  Systolic blood pressure (mmHg), hypertension, cerebrovascular disease (transient ischaemic attack or 
stroke), cardiovascular disease (myocardial infarct or angina), Diabetic retinopathy, Total cholesterol (mmol/l), smoking (current, ex, or non-
smoker), alcohol units, anxiety, depression, BMI; Body Mass Index. 
Table 34. The cross-sectional association between physical activity and sedentary time score and dementia at year 10 follow-up 
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Chapter 6: Discussion 
This chapter provides a summary of the main results of this thesis and discusses these in 
the context of previous studies. The strengths and limitations of the methods are discussed 
and recommendations for further work are presented. 
 
6.1 Main results 
In the ET2DS, a prospective cohort representative of older people living in Scotland, the 
work presented in this thesis has shown that a selection of potentially modifiable risk 
factors are associated with cognitive decline over a 10 year follow-up period in older people 
with type 2 diabetes. By using data collected at baseline and at the year 10 follow-up, 
multivariable analyses models showed associations of measures of systemic inflammation, 
obesity and physical activity with cognitive outcomes, including cognitive decline and 
dementia. Statistical models were developed to adjust for known vascular and diabetes-
related risk factors in an attempt to determine independence of the findings and explore 
potential biological mechanisms underlying the development of cognitive decline. 
 
6.1.1 Inflammation 
Inflammation and cognitive decline 
Results presented in this thesis provide evidence for an association between increased 
levels of systemic inflammation as measured at baseline and subsequent cognitive decline 
over a ten year period. Of four inflammatory markers tested, those significantly associated 
with a decline in general cognition were IL-6 and fibrinogen, however, in fully adjusted 
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models for a wide range of potential confounding and/or mediating factors, these 
associations were no longer statistically significant. Although the inflammatory markers 
were all shown to be highly correlated, the results indicated that only specific markers may 
be associated with cognitive decline, and that at least some of the association may be due 
to confounding effects of vascular and diabetes risk factors. Alternatively, it may also be 
that power in the fully adjusted model may not be sufficient to detect a significant 
association. 
 
Inflammation and dementia 
Results from a range of models adjusted for age and sex alone, or additionally for vascular 
and diabetes-related risk factors indicated no strong association between increased levels 
of any of the inflammatory markers measured at baseline and incident dementia over the 
10 years of the study. However, a possible suppression effect of other inflammatory 
markers was observed in fully-adjusted models which included all inflammatory markers. In 
these models, a statistically significant association was seen between increased level of IL-6 
and incident dementia. This suggests that increased levels of IL-6 may be associated with an 
increased risk of dementia once generalised systemic inflammatory status is taken into 
account. IL-6 was strongly correlated with the other inflammatory markers, some of which 
showed very little positive association with dementia (and possibly even a negative 
association for CRP), and so it is plausible that the effect of IL-6 level on risk of dementia is 
only evident when accounting for the other inflammatory markers and removing their 
suppression effect, sometimes considered negative confounding, on the model (MacKinnon 
et al., 2000). Similarly, an association between CRP and dementia was also shown which 
may also be masked by the effects of the other inflammatory markers. However, results 
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indicated that in the case of CRP, lower levels of this individual inflammatory mediator may 
be associated with a higher risk of dementia once overall systemic inflammatory status is 
taken into account.  
The work presented in this thesis is supportive of the theory that the inflammatory marker 
IL-6 may act directly on cognitive decline although is confounded by other lifestyle factors 
such as obesity and inactivity. Furthermore, IL-6 is able to cross the blood-brain barrier and 
so may have a direct or  indirect intracerebral effect on cognition (Varatharaj and Galea, 
2017). Other factors are likely at play and findings presented here are also suggestive of a 
network effect of a combination of factors each contributing to a different extent on the 
relationship between inflammation and cognitive decline. This suggests that by reducing 




Obesity and cognitive decline 
Results indicated an association of increased WHR and WC with subsequent cognitive 
decline over 10 years in people with type 2 diabetes, but no strong association with BMI.  
However, after adjustment for diabetes risk factors, the association between increased WC 
and cognitive decline was no longer statistically significant, suggesting that diabetes may be 
confounding factor in this association. On the other hand, the association between 
increased WHR and cognitive decline persisted even after further adjustment for 
inflammation and BMI. As BMI is a measure of total body mass, and WHR is predominantly 
a measure of visceral fat, these findings suggest that visceral fat, or body shape, is 
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associated with cognitive decline independent of diabetes, vascular and inflammatory risk 
factors, and also independent of total body mass. 
WHR is known to vary considerably between men and women and is known to have 
different effects on cardiovascular disease in men and women in models that adjust for 
total body mass (Li et al., 2006).  The unexpectedly different findings for BMI and WHR 
were therefore explored further by performing the analyses on WHR separately for men 
and women, in case the result may simply be a reflection of WHR acting as a proxy for sex. 
The association between WHR and cognitive decline remained significant in fully adjusted 
models that included inflammation and BMI for both men and women separately, 
suggesting that WHR may indeed be a risk factor for cognitive decline, and in both men and 
women  
A final analysis on WC as a predictor for cognitive decline was carried out. WC is a 
component of WHR and so it was important to explore the associations shown in models of 
WHR further by looking at only WC. The results of this analysis indicated that WHR 
measures a unique obesity phenotype that is distinct from WC, which measures only 
visceral fat, and is also distinct from BMI, which measures overall mass. 
Overall, results suggest that WHR is a distinct obesity-related phenotype, greater levels of 
which are associated with cognitive decline, and that this relationship is not confounded by 
diabetic/ vascular-related risk factors or by systemic inflammation. 
 
Obesity and dementia 
In contrast to the association between increased levels of obesity-related markers and ten-
year cognitive decline as measured by ‘g’, results suggested that decreased BMI, WC and 
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percentage body fat at baseline were associated with an increased risk of incident 
dementia. This association was only found to be statistically significant when fully adjusting 
for vascular risk factors, indicating that there may be a suppression effect or negative 
confounding effect of vascular disease risk factors on this association. This shows that 
increased body fat is only protective of dementia, if vascular disease (known to also be 
associated with dementia) is accounted for.  An increased WHR was shown to be associated 
with risk of incident dementia, however this association was not statistically significant.  
As weight loss is a symptom of dementia (Johnson et al., 2006), it is possible that the 
direction of these associations, where it seems a higher BMI or WC reduce the risk of 
dementia (contrasting the results shown with ‘g’), are due to pre dementia being present in 
the cohort at baseline. If cases of pre dementia are affecting the direction of the 
association, it may be that using an obesity measure taken during mid adulthood, as a 
predictor variable, would change the direction and strength of this association. For WHR, 
the association with dementia was in the same direction as the results of the analyses with 
‘g’, which could be consistent with WHR being a measure of body shape, which although 
associated, is less affected by weight loss than BMI, especially in men (Wing et al., 1992). 
This pattern where increased WHR and decreased BMI and WC are associated with 
dementia are also seen in other general population cohorts, especially when measures of 
obesity were taken just prior to dementia diagnosis (Gustafson et al., 2009). WHR has also 
been shown to increase the risk of cardiovascular disease in the general population by 5%, 
which was more than double the risk by increased WC alone (De Koning et al., 2007). In 
people with diabetes, WHR has also been shown to be the best indicator of cardiovascular 
disease outcomes when compared to WC alone and there was no significant association 
with BMI (Czernichow et al., 2011). 
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6.1.3 Physical activity  
Physical activity and cognitive impairment  
Cross-sectional analyses showed that lower levels of physical activity and higher levels of 
sedentary behaviour were associated with lower levels of cognition and also with decline in 
general cognition. This association persisted in post hoc sensitivity analyses that corrected 
for dementia. It should be noted that the associations with (in) activity and cognitive 
decline, despite using a baseline variable, should be regarded as cross-sectional and the 
likelihood of reverse causation should be considered when interpreting these results. From 
these analyses no temporal association can be assumed and it is likely that a decline in 
cognition promotes a sedentary, inactive lifestyle. The directionality of these associations 
cannot be inferred from the results presented in this thesis. 
 
Physical activity and dementia 
Cross-sectional analyses showed that lower levels of physical activity and higher levels of 
sedentary behaviour were associated with increased risk of dementia, indicating that a 
lower level of activity and a higher level of sedentary time may be associated with an 
increased risk of dementia. It should be noted that because this analysis is cross-sectional, 
and that dementia was diagnosed over a period of 10 years, preceding the (in) activity 
measurement, in this analysis dementia should be regarded as cross- sectional prevalence 
variable at year 10. Dementia likely precedes the observed (in) activity levels and it is 
possible that more sitting and less activity occur as a direct result of dementia or are 
175 
symptoms of pre dementia and so it is likely that these associations are examples of reverse 
causation. Therefore the directionality of these associations cannot be inferred. 
 
6.1.4 Biological Mechanism 
Adipose tissue is an endocrine organ comprised of two main types, brown adipose tissue 
and white adipose tissue. The physiological roles of each type are different, brown adipose 
tissue is primarily important for heat generation and white adipose tissue for the storage of 
excess dietary energy. White adipose tissue can be found both subcutaneously and in the 
abdomen, termed visceral adipose tissue. It has been established that subcutaneous and 
visceral adipose tissues have different physiological features (Gomez-Hernandez et al., 
2016). Visceral fat is involved in other metabolic processes aside from its main function as 
energy storage, including inflammation (Gomez-Hernandez et al., 2016). The pro-
inflammatory cytokines TNF-α and IL-6 are secreted by white adipose tissue (Fruhbeck et 
al., 2001) and in particular IL-6 expression is found to be up to 3 times higher in visceral fat 
than other types and distributions of adipose tissue (Fried et al., 1998). 
In obesity visceral fat deposits often increase which results in an increased inflammatory 
response in the adipose tissue (Fain et al., 2004). This can also activate an inflammatory 
response in the liver, and the combination of the adipose tissue and hepatic inflammation 
can result in systemic inflammation. The effect of this systemic inflammation on peripheral 
tissues includes insulin resistance, hypertension and atherosclerosis (Gomez-Hernandez et 
al., 2016). The link between central obesity, systemic inflammation and vascular disease is 
well established (Van Gaal et al., 2006). Therefore, as dementia is thought to occur as a 
result of vascular disease (Crichton et al., 2014) central obesity may be associated with an 
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increased risk of dementia (Razay et al., 2006), and at least partly  mediated by 
inflammation (Festa et al., 2001). 
 
Clinically, BMI can give an estimation of total body adiposity, with no indication of fat 
distribution, whereas WC or WHR can give an estimation of visceral adiposity or fat 
distribution. Obesity is often measured using BMI, however as individuals with increased 
central obesity are at an increased risk of inflammation mediated vascular diseases such as 
dementia, WC or WHR may be more clinically relevant measurements. 
An alternative biological mechanism to explain these findings may be that the WHR genetic 
variant may directly, through distribution or utilisation of body fat, influence cognitive 
impairment through the actions on specific components of inflammation e.g. IL-6. 
Alternatively, it may also be that the genetic loci of WHR genetic variants may be located 
proximally close to specific cognitive loci, and so it may also be possible that WHR variants 
have an impact on the expression of specific genes for cognitive ageing. It is also possible 
that epigenetics play a role by the modification genes located close to either inflammation 
or WHR loci. 
 
6.2 Strengths of the Study 
The ET2DS was designed as a prospective cohort where cognitive change over time could 
be assessed along with other risk factors and characteristics of the cohort. Prospective 
cohorts are advantageous, when compared to retrospective cohorts or cross sectional 
studies, as they enable observations of incident disease and change in outcomes over time. 
Despite not being able to infer causality, temporal relationships between risk factor and 
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outcome can be established through this prospective design that can inform further work 
that investigates causality. The relatively large sample size recruited at baseline enabled 
analyses to be adequately powered in order for associations to be detected. The sample 
recruited at baseline was largely representative of all those invited (Marioni et al., 2010), 
and due to participants being selected at random from the Lothian Diabetes Register (LDR), 
we can be confident that the results obtained are generally representative of the local 
diabetes population. Furthermore, this population included both people living in the city of 
Edinburgh itself and people living in more rural areas (including smaller towns with 
generally lower SES) outside the city in the Lothians. This feature of the study allows the 
results to represent a broad spectrum of people with type 2 diabetes with differing severity 
of disease, from a range of different areas and socioeconomic backgrounds. For these 
reasons, the external validity of the study can be accepted to be relatively high and results 
can be generalised to other regions, and nationally.  
Cognitive ability was assessed in the same way at follow-up as it was at baseline, using a 
comprehensive battery of validated cognitive tests, taking care testing conditions were 
consistent between participants and between phases of the study. The general cognition 
factor ‘g’, was derived at baseline and year 10 using the same factor loadings and the 
standardised residual scores were calculated using a method that allowed for a direct case-
wise comparison between scores at each time point.  All research staff involved in baseline 
and year 10 clinics received training in physiological examination, interviewing and 
cognitive testing.  Clinical procedures were carried out at year 10 by myself and one other 
researcher where periodic checks took place every 3 months to ensure consistency 
between researchers, where one researcher would sit in on the other’s appointment at 
random and give feedback on how the appointment was conducted according to the 
178 
standard operating procedures (SOPs). SOPs were developed at year 10 to closely follow 
procedures at baseline and were strictly adhered to, reducing observer bias.  
Incident dementia cases were identified by consulting a variety of sources adopting an 
inclusive criteria that required a primary source of medical information, such as a clinical 
diagnosis, along with a secondary source of medical information, such as a self-report. This 
enabled evidence for a diagnosis to be built and allowed for cases with only one piece of 
information to be identified and discussed at consensus meetings to determine probable 
dementia status. This method allowed for everyone with some form of information to be 
discussed and resulted in a final dementia group to be established based on all available 
evidence, regardless of whether they attended the year 10 follow-up clinic. The criteria and 
consensus model for determining the dementia group was conservative in its approach, 
inferring that everyone in the group has a very high chance of having clinical dementia, 
however it should be noted that some cases may have been missed for lack of evidence of 
diagnosis, death before formal diagnosis, personal or family decision to not be formally 
assessed for stress or emotional reasons, and decision to not to be prescribed or take 
medications. 
Missing data were systematically dealt with where baseline variables were inspected and 
where missing data were substantial (e.g. HbA1c), original files were consulted to find if 
these data could be located or if truly missing, data within a specific time frame (e.g. within 
6 months of baseline appointment), could be used as a proxy value. Full cognitive data were 
not available for each participant at both time points, which is problematic when deriving 
the general cognition variable ‘g’. In deriving ‘g’, full data are required when running a 
principal component analysis (PCA), and so any missing cognitive data would negatively 
impact on the statistical power of analyses using this variable. Data may be missing for a 
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number of reasons such as a visual impairment or hearing impairment that impacts on the 
ability of the participant to carry out specific tests, regardless of their cognitive ability. 
Other participants may have missing data as a cognitive test is beyond their cognitive 
capability, they fail to understand instructions, or they anticipate the test being too 
challenging for them to do. As both these types of missing cognitive data are not the same, 
any attempt at minimising missing data must be sensitive to the fact that these data may 
not be missing at random. A multiple imputation method was used to reduce missing data, 
on a case-wise basis, using other cognitive tests that were not missing to aid in the 
prediction of the tests that were missing. This allowed for participants of relatively high or 
low cognitive ability to have a score imputed for missing tests, based on their cognitive 
ability at a time point. This was done only in people who had completed over half of their 
cognitive tests, to increase the reliability of the imputation, and was carried out for both 
baseline and year 10 follow-up phases of the study.  This sensitive approach to data 
imputation was adopted as this would increase the number of cases with a ‘g’ score, take 
into account both cognitive and physical impairments of the cohort and increase power 
analyses using ‘g’ as a variable. Moreover, it could be argued that bias is reduced in the 
derived final ‘g’ variables, as ‘g’ would otherwise only be available for the most physically 
and cognitively healthy, and this would impact on the external validity of any analyses using 
this variable. 
 
6.3 Limitations of the study 
Missing data 
The ET2DS has a number of key limitations that need to be acknowledged in order to be 
able to interpret any findings appropriately. The main limitation, common to most 
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prospective cohort studies, is around loss to follow-up and missing outcome data. The 
‘attender vs non-attender’ analysis reported in this thesis acknowledges that there was a 
systematic drop-out in the ET2DS.The retention rate at the year 10 follow-up phase was 
55%, which is in line with other studies (Okely and Deary, 2018), and high when taking into 
account both participant age (Tilvis et al., 2004) and diabetes status (Holman et al., 2008). 
For analyses of dementia, all participants recruited at baseline were included. To maintain 
power in analyses on cognition, considerable effort was made to ensure that as many of the 
surviving original cohort as possible were seen at year 10, through recruitment strategies 
involving numerous modes of contact and by offering transport to the clinic as well as 
home visits. This was done to ensure data were collected on as wide a range of participants 
as possible (taking into account a range of health and economic statuses), enabling results 
of analyses to be reflective of the true local population. Despite these efforts to minimise 
missing data, there was loss to follow up in the cohort, which is unsurprising when 
considering the age and diabetic status of the participants. The main outcome of interest in 
these analysis is cognitive decline and dementia, which by the nature of the condition is 
systematically affected by loss to follow-up, and only the most cognitively and physically 
healthy, on average, were seen at follow-up. It must therefore be acknowledged that in the 
cognition outcome variables, a systematic attrition will have occurred which may affect the 
results. The outcome dementia was however less affected by this as all cases were 
examined throughout the 10 year time frame of the study, and so even if a participant had 
died, or was still alive but was not able to attend the follow-up clinic, dementia status was 
still assessed by means of the criteria described.  Similarly, as dementia and cognitive 
impairment are conditions that occur on a spectrum, over an extended period of time, it is 
also likely that in some cases dementia, or various degrees of pre dementia, will have been 
prevalent in the cohort at baseline, again affecting the results presented here. In both 
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scenarios, this would result in a drop in effect size and so any associations that fail to reach 
statistical significance may be subject to type 2 error, a phenomenon known as left 
truncation (Cain et al., 2011). The more extreme cases of the cognitive change outcome will 
also be affected by this and so analyses should be regarded as a snapshot of only the 
relatively healthy cases.  
In linear and logistic regression models, only complete cases are analysed at each stage of 
the model. This in practice results in more cases being part of the analysis in models 
adjusted for age and sex, than fully adjusted models, where a case with any of the 
covariates missing is excluded from the analysis. Therefore, each step in the regression 
models may not include the exact same cases. A list wise deletion method would have 
allowed for a more literal and direct comparison between steps of the model, however this 
would have also resulted in losing a large amount of data, essential for exploring small 
associations in preliminary models that may have otherwise been missed. A pairwise 
deletion method was used in this thesis as the principal objective throughout was to 
investigate associations by building novel models to explore the data, as opposed to testing 
a known model on this population. The results should therefore be interpreted formally as 
standalone results for each step in the various models. 
 
Bias and error 
This thesis presents the findings of numerous analysis and so a limitation in the results 
reported is that there is possibility of type 1 error, false positive results, due to multiple 
comparisons. When deriving the component ‘g’, the decision was made to use principle 
component analysis (PCA) as opposed to factor analysis (FA) as a data reduction technique. 
The component ‘g’ used in this thesis is purely a summary variable, combining the weighted 
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cognitive test scores, per case, into a single variable. True latent variables, often used and 
preferred in cognitive psychological research for their ability to represent traits that are 
difficult to quantify, are derived using FA and take into account testing error. By 
incorporating error into the derived factor scores, analyses using this latent factor ‘g’ would 
then have to be corrected for multiple testing as it is a new distinct variable, which no 
longer merely summarises the other cognitive test data. Both forms of ‘g’, factor or 
component, would in practice be fairly similar, however one could argue that a factor when 
discussed without the context of the other cognitive tests would be more informative in 
terms of interpretation. A component form of ‘g’ was used here as a formal correction for 
multiple comparisons, such as Bonferroni, would result in a very conservative p-value 
threshold and also a component form of ‘g’ can be explored more directly by looking at the 
outcomes of analyses using the individual cognitive tests. Moreover, as described above, 
the cohort is subject to healthy survival bias and some non-dementia cases are likely 
misclassified, thus the majority of findings at significance level p<0.05 are deemed unlikely 
to be chance findings, therefore results presented here are likely to be accurate reflections 
of the associations. 
Cognitive testing, reliant on a host of skills including cognitive as well as physical abilities, 
are also susceptible to bias and error. Age increases the intra-individual variability in test 
performance, and disproportionately so in those of lower ability (Rabbitt et al., 2001), so a 
systematic error in recoding ability by using only one score per person for each test is 
possible. Multiple testing, and taking an average of three may overcome this, however 
results would then be subject to practice effect (Salthouse, 2010). In this thesis, intra-
individual variability is minimised by deriving a general cognition component ‘g’ as a 
primary outcome variable, from a number of different testing opportunities that takes into 
account performance in all 7 tests.  
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The analysis which incorporates baseline and year 10 variables, despite successfully 
capturing general cognitive change, does not take into account individual differences in the 
temporal pattern of cognitive change pathways experienced (Deary et al., 2009). Cognitive 
measures recorded more frequently, for example every year or 6 months, would provide a 
more accurate representation of the cognitive change trajectory over time. However similar 
to the point mentioned above, practice effect would likely skew results if tests were given 
on a more regular basis. 
 
Study design 
As this study was observational by design, any findings reported are only able to 
acknowledge that specific correlations or associations exist between predictors and 
outcome. Causal relationships can only be established by using evidence presented from 
intervention based studies in the form of randomised controlled trials where numerous 
experimental features are kept constant and often a placebo group is used along with the 
control group. Although causal associations cannot be determined, the temporal design of 
data collection over an extended follow-up period does allow for speculation and comment 
regarding the likely direction of these associations. Namely, that if the risk factor variable 
was observed at baseline and an outcome variable observed at follow-up, it is likely that 
the risk factor predicts the likelihood of an outcome and not vice versa. Yet, the notion of 
reverse causality should not be underestimated in observational research. The age old 
question of the chicken and the egg, and what came first, is a metaphor that describes this 
notion well, and even though it may seem initially obvious that a given risk factor likely 
‘causes’ a given outcome to occur, it may well be that other factors, often not easily 
quantifiable, may in fact be influencing this relationship. In the example of the research 
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presented in this thesis where specific modifiable risk factors are associated with 
subsequent cognitive change, it may well be that the severity of follow-up cognitive change 
may be correlated with, amongst other risk factors, cognitive ability at baseline (or even 
before, in early adulthood), which may affect lifestyle choices that result in the associations 
observed. Cognitive reserve theory (Stern, 2002) hypothesises that the greater the neural 
network, the longer it takes to decline and the later clinical symptoms of cognitive 
impairment present (Stern, 2012). Similarly, midlife cognitive reserve may have 
proportional effect on lifestyle choices in midlife. 
The issue of confounding was explored by including numerous covariates in multivariable 
models in an attempt to eliminate the potential confounding effect of these variables. 
When associations persisted, further investigation is required into possible confounding of 
elements not measured directly in the ET2DS. This can be achieved in RCTS that keep 
experimental conditions and exposures consistent. For the longitudinal analyses that used 
incident dementia as an outcome, associations between baseline variables and dementia 
outcome are likely affected by when dementia was diagnosed so a major limitation of these 
analyses is that it was not possible to determine an approximate date of dementia 
diagnosis for individual cases, which would have allowed for a sensitivity analysis that 
excluded cases diagnosed within a set time frame (e.g. 2 years) of baseline. This limitation 
should be taken into account when interpreting the results of these analyses and continued 
data collection in future years of the ET2DS may be able to address this. 
Confounders were chosen to improve the reliability of the models, however a balance 
between the numbers of confounding variables entered into the model and the power of 
the model needs to be maintained. The power is impacted by adding more variables into 
the model and as a result a judgment was made as to which adjustments were included. A 
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number of variables were not included in the final model but it can be argued that these 
should have been adjusted for. The level of deprivation as measured by SIMD was not 
included in the final models used in this thesis as it was deemed a fairly crude measure of 
an individual’s SES, however SES is likely to have effect on both the outcome of interest and 
predictors. Similarly, hypoglycaemia is also traditionally adjusted for in models with 
cognitive outcomes, however as the models in this thesis included diabetic medication it 
was argued that insulin medication would act as a proxy for hypoglycaemia. In all regression 
models the pros and cons of including specific covariates needs to be considered carefully 
and it is rarely possible to adjust for everything.  
 
Survivor Bias and the role of competing risks 
Survivor bias is a when survivors of a potentially lethal disease are likely to enter a study 
than the true population (Delgado-Rodriguez and Llorca, 2004). The results obtained 
through investigating the ET2DS study population used in this thesis is particularly at risk of 
this type of bias as this particular population exclusively consists of people with type 2 
diabetes who have survived until the age of 65 years. It should therefore be acknowledged 
that upon entering the study, the ET2DS participants are presumably a healthier subgroup 
of all people with type 2 diabetes as many people with more severe forms of the disease or 
with multiple comorbidities, will have died before reaching this age.  
A 10 year follow up of people aged approximately 65 years at baseline was deemed 
appropriate for detecting cognitive decline and dementia onset in a cognitively healthy 
group at baseline. However by selecting an already aged group at baseline the risk of 
survivor bias may become problematic. Selecting a younger cohort for baseline would 
reduce survivor bias, however the length of a study to measure the primary outcome in this 
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cohort would be prohibitively long.  When interpreting results obtained from this cohort 
this bias should be taken into account as it is likely that estimates will lie closer to the null 
with a smaller effect size than that in the true population, affecting the external validity of 
the outcomes (Delgado-Rodriguez and Llorca, 2004).  
Survivor bias also effects any of the analyses that have cognitive decline as measured at 
follow-up and should be considered when reading results. Only surviving participants were 
able to provide cognitive information at follow-up and those that had died during the 10 
year course of the study were not taken into account in the results. This must be 
acknowledged as in essence cognitive change in only the relatively healthy population, who 
have survived until the age of 75 years, is measured. A large percentage of people with type 
2 diabetes will die before this age and these cases are not represented in this analyses.  
Survivor bias has a lesser effect on analysis that have dementia diagnosis as an outcome 
variable. Although there is survivor bias upon entry into the study, there is less survivor bias 
at follow-up as death certificates and other records were consulted in all study participants, 
i.e. not only those still attending the clinic at year 10. It should be noted that death 
certificates do not always include dementia as a cause of death and it is possible that 
someone who would have gone on to develop dementia dies before any cognitive issues 
are recorded. Therefore, it is more likely to pick up a dementia diagnosis in those still alive 
at year 10.  By consulting death records and medical records for all people included at 
baseline active steps were taken to reduce the effect of survivor bias at follow-up, although 
this cannot be eliminated entirely.  
The competing risk of death, where participants die without experiencing the outcome of 
interest is often a consideration in studies involving older people (Berry et al., 2010). For 
analyses of cognitive decline, competing risks also include any reason an individual failed to 
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complete follow-up cognitive testing. The main reason being death, although any disability 
(e.g. blindness) or comorbidity (e.g. stroke) that meant that testing was not feasible on the 
day would also be included as a potential competing risk for the measurement of cognitive 
decline. Competing risks for dementia would presumably be limited to death, discussed 
previously as reducing the likelihood of diagnosis being recorded. This would result in an 
underestimation of the incidence of dementia in the study. The impact of death as a 
competing risk is that the association between risk factor and outcome is weakened as only 
the healthiest sub-group of the study population is taken into account. Others have shown 
that, compared to people without diabetes,  dementia onset in people with diabetes is 
earlier although people with diabetes  have a higher risk of premature death and failing to 
take this into account can exaggerate the strength of the association between diabetes and 
dementia (Davis et al., 2017). This highlights the need to take the competing risk of death 
into account when investigating dementia in this particular population. 
 
6.4 Comparison to other work 
Inflammation and cognitive impairment 
The inflammation marker IL-6 was previously shown to be associated with cognitive decline 
in the general population, and has been linked to a diet consisting of a high intake of red 
meat and processed and fried foods (Ozawa et al., 2017). Recently, a systematic review on 
the effect of systemic inflammation on cognitive decline and dementia has shown that 
increased levels of systemic inflammation markers increased the risk of developing 
dementia (Darweesh et al., 2018). The inflammatory response has been linked to the 
pathogenesis of diabetes (Yan et al., 2008). Single nucleotide polymorphisms (SNPs) in the 
gene for the insulin degrading enzyme (IDE) have been associated with type 2 diabetes 
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(Karamohamed et al., 2003) and dementia (Bertram et al., 2000), and IL-6 has recently been 
shown to increase the expression of IDE (Kurauti et al., 2017). Despite a lack of prospective 
cohort studies investigating the effect of IL-6 on cognitive decline and dementia in people 
with type 2 diabetes, the results presented in this thesis are in line with the evidence 
presented from studies in the general population (Singh-Manoux et al., 2014).  The results 
of this thesis aid in building the evidence for a specific role of the inflammatory marker IL-6 
in cognitive decline and the potential synergistic role IL-6 and diabetes may play in effects 
on cognition. 
 
Obesity and cognitive impairment 
The results presented in this thesis are supported in part by the findings of previous studies. 
Others have shown a stronger association of WHR as an obesity variable and cognitive 
impairment than BMI and WC in the general population (Liu et al., 2018). This recent study 
included a number of people with type 2 diabetes (26.7%) of which 11.4% were obese as 
measured by BMI. There may be considerable overlap between these groups and so it 
would not be unrealistic to hypothesise that if they controlled for diabetes (known to be 
associated with cognitive impairment), BMI may not be significantly associated with 
cognitive impairment. 
The results of the systematic review on obesity and cognitive decline in type 2 diabetes 
(Chapter 3) were in line with the results presented in this thesis, as many studies did not 
find an association with BMI. WHR as an alternative measure of obesity was rarely 
investigated, however Abbatecola et al. (2010) provided results that are in line with the 
results of the ET2DS where WHR was associated with cognitive decline while BMI was not. 
In a further paper, that failed to be identified though the systematic review as it was 
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incorrectly indexed, by Bruce et al. (2008) it was shown that in their cohort of older people 
with type 2 diabetes WHR was significantly associated with cognitive impairment, while 
BMI failed to show a significant association. As a result of identifying this study, the terms 
used to index this paper were added to the search strategy described in chapter 3 of this 
thesis, to see if other papers could be identified that may have also met the inclusion 
criteria. This was carried out on the 20th of August 2018, and resulted in no additional 
papers being found. 
The systematic review identified two studies that explored the association between obesity 
and dementia in type 2 diabetes. These studies found no association between BMI and 
dementia in cross-sectional analyses (Espeland et al., 2017) and showed that in longitudinal 
analyses a higher BMI was associated with a lower risk of dementia (Hu et al., 2012). The 
result by Hu et al. (2012), was in line with the results of the ET2DS presented in this thesis, 
and the authors noted that these findings may be due to weight loss in pre dementia, 
despite noting that associations persisted even after sensitivity analyses were carried out 
that removed individuals diagnosed within 2 years of baseline. No previous study was 
identified that investigated the effect of WHR on dementia so the results of this thesis 
cannot be placed in context of other work. The direction of the association observed in the 
ET2DS, although not statistically significant, was in line with the results of the cognitive 
decline analyses, and opposite in direction to the association seen with BMI and dementia, 
providing further evidence that WHR and BMI measure distinct obesity phenotypes. 
 
Physical (in) activity and cognitive impairment 
A comprehensive meta-analysis on the effect of physical activity on cognitive decline in the 
general population found that increased levels of activity may act as a protective factor on 
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cognitive decline (Sofi et al., 2011). The association between physical activity and cognitive 
ability and decline in people with diabetes is yet to be extensively investigated. The results 
of the studies identified in the systematic review chapter of this thesis are mixed, as some 
find an association between level of activity and cognitive status, while others do not. The 
results presented in this thesis provide evidence to support the notion that level of physical 
activity is related to cognitive ability in diabetes, as noted also by Valiente-Barroso et al. 
(2015) and Devore et al. (2009). However, the ET2DS does not have the temporal data to 
support any link with cognitive decline short of dementia. Physical activity and dementia 
are shown to be associated in the ET2DS, however no other studies could be identified that 
investigated this in people with diabetes. 
The association between sedentary behaviour and cognitive ability or dementia as seen in 
the ET2DS cannot be placed in context of previous work as no studies investigating this in 
people with diabetes could be identified. Moreover, studies reporting on sedentary 
behaviour and cognitive decline and dementia in the general population are also limited in 
number and in employing valid measures of time spent sitting. One study measuring 
sedentary time as time spent watching television and time spent on a computer as proxy 
measure of global sitting behaviour (Hamer and Stamatakis, 2014). This study reported 
conflicting results between the two sedentary measures, and their association with 
cognitive impairment, which seemed unsurprising as both activities require different 
cognitive abilities and skills, where TV watching can be seen as cognitively passive and 
computer time cognitively active, making the interpretation of their result difficult. A more 
recent systematic review of sedentary behaviour and cognitive health in the general 
population found that increased sedentary time was associated with poorer cognitive 
performance, although it could not identify evidence for the association between sedentary 
time and cognitive decline or dementia (Falck et al., 2016). 
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6.5 Conclusions and Further work 
The work presented here primarily aimed to determine the association between potentially 
modifiable risk factors and cognitive impairment, to identify where it may be possible to 
develop and/or target preventive measures in the future.  Overall conclusions and 
suggestions for further work in this area are listed below:  
 
 
1.  Evidence presented here supports the hypothesis that in people with diabetes 
there may be an association between obesity and increased cognitive decline 
during aging, independent of diabetes-related, vascular and inflammatory risk 
factors.  However, this was only evident when obesity was measured by elevated 
WHR, not by raised BMI. Moreover, results indicated that increased BMI and WC 
were associated with a lower risk of developing dementia.  Overall, findings suggest 
that further work is required to establish the direction and strength of associations 
between obesity and cognitive decline, preferably including populations free of pre 
diabetes and using a range of different obesity measures.  
 
2. Increased levels of inflammatory markers in people with diabetes (IL-6 and 
fibrinogen) may be predictive risk factors for cognitive decline, although diabetes-
related and vascular risk factors appear to confound this relationship.  
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3. Increased levels of IL-6 and decreased levels of CRP were shown to be risk factors 
for dementia, but only when adjusting for other inflammatory markers, suggesting 
the possibility of suppressor effects which warrant further investigation.   
 
4. Cross-sectionally, physical inactivity was shown to be associated with poorer 
cognition and greater levels of dementia in people with diabetes, but further 
longitudinal work needs to be carried out to establish the temporal nature of this 
relationship. 
 
5. Models using dementia as an outcome could be developed further to explore the 
strength and direction of associations. For example, adjustment for a low MMSE 
(e.g. MMSE <24) could help explore the effect of pre dementia on associations, as 
could a sensitivity analysis of those people who were diagnosed with dementia a 
number of years after their baseline assessment.  
 
6. To explore temporal relationships between risk factor and ‘g’ further, growth curve 
analysis could be a useful next step (Deary et al., 2011a). Currently, the ET2DS only 
has cognitive data on people collected at year 4 (2010/2011), if/when future phases 
of data collection are to take place, modelling incorporating baseline, year 4, year 
10 and future phases would help to confirm the results presented here and would 
explore associations in more detail over an extended period of time. In addition to 
this the relationship with the outcome variable dementia could be explored further 
193 
by exploring hazard ratios (Atti et al., 2008), which incorporate time to event in the 
model.  
 
7. Exploration of causality could involve the use of genetic variants for the obesity 
variables, for example in a Mendelian Randomisation analysis (Lawlor et al., 2008).  
Exploring the genetic loci of the WHR phenotype and determining if associations 
between genetic variants of these genes and cognitive outcomes exist could also 
help in determining why differences in key associations with cognition are observed 
for WHR and BMI, when both are thought to measure the same phenotype.  
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Distribution of selected variables at baseline that were used in models. 
 
 
Figure A.1 Distribution of age at baseline 
 
  





Figure A.3 Distribution of HbA1c at baseline 
 
 
Figure A.4 Distribution of HDL at baseline 
 
 
Figure A.5 Distribution of Serum triglycerides at baseline 
 
 
Figure A.6 Distribution of Alcohol units at baseline 
 
 
Figure A.7 Distribution of Anxiety at baseline 
 
 
Figure A.8 Distribution of Depression at baseline 
 
 




Figure A.10 Distribution of Waist to hip ratio at baseline 
 
 
Figure A.11 Distribution of Waist circumference at baseline 
 
 




Figure A.13 Interleukin 6 at baseline (before and after natural log transformation) 
 
 
Figure A.14 C- reactive protein at baseline (before and after natural log transformation) 
 
 





Figure A.16 Fibrinogen at baseline 
 
 
Figure A.17 g at baseline 
 
 





Figure A.19 Trail making task B at baseline (before and after natural log transformation) 
 
 
Figure A.20 Faces task at baseline 
 
 





Figure A.22 Digit symbol test at baseline 
 
 
Figure A.23 Verbal fluency task at baseline 
 
 









Figure B.1 HbA1c at year 10 follow-up (before and after natural log transformation) 
 
 
Figure B.2 Systolic Blood pressure at year 10 follow-up 
 
 




Figure B.4 Alcohol units at year 10 follow-up 
 
 
Figure B.5 Anxiety at year 10 follow-up 
 
 








Figure B.8 Distribution of Waist to hip ratio at year 10 follow-up 
 
 





Figure B.10 Distribution of Physical activity score at year 10 follow-up (before and after 
natural log transformation) 
 
 








Figure B.13 Logical memory task at year 10 follow-up 
 
 










Figure B.16 Matrix reasoning task at year 10 follow-up 
 
 
Figure B.17 Digit symbol test at year 10 follow-up 
 
 
Figure B.18 Verbal fluency task at year 10 follow-up 
 
 
Figure B.19 Letter number sequencing task at year 10 follow-up 
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PLEASE NOTE:  ONE OF OUR RESEARCH NURSES WILL GO OVER THE 
QUESTIONNAIRE WITH YOU AT THE CLINIC AND MAY ASK A FEW ADDITIIONAL 
QUESTIONS 
 
THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL AND IS 
PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly confidential and 
will be available only to your own doctor and the study team.  The results of the research 
will appear only in the form of general statistics from which it will be impossible to identify 




Please complete the following: 
 
 









If you have any difficulties in answering some of the questions, you will have a chance to 
discuss these with a member of the study team.   
 
If you find that the questionnaire is too long for you to complete today, you will be able to 
take part 2 home with you to complete (we will give you a reply paid envelope to return it 



















1. Please tick one box:            Male    Female      
                  1            2   
                 
                  Day    Month          Year 
2. Enter your date of birth:         
 
 
3.  Please tick the box showing your present marital status: 
 
  Married and/or living with long-term partner  1 
  Single       2 
  Widowed      3    
Divorced or separated     4 
 
4. Please enter your address (including postcode) and telephone no.   
 
  Address:   …………………………………………………………………. 
 
    …………………………………………………………………. 
 
  Postcode: ……………………………….. 
 
Telephone no: ………………………………… 
 
                        
5. Please enter the details of your GP       
 







6. What is the HIGHEST level of education you and your spouse/ex-spouse or long-term partner  have 
completed? 
 Please tick appropriate boxes:  
         You Spouse/ex-spouse 
           partner 
 University/college degree course     1   1 
 Other professional/technical qualification after leaving school  2   2 
 Secondary school      3   3 




7. What is your ethnic group? 
 
 Please choose ONE section from 1 to 5, then tick the appropriate box to indicate your ethnic Group 
 
 (i)  White  
 
 11    British 
 12    Any Other White background, please write in   __________________________________ 
 
 (ii)  Mixed 
 
 21    White and Black Caribbean 
 22    White and Black African 
 23    White and Asian 
 24    Any Other Mixed background, please write in  __________________________________ 
 
 (iii)  Asian or Asian British 
 
 31    Indian 
 32    Pakistani 
 33    Bangladeshi 
 
 34    Any Other Asian background, please write in  __________________________________ 
 
 (iv)  Black or Black British 
 
 41    Caribbean 
 42    African 
 43    Any Other Black background, please write in  __________________________________ 
 
 (v)  Chinese or other ethnic group 
 
 51    Chinese 
 52    Any Other, please write in  __________________________________ 
 
CURRENT EMPOYMENT STATUS 
8. At the moment, what is the employment status of you and your spouse/ex-spouse or long-term 
 partner? 
 You                 Spouse/ex-spouse/partner 
 Employed, full-time    1      Employed, full-time    1 
 Employed, part-time    2        Employed, part-time   2 
 Unemployed     3        Unemployed     3 
 Retired      4        Retired      4 
 A Housewife (full-time)    5        A Housewife (full-time)    5 
 Other      6        Other       6 






9. When was your diabetes diagnosed (if known)?    Year ……..…… 
 




(i) Tablets    1  2  
 
If ‘yes’, please give name(s)  ……………………................................................. 
 
  Yes No 
(ii) Insulin injections  1  2  
 
If ‘yes’,  
 
(a) give total number of units per day                            ……………….…units/day 
(b) give date (year) when you started insulin       year   ………………… 
 
Yes No Don’t Know 
11. Have you ever had an episode of low blood glucose (hypoglycaemia)  1  2       3 
 when you have needed someone else to treat you eg. give sugary  
drink or glucagon?    
 
 If ‘yes’, how many times has this ever happened? 
 
  1-2   1 
3-4   2 
5 or over  3 
 
 How many times has this happened over the past year? 
 
  1-2   1 
  3-4   2 
              5 or over   3 
 
            
12.  Are you on any regular medical treatment from a doctor as follows:  
        Yes No Don’t Know 
   Aspirin?      1  2     3 
   Drugs for angina (including spray)?   1  2      3 
   Drugs to lower blood pressure?    1  2              3 
   Drugs to lower cholesterol?    1  2              3 
 
   
(If you have answered YES to any of these, please give details below) 
13. Give names of all current medication if possible (including regular skin creams, eye drops, inhalers, tablets 
and injections which may or may not be repeat prescriptions): 
  
……………………………………………  ……………………………………………….... 
……………………………………………  ……………………………………………….... 
 
……………………………………………  ……………………………………………….... 
……………………………………………  ……………………………………………….... 
 
              Yes   No Don’t Know 
14. Have you taken any oral steroids, used steroid inhalers or used       1      2        3 





15. Have you ever been told by a doctor that you have or have had any of the following? 
  
Yes   No  Don’t Know 
(i)    Heart attack (coronary thrombosis, myocardial infarction)?  1   2   3 
(ii)    Angina?        1   2   3  
(iii)  Stroke?        1   2   3  
(iv)  Hardening of the arteries in the legs?    1   2   3  
(v)  High blood pressure?      1   2   3 
 
If you have answered ‘yes’ to any of the above, please give the year in which the event occurred and/or 
condition was diagnosed (as near as you can remember) and the name of the hospital/GP surgery where you 
were/are treated for the condition 
 
Event/condition   Year of event/diagnosis  Hospital/GP surgery  
where treated 
 
 …………………………… ……………………….  …………………………. 
 




16. Have you ever undergone any of the following procedures/operations? 
            Don’t 
          Yes No Know 
 
(i) An operation or balloon treatment to relieve a blockage in    1  2  3 
the arteries of your heart (coronary by-pass or angioplasty)?     
 
(ii) An operation or balloon treatment to relieve a blockage in   1  2  3 
the arteries of your leg(s) , other than for varicose veins?  
 
(iii) Surgery to remove toes or leg (above or below the knee)?   1  2  3 
 
(iv)   An operation or balloon treatment to relieve a blockage in    1  2  3 
the arteries of your neck (carotid surgery/angioplasty/stenting)? 
 
 
If you have answered ‘yes’ to any of the above, please give the year in which the procedure was performed 
and the name of the hospital you attended 
 
Procedure/operation  Year performed   Hospital attended  
 
 …………………………… ……………………….  …………………………. 
 





17. Have you ever been told by a doctor that you have or have had any of the following? 
  
Yes  No      Don’t Know 
(i) Hepatitis?       1   2    3 
(ii) Cirrhosis of the liver?      1   2    3 
(iii) Any other disease/medical condition affecting the liver?  1   2    3  
            
 
If you have answered ‘yes’ to any of the above, please give the name of the condition, the year in which it 
was diagnosed (as near as you can remember) and the name of the hospital where you were/are treated for 
the condition 
 
Name of condition  Year of diagnosis  Hospital where treated 
 
 …………………………… ……………………….  …………………………. 
 




18. Have you ever had any of the following investigations of your liver 
   
Yes  No   Don’t Know 
(i)         Abnormal blood tests of liver function?    1   2   3 
(ii)         Liver biopsy?       1   2   3 
(iii) Scan (ultrasound or CT etc.) of the liver?    1   2   3 
(iv)        Other investigation of the liver?     1   2   3 
 
If you have answered ‘yes’ to any of the above, please give the name of the investigation, the year in which 
it was done (as near as you can remember) and the name of the hospital where the test/investigation was 
performed 
 
Name of investigation  Year done   Hospital where  
performed 
 
 …………………………… ……………………….  …………………………. 
 
 …………………………… ………………………..  …………………………. 
      
 
Other Medical Conditions 
Yes No Don’t Know 
19. Do you suffer from disease of the thyroid gland?    1  2  3 
  
20. Do you have any other medical conditions not mentioned above?   1  2  
 
 If yes, please specify:   ………………………………………………………………….. 
 
       ……………………………………………………………………………………………… 
 
       ……………………………………………………………………………………………..   
  
             
ALCOHOL 
 
21. Current alcohol intake 
 
(i)  Think back carefully over the last seven days.  Please write in each column the exact number of alcoholic 
drinks you consumed on each day during the past week.  If none consumed write ‘0’  in the boxes. Try to 
remember where and who you were with on each day.  This may help you remember what you had to drink. 
 
 
            Pints of beer,       Single glasses of        Single glasses of 
           lager, cider etc      whisky, vodka, gin etc       martini, wine, sherry, etc 
 
        
Monday                          
Tuesday                          
Wednesday                             
Thursday                        
Friday                        
Saturday                        
Sunday                         
 
          Yes No 
(ii) Would you say that last week was fairly typical of what you usually 
have to drink in a week? 
          
          More Less 
(iii) If last week was not typical, would you normally drink more or 




22.  Alcohol intake over past year 
 
(i)   How often did you have a drink containing alcohol in the past year?  
 Consider a “drink” to be a can or bottle of beer, a glass of wine, or one cocktail or a measure of  spirits 
(like scotch, gin, or vodka).  
 
never      1  
monthly or less    2 
2 to 4 times a month    3 
2 to 3 times a week    4 
4 to 5 times a week    5 
6 or more times a week   6 
 
 (ii)  How many drinks did you have on a typical day when you were drinking in the past year?  
 
0 drinks     1 
1 to 2 drinks     2 
3 to 4 drinks     3 
5 to 6 drinks     4    
7 to 9 drinks     5 




 (iii)  How often did you have 6 or more drinks on one occasion in the past year?  
 
never     1 
less than monthly    2 
monthly     3 
weekly     4 
daily or almost daily    5 
 
23.   Have you or your doctor ever considered that you suffer/have   Yes No 





Smoking has been linked with many health problems.  It is important that you answer the following section as accurately 
as possible. 
         Yes No 
24. Do you smoke at present?        1  2        
 
If no, proceed to Question 29 
 
25. What do you usually smoke now? 
Yes No 
 Cigarettes        1  2        
Pipe         1  2  
Cigars         1  2 
          
 
26. How many do you usually smoke now? 
 
Cigarettes per day      ……… cigarettes 
 
Oz. tobacco per week      ……… oz. 
 
Cigars per week       ……… cigars 
  
 
27. For how many years during your life have you smoked cigarettes?  ……… years 
           
 
28. How many cigarettes have you smoked on average per day during  
 the period you have smoked?      ………cigarettes 
       
 Now proceed to Question 34      
       Yes No  
29. Have you ever smoked regularly?        1  2 
    
   If no, proceed to Question 34 
           
30. What did you usually smoke?       Yes No 
Cigarettes        1  2  
Pipe         1  2  
Cigars         1  2 








31. How much did you smoke on average while you were a smoker? 
 
Cigarettes per day      ……… cigarettes 
 
Oz. tobacco per week      ……… oz. 
 
Cigars per week       ……… cigars 
 
32. For how many years did you smoke cigarettes?    ……… years 
 
33.        If you smoked cigarettes, how long is it since you finally  
 gave up?   





34. Do you ever get pain or discomfort in your chest?      1  2  
                     
 
IF NO, PROCEED TO QUESTION 40 
         Yes No 
35. Do you get this pain or discomfort when you walk uphill or hurry?   1  2 
         
  
  IF NO, PROCEED TO QUESTION 40 
            
          Yes No 
36. Do you get it when you walk at an ordinary pace on the level?    1  2  
          
           
37. When you get any pain or discomfort in your chest what do you do?  
                      Tick one 
Stop         1  
 
Slow down        1 
 
Continue at the same pace      1  
   
        Yes No 
38. Does it go away when you stand still or sit down?      1  2  
 
How soon?                       Tick one 
10 minutes or less       1  
 
More than 10 minutes       2  
 
 
39. Where do you get this pain or discomfort?  Mark the place(s) 
with an ‘X’ on the diagram 
 
 Yes No 
 
40. (i) Have you ever had a severe pain across the front of your   1  2 
  chest lasting for half an hour? 
 
(ii)         What was the cause?  ……………………………………………………………… 
 
LEG PAIN 
Yes No I am unable 
   to walk 
 41.  Do you get a pain or discomfort in your leg(s) when you walk?   1  2  3  
  
 
If you answered ‘yes’ to question 41, please answer the following questions.   
 
           Yes No 
 (i)  Does this pain ever begin when you are standing still or sitting?   1  2 
 (ii)  Do you get it if you walk uphill or hurry?      1 2 
 (iii) Do you get it when you walk at an ordinary pace on the level?   1  2 
 (iv) Does the pain ever disappear while you are still walking?    1  2 
 (v)  What do you do if you get it when you are walking?     1  2 
 
         Tick one 
   Stop         1 
Slow down        2 
  Continue at same pace       3  
 
 
(vi) What happens to it if you stand still? 
        Tick one 
 Usually continues for more than 10 minutes    1 
 Usually disappears in 10 minutes or less    2 
 
  
(vii) Where do you get this pain or discomfort? 
          Yes No 
  (a) Do you get this pain in your calf (or calves)?    1  2  
  







THANK YOU FOR COMPLETING THIS QUESTIONNAIRE – PLEASE BRING IT WITH YOU TO YOUR 














THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL AND IS 
PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly confidential and 
will be available only to your own doctor and the study team.  The results of the research 
will appear only in the form of general statistics from which it will be impossible to identify 




Please complete the following: 
 
 




DATE:            ……………………………………………………………….. 
 
 
THANK YOU FOR YOUR CO-OPERATION IN THIS STUDY 
 
For Office Use: Study No….................... 
 
 
EMPLOYMENT STATUS / OCCUPATION  
The following questions refer to your current main job, or (if you are not working now) to your last main job. Please 
complete for both yourself (I) and for your spouse/ex-spouse or long-term partner (II) 
(I) Yourself   (Please tick one box only per question) 
1. Do (did) you work as an employee or are (were) you self-employed? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 4)    
Housewife 
(go to question 4)    
No previous paid employment (excluding housewife) 
(go to question 4)    
2. Number of employees 
For employees: indicate below how many people work (worked) for your employer at the place where you work 
(worked).  Then go to question 3. 
For self-employed: indicate below how many people you employ (employed). Then go to question 4. 
                                                     1 to 24    1                                         25 or more  2 
3. Do (did) you supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-to-day basis 
                                                          Yes    1                                                      No  2 
4. Please tick one box to show which best describes the sort of work you do. (If you are not working now, please tick 
a box to show what you did in your last job). PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - police officer 
(sergeant or above) - software designer 
 
1 
Clerical and intermediate occupations 




Senior managers or administrators 
(usually responsible for planning, organising and co-ordinating work and for finance) 




Technical and craft occupations 




Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering assistant - 
receptionist - sales assistant  
 
5 
Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - labourer - 
waiter / waitress - bar staff 
 
6 
Middle or junior managers 




Traditional professional occupations 
such as: accountant - solicitor - medical practitioner - scientist - civil / mechanical engineer  
8 
 
EMPLOYMENT STATUS / OCCUPATION (cont.) 
(II) Your spouse/ex-spouse/long term partner   (Please tick one box only per question) 
5. Do (did) he/she work as an employee or is (was) he/she self-employed? 
Employee   
Self-employed with employees   
Self-employed / freelance without employees 
(go to question 4)    
Housewife 
(go to question 4)    
No previous paid employment (excluding housewife) 
(go to question 4)    
6. Number of employees 
For employees: indicate below how many people work (worked) for his/her employer at the place where he/she work 
(worked).  Then go to question 3. 
For self-employed: indicate below how many people he/she employs (employed). Then go to question 4. 
                                                     1 to 24    1                                         25 or more  2 
7. Do (did) he/she supervise any other employees? 
A supervisor or foreman is responsible for overseeing the work of other employees on a day-to-day basis 
                                                          Yes    1                                                    No  2 
 
8. Please tick one box to show which best describes the sort of work he/she does. 
(If not working now, please tick a box to show what he/she did in his/her last job).PLEASE TICK ONE BOX ONLY 
Modern professional occupations 
such as: teacher - nurse - physiotherapist - social worker - welfare officer - artist - musician - police officer 
(sergeant or above) - software designer 
 
1 
Clerical and intermediate occupations 




Senior managers or administrators 
(usually responsible for planning, organising and co-ordinating work and for finance) 
such as: finance manager - chief executive 
 
3 
Technical and craft occupations 




Semi-routine manual and service occupations 
such as: postal worker - machine operative - security guard - caretaker - farm worker - catering assistant - 
receptionist - sales assistant  
 
5 
Routine manual and service occupations 
such as: HGV driver - van driver - cleaner - porter - packer - sewing machinist - messenger - labourer - 
waiter / waitress - bar staff 
 
6 
Middle or junior managers 




Traditional professional occupations 

















THE INFORMATION IN THIS QUESTIONNAIRE IS HIGHLY CONFIDENTIAL AND IS 
PART OF A MEDICAL RESEARCH STUDY 
 
 
The information you give in this questionnaire will be treated as strictly confidential and 
will be available only to your own doctor and the study team.  The results of the research 
will appear only in the form of general statistics from which it will be impossible to identify 




Please complete the following: 
 
 




DATE:            ……………………………………………………………….. 
 
 











Stress means feeling irritable, filled with anxiety, or having sleeping difficulties as a result of conditions at work or at 
home.  
 
1.  How often have you felt stress at work in the past year?  
 
 Never     1 
 Some periods    2 
 Several periods    3 
 Permanently    4 
 Not working in past year   5 
 
2.  How often have you felt stress at home in the past year?  
 
 Never     1 
 Some periods    2 
 Several periods    3 
 Permanently    4 
 
 
3.  What level of financial stress do you feel? 
 
 Little or none    1 
 Moderate    2 
 High or severe    3 
 
 
4. Have you experienced any of the following in the past year? 
 
 Marital separation or divorce     1 
 Loss of job or retirement      2 
 Business failure       3 
 Violence        4 
 Major intrafamily conflict      5 
 
 Major personal injury or illness     6 
 Death or major illness of a close family member   7 
 Death of a spouse      8 
 Other major stress      9 




5. SATISFACTION WITH LIFE SCALE 
 
Below are five statements with which you may agree or disagree. Using a 1-7 scale, indicate your 
agreement with each statement by ticking the appropriate box next to that item. Please be open and honest 
in your responses. 
 
 The 7-point scale is: 
 
 1= Strongly disagree 
 2= Disagree 
 3= Slightly disagree 
 4= Neither agree nor disagree 
 5= Slightly agree 
 6= Agree 
 7= Strongly agree 
 
                  1           2            3           4     5             6            7 
 In most ways my life is close to ideal.                                   
   
                                 1             2           3        4  5             6             7 
 The conditions of my life are excellent.                                                           
 
             1            2            3             4            5            6             7 
 I am satisfied with my life.                                                             
 
            1              2           3          4    5            6            7
 So far I have got the important things I want in life.                                            
 
               1            2           3          4    5            6            7





6.  SUBJECTIVE SOCIAL STATUS 
 
     Scotland 
Think of this ladder as representing where people stand in Scotland. At the top of the ladder are the people who 
have the most money, most education, and the most respected jobs. At the bottom are the people who have the 
least money, least education and the least respected jobs or no job. The higher up you are on this ladder, the 
closer you are to the people at the very top. The  lower you are on this ladder, the closer you are to the people 
at the very bottom. Where would you place yourself on this ladder? Please place a large “X” on the rung where 















Think of this ladder as representing where people stand in their communities. People define community in different 
ways, e.g., including friends, neighbours, or co-workers. Please define it in whatever way is most meaningful to you. 
At the top of this ladder are the people who have the highest standing in their community. At the bottom are the 
people who have the lowest standing in their community. The higher up you are on this ladder, the closer you are to 
the people at the very top. The lower you are on this ladder, the closer you are to the people at the very bottom. 
Where would you place yourself on this ladder? Please place a large “X” on the rung where you think you stand at 
this time in your life, relative to other people in your community.  
 
 













Below are a number of phrases that describe people’s behaviours. Read each statement, and then tick the response that most 
accurately describes you. Describe yourself as you honestly see yourself. Read each statement carefully, but try not to take too 
long on each statement, as your first response is likely to be best.  
 













































































































































































































































































































































































































































































































































































































































8. ANGRY FEELINGS QUESTIONNAIRE:  
 
(i) Below are a number of statements that people use to describe themselves. Read each statement and then tick the box that 
indicates how you generally feel or react. There are no right or wrong answers. Do not spend too much time on any one 
statement. Mark the answer that best describes how you generally feel or react. 
 
How I generally feel……. 
 
  Almost never Sometimes Often Almost always 












































I feel annoyed when I am not given 































It makes me furious if I am criticised in 























I feel infuriated when I do a good job and 










 (ii) Everyone feels angry or furious from time to time, but people differ in the ways they react when they are angry. A number of 
statements are listed below which people use to describe their reactions when they feel angry or furious. Read each statement 
and then tick the box which indicates how often you generally react or behave in the manner described when you are feeling 
angry or furious. Remember that there are no right or wrong answers. Do not spend too much time on any one statement. 
 
When I am angry or furious, ….. 
 
  Almost never Sometimes Often Almost always 
61 
 
















































66 If someone annoys me, I’m apt to tell him 



















































  Almost never Sometimes Often Almost always 
71 
 




























































































































































































90 I’m irritated a great deal more than people 













THANK YOU FOR COMPLETING THIS QUESTIONNAIRE – PLEASE RETURN IT TO ONE OF THE CLINIC 
STAFF BEFORE YOU LEAVE (or in the reply paid envelope from home) 
